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BACKGROUND: The incidence rates of HPV positive oropharyngeal cancers (OPSCCs) are on the 
rise, yet oral HPV prevalence rates in clinically healthy populations are poorly understood. To determine 
the risk of healthy adults developing OPSCCs, first we must establish oral HPV prevalence, viral load, 
persistence, and clearance rates in healthy populations to understand the link between oral HPV and 
OPSCCs. This is even more pertinent within the young adult population as the HPV vaccination 
programme has been shown to reduce cervical cancer incidence but not OPSCC incidence. Therefore, 
other factors that could affect oral HPV contraction and OPSCC development need investigation such 
as population demographics, lifestyle risk behaviours, HPV screening methods and vaccination status. 
OBJECTIVES: The aims of this study were centred on establishing reproducible and sensitive HPV 
screening methods for the detection of oral HPV in clinically healthy young adults, for determining 
prevalence and abundance, and establishing if oral HPV was influenced by vaccination status, 
demographics, and lifestyle risk behaviours.  
METHODS: The study established a novel and sensitive real-time PCR HPV consensus screening 
method for the detection of multiple HPV subtypes in the oral cavity of 408 clinically healthy UK-based 
young adults (92.01%; 18-25 years old in 2016-17). HPV positive or undetermined samples were then 
screened using qPCR for HPV subtypes, HPV-6, HPV-11, HPV-16, HPV-18. All results were analysed 
alongside vaccination status, demographics and lifestyle risk behaviour data collected via questionnaire. 
RESULTS: An oral HPV prevalence rate of 22.79% was found, with HPV-16 being the most prevalent 
and abundant subtype at 19.12%; 1.08x105 copies/million cells, followed by HPV-18 at 1.72%; 1.89x104 
copies/million cells, HPV-6 at 0.49%; 4.50x102 copies/million cells and HPV-11 at 0.25%; 1.06x102 
copies/million cells. Unknown HPV subtypes were detected in 2.21% of the cohort. Oral HPV was 
found to be significantly associated with open-mouth kissing (p <.001), oral sex (p = .049), masturbation 
in males (p = .020), sexual intercourse (p = .026), sexual activity diversity (p = .043), frequent smoking 
(p = .024), wine drinking (p = .045) and drinking ≥2 types of alcohol per sitting (p = .015), especially 
in males (p = .023). HPV-16 was significantly associated with masturbation (p = .004), whilst there was 
a reduction in viral load in vaccinated individuals, but this was not statistically significant.  
CONCLUSIONS: Oral HPV is prevalent in the young adult UK population, especially HR-HPV 
subtype HPV-16, questioning the efficacy of the HPV vaccination on reducing oral prevalence. 
However, HPV vaccination may instead influence oral HPV viral load, but further research is required, 
demonstrating the importance of measuring both presence and abundance. Oral HPV prevalence did 
appear to be influenced by sexual practice, including open-mouth kissing and oral sex, but less so by 
smoking and alcohol consumption, reaffirming the link between oral HPV and OPSCCs.





1.1 Human Papillomavirus (HPV) Overview 
The Human Papillomavirus (HPV) is a small, non-enveloped double-stranded 
deoxyribonucleic acid (dsDNA) virus that resides in the large taxonomic family known as 
Papillomaviridae (Sabarad & Koppad, 2015). Papillomaviruses are ubiquitous and able to 
infect a wide variety of mammalian species. establishing infections within cutaneous and 
mucosal epithelium (McBride & Warburton, 2017). As a result, HPV infections are common 
due to targeting a wide range of anatomical infection sites. In fact, it is estimated that incidence 
rates in the United States range from 1-5.5 million infections per year (Burd, 2003). Despite 
global prevalence, most HPV infections go unnoticed as a high proportion are asymptomatic 
(Gheit, 2019). During an adult’s lifetime, there is a 65-100% chance of encountering HPV, 
with ~80% of sexually active adults having encountered the virus by their mid-twenties and 4 
out of every 5 women becoming infected by the age of 50 years old (Cubie, 2013; CDC, 2017).  
Due to this, HPV infections are commonly categorised as sexually transmitted infections and/or 
diseases (STI and/or STD) but HPV exhibits a variety of transmission routes including saliva 
exchange, skin-to-skin contact, perinatal fluid and shared contaminated objects (Wang et al., 
2015; Liu et al., 2016; Sabeena et al., 2017; Wood et al., 2017a). Recent studies have also 
detected HPV DNA within blood samples, proposing that the infection could spread via blood 
transfusions, whilst other research has even suggested that surgeons could acquire an infection 
via inhalation of HPV viral particles during treatments such as laser ablation and electrocautery 
(Garden et al., 2002; Watson, 2005).  
Despite the high chance of contraction through a range of transmission routes, the human body 
will clear 90% of infections within 18-24 months of exposure (LaCour & Trimble, 2012; 
Miranda et al., 2013; Gheit, 2019). However, for the remaining 10%, persistent infections may 
establish which has been linked to malignant tissue transformation, dependent on risk factors 
and HPV genotype (McBride & Warburton, 2017; Serrano et al., 2018). 
There are over 200 genotypes of HPV that have been identified to date, with all exhibiting at 
least 10% divergence within the L1 viral capsid gene sequence to enable classification as a new 
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HPV subtype (Egawa et al., 2015; Gheit, 2019). More than 13 HPV genotypes have been 
classified as “high-risk” (HR) HPV subtypes due to being directly associated with or known 
causative agents of a variety of different human cancers such as head and neck squamous cell 
carcinomas (HNSCCs), anogenital cancers, and cervical carcinomas (Burd, 2003; Dickson et 
al., 2015; WHO, 2016). HPV has, therefore, been termed an “oncogenic” virus due the ability 
of HR-HPV genotypes to promote oncogenesis of healthy epithelial cells (McBride & 
Warburton, 2017). HR-HPV genotypes include -16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -
58, -59, -66, and -70 (Burd, 2003; Serrano et al., 2018), with HPV-16 and HPV-18 being the 
most common and the predominate causative agents of genital cancer. In fact, over ~70% of 
cervical intraepithelial neoplasia precursors (CIN I/II/III) and cancers worldwide are attributed 
to having a long-term HPV-16 infection (Burd, 2003). Over the past ~10-15 years, HPV-16 
has also become more prominent in oral regions, whilst HPV-31 has increasingly been found 
within cervical cancer (Söderlund-Strand & Dillner, 2013; Ahmed, Bensumaidea & 
Ashankyty, 2015). Yet, the role of these HR-HPV subtypes in HNSCCs and cervical cancer, 
respectively, remains unclear. 
Not all HPV genotypes exhibit oncogenic potential and only 10% of individuals with a HR-
HPV infection will develop a pre-cancerous lesion or malignant tumour (CDC, 2017). HPV-6 
and HPV-11 are examples of such HPV subtypes not associated with malignant transformation 
(Egawa & Doorbar, 2017). Instead, HPV-6 and HPV-11 are the most common “low-risk” (LR) 
HPV subtypes in the population world-wide (Serrano et al., 2018; Gheit, 2019). Other 
identified LR-HPV genotypes include -40, -42, -43, -44, -53, -54, -61, -72, -73 and -81 (Burd, 
2003). These are classified as LR-HPV subtypes as many are asymptomatic or result in benign 
tumour growth in the form of papillomas, known as warts (Egawa & Doorbar, 2017). HPV-6 
and HPV-11 are largely responsible for the formation of genital warts (Serrano et al., 2018), 
whilst, HPV-1, HPV-2, HPV-27 and HPV-57 have been shown to cause ~88% of plantar warts 
(Bruggink et al., 2012). Other HPV genotypes lack classification due to insufficient evidence 
for or against oncogenic potential; HPV-68 is one such genotype despite frequent debate in 
favour for HR-HPV categorisation (Burd, 2003; Gheit, 2019). Studying the aetiology of 
associated diseases and persistence of HPV infection, through conducting widescale screening 
studies to determine prevalence of HPV subtypes in the global population, may help 
classification.  
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1.2 HPV Viral Lifecycle & Gene Expression 
Structurally, each HPV virion is icosahedral in shape and contains a circular genome of ≈8000 
base pairs (bp) which is organised into two distinct coding regions with eight open-reading 
frames (ORFs) (Berti et al., 2017; Martin et al., 2017). The early region encodes for all the 
non-structural proteins such as E1, E2, E4, and the oncoproteins, E5, E6 and E7, whilst the late 
region encodes for the structural assembly proteins necessary for capsid production; L1 and L2 
(Leão et al., 2017) (Figure 1).  
 
 
Figure 1. HPV Genome Organisation. Circular genome structure of HPV viral genome including 
position, relative sequence lengths and role of the HPV early (E) and late (L) gene products. 
 
The nomenclature of the HPV genes indicates the stage of viral lifecycle in which they are 
expressed; early or late. Expression of the non-structural early proteins predominately occurs 
following initial HPV infection within basal cutaneous and mucosal epithelium, continuing 
throughout cellular differentiation as the early proteins are responsible for viral lifecycle 
regulation and manipulation of host cell machinery for viral replication, transcription, and 
translation (Gheit, 2019) (Figure 1).  
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HPV infection occurs in basal membrane epithelium, as studies have found that recipient host 
cell must enter M (mitosis) phase and allow for early prophase for the successful downstream 
transcription of the HPV genome (Pyeon et al., 2009). HPV is thought to gain entry to basal 
membrane epithelium through microabrasions or squamo-columnar (SC) junctions in the 
epithelium such as in tonsil crypts and between the endocervix and ectocervix (Frazer, 2004; 
Morbini et al., 2015; Graham, 2017). 
HPV virions bind to basal cell surface receptors, allowing for cell entry. Glycosaminoglycans 
(GAGs), such as heparan sulphate, are suggested to be these initial attachment receptors for 
HPV virions due to wide expression and evolutionary conservation (Sapp & Bienkowska‐
Haba, 2009; Schiller, Day & Kines, 2010). Heparan sulphate proteoglycan (HSPG), in 
particular, has frequently been found in the extracellular matrix (ECM) deposited by many 
epithelial cell lines grown in vitro and on the surface of cells in vivo, so has become widely 
accepted as an accessible and critical primary attachment factor for HPV (Horvath et al., 2010). 
Binding of HSPG has been shown to cause a conformational change in HPV capsid protein, 
L2. This is thought to trigger endocytic pathways involved in internalisation and intracellular 
trafficking of HPV virions (Schiller, Day & Kines, 2010). Despite extensive research, there is 
much debate as to how this occurs as various HPV genotypes have been shown to use different 
endocytic pathways.  
Once HPV enters a host basal cell via endocytosis, antibody staining has suggested that capsid 
uncoating occurs within endocytic vesicles (DiGiuseppe, Bienkowska-Haba & Sapp, 2016; 
Faraji et al., 2017). Virions are localised in early endosomes within 4 hours of internalisation, 
which is relatively slow in comparison to other types of virus (Schiller, Day & Kines, 2010). 
After another 4-8 hours, uncoating occurs within late endosomes, and the HPV genome 
complexed with L2 is released into the cytoplasm. From here, the HPV genome complexed 
with L2 is transported to host nuclei via microtubules networks in the cytosol (DiGiuseppe, 
Bienkowska-Haba & Sapp, 2016). Studies have shown that intact HPV capsids are too large 
for transit across nuclear pore complex channels so disassembly of viral particles must occur 
in endosomes prior nuclear import (Nelson et al., 2000; Sapp & Bienkowska‐Haba, 2009). In 
cultured cells, there is also evidence that cell division is required for establishment and 
expression of the HPV genome in host nuclei (Pyeon et al., 2009). This suggests that nuclear 
membrane breakdown during mitosis may instead allow for HPV genome transfer rather than 
active transport through nuclear pores – suggested also to be dependent on HPV genotype 
(Schiller, Day & Kines, 2010). 
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Following viral entry into the host nuclei, E1 and E2 expression is activated which leads to 
replication of HPV episomal genomes at a low copy number (~50-100 copies per cell) in 
undifferentiated basal keratinocytes (del Mar Peña & Laimins, 2001; Doorbar, 2005; Kajitani 
et al., 2012; Doorbar et al., 2015). For the continuation of the HPV viral lifecycle, both 
cutaneous and mucosal basal keratinocytes must differentiate. At this stage, vegetative or 
productive viral replication is initiated, with the subsequent production of progeny virions 
(Gheit, 2019). 
In epithelial infections, the host basal keratinocytes differentiate into spinous and granular 
epithelium to form parabasal and suprabasal (intermediate) layers. Here, all early HPV proteins 
are expressed (E1, E2, E4, E5, E6 and E7) which increases viral copy number via genome 
amplification (Garner-Hamrick & Fisher, 2002; McBride, 2008). HPV is non-lytic so must 
remain in differentiated cells until they have reached the degrading surface epithelium for 
shedding (Doorbar, 2005). In cutaneous epithelium, spinous and granular cells differentiate 
again into cornified epithelium, whilst mucosal epithelium form mature superficial squamous 
layers. At this final stage, HPV L1 and L2 protein expression occurs for capsid production and 
release, coinciding with E1 and E2 expression for further episomal genome amplification 
(Wang et al., 2009; Xue et al., 2010; Paris et al., 2015; Graham, 2017). 
As HPV viral genome copy number varies with each stage of the viral lifecycle, and with cell 
type, stage of infection has been shown to have an impact on HPV screening (Kajitani et al., 
2012). At low copy number lifecycle stages, HPV may be more difficult to detect so screening 
assays have been designed to collect surface epithelium where HPV copy number may be at its 
highest (McBride, 2008). As a result, HPV DNA screening is preferable for determining HPV 
prevalence within a population but cannot determine if the infection is transcriptionally active. 
Instead, RNA and protein assays are designed to detect early protein expression, also providing 
an indication of stage of infection. 
Furthermore, HPV DNA can exist episomally within a host cell or integrated into the host’s 
genome; also varying copy number (Garner-Hamrick & Fisher, 2002; Egawa & Doorbar, 
2017). Integration usually occurs at the E1/E2 region of the HPV viral genome which disrupts 
the open reading frame (ORF) and subsequent protein expression (McBride & Warburton, 
2017). As the E1 and E2 proteins are DNA-binding, regulatory proteins directly involved in 
the regulation of viral transcription and DNA replication, ORF disruption can result in 
dysregulation of other HPV early proteins (Gheit, 2019). In HR-HPV types HPV-16 and HPV-
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18, research has shown E2 acts as a repressor of the P97 promoter from which E6 and E7 are 
transcribed (Kajitani et al., 2012) (Figure 2a).  
 
 
Figure 2. HPV Early Gene Expression and Regulation. HPV genome in linear form revealing early 
gene expression and regulation. a) Initial HPV gene expression after infection; E2 expression disrupts 
the transcription of E6 and E7. b) HPV genome integration results in partial loss of the E2 sequence 
which inhibits transcription; E6 and E7 transcription occurs. 
 
As a consequence of integration, and subsequent disruption of HR-HPV E1/E2 ORFs, regular 
E6 and E7 oncoprotein expression occurs (Gheit, 2019) (Figure 2b). E6 and E7 oncoproteins 
interfere with cell cycle checkpoints to promote cellular proliferation and genetic instability of 
infected mucosal and cutaneous epithelium (McBride & Warburton, 2017). Cellular 
proliferation and genetic instability are hallmarks of cancer (Urra et al., 2016), therefore, 
regular expression of E6 and E7 can lead to malignant transformation of an infected clinically 
“healthy” cell into a neoplastic cell.  
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Figure 3. HPV E6 and E7 Cell Cycle Interference. Degradation and inactivation of the tumour 
suppressor proteins by HPV viral proteins. a) HPV E6 causing the degradation of tumour suppressor 
protein p53 via trimeric complexes. b) HPV E7 promoting transition to S phase via binding of pRb. 
 
E6 promotes cellular proliferation by activating the degradation of p53, a host tumour-
suppressor protein (McBride & Warburton, 2017) (Figure 3). E6 forms a trimeric complex with 
p53, and the cellular ubiquitination enzyme, E6-AP, which interferes with the biological 
growth-arrest and apoptosis-inducing functions of p53 (Yim & Park, 2005; Chen, 2016). In 
non-infected cells, p53 prevents the propagation of cells with DNA damage by arresting the 
cell cycle to allow DNA repair and/or apoptosis to occur (Ozaki & Nakagawara, 2011). As p53 
is involved in cell cycle checkpoint control, degradation by E6 leads to unchecked progression 
of infected and genetically unstable cells, resulting tumour growth (Gheit, 2019). E6 also 
activates human telomerase reverse transcriptase (hTERT) transcription in human 
keratinocytes; overexpression of which has frequently been shown to cause immortalisation 
(James, Lee & Klingelhutz, 2006). 
As E6 and E7 function together to promote cellular proliferation, E7 simultaneously binds with 
the retinoblastoma protein (pRb), another tumour suppressor protein expressed by the host cell 
(Figure 3). In HR-HPV types, E7 has a much higher affinity for pRb than E7 encoded by LR-
HPV types, such as HPV-6 and HPV-11, increasing oncogenic potential (Egawa & Doorbar, 
2017). The role of pRb is to supress E2F-family transcription factors which prevents transition 
into S (synthesis) phase of the cell cycle in which DNA replication occurs (Giacinti & 
Giordano, 2006). When E7 binds to pRb, it prevents suppression of these factors, accelerating 
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the transition into S phase which causes early cellular replication, including the integrated viral 
genome, and cell division (Yim & Park, 2005). As a result, the combination of both HPV E6 
and E7 expression disrupts the normal physiological functions of the tumour suppressor 
proteins, promoting cancer development.  
Therefore, research associating HR-HPV infections with cancer development have 
predominately measured E6 and E7 protein expression levels rather than loss of E2 expression 
and/or HPV DNA presence (Lindquist et al., 2007). Whilst this is useful in cancer studies due 
to an abundance of material to extract protein from (HPV positive cell lines and/tissue), studies 
on clinically “healthy” individuals are limited by sample size and type. Therefore, HPV viral 
DNA copy number can be used instead to provide an indication of severity of infection, whilst 
E6 and E7 mRNA can be targeted as an indicator of transcriptionally active HPV infection via 
real-time quantitative PCR (qPCR). Either way, E6 and E7 are ideal targets for screening 
individuals for risk of cancer development and genotype identification but not overall HPV 
prevalence (Andersson et al., 2006). 
Alternatively, the late region of the HPV genome encodes for the L1 major capsid protein 
involved in viral entry into the host cell and structural assembly (Bruggink et al., 2012; Doorbar 
et al., 2015). In comparison to E6 and E7, the L1 gene is highly conserved and consistently 
expressed towards the end of the viral lifecycle in the upper layers of infected epithelium for 
capsid protein production, assembly of virions and release. This, in combination with infected 
surface epithelium providing highest HPV copy number, makes L1 an ideal target for HPV 
consensus screening in clinically healthy individuals for overall HPV prevalence (Norman, 
Hjerpe & Andersson, 2013; Doorbar et al., 2015). 
 
1.3 HPV & Cancer 
Due to oncogenic potential of HR-HPV genotypes, HPV has been frequently associated with 
many different types of human cancers such as HNSCCs, anogenital cancers, cervical 
carcinomas and lung carcinomas (Syrjänen, 2002; Burd, 2003; Dickson et al., 2015; WHO, 
2016). More recent research has also linked HPV to oesophageal adenocarcinomas in those 
that have been diagnosed with Barret’s dysplasia (Rajendra et al., 2016; Rajendra et al., 2017), 
revealing the versatility of HPV to adapt for survival in many different tissue and cell types. 
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But despite being linked to many types of cancer, HPV has yet to be shown to directly cause 
oncogenesis resulting in malignant transformation in many them bar cervical cancer. 
HR-HPV type HPV-16 has become known to be the causative agent of cervical cancer (Arbyn 
et al., 2020). In the early 2000’s, cervical cancer was the third most common cancer in women 
world-wide (Zeferino & Derchain, 2006), but the past ~10-15 years has seen a reduction in 
incidence, resulting in a drop to fourth place (Arbyn et al., 2020; WHO, 2020). This is largely 
thought to be as result of the HPV vaccination programme (de Sanjose et al., 2019), introduced 
in the UK in 2008. Countries that achieved high vaccination coverage have reported a large 
decline of CIN II/III cervical lesions amongst young women by 41–57%, less than 10 years 
after the HPV vaccination programme was implemented (Brisson et al., 2020). This has led to 
terminology such as “elimination” being included in the titles of publications on cervical cancer 
and one study has even predicted cervical cancer elimination by 2072 with 95% vaccination 
coverage (Xia et al., 2019). However, more research is required assess full impact of HPV 
vaccination globally, including the impact on other HPV related cancers. 
This is important for HNSCCs as research has shown HPV is also attributed to ~25-30% 
globally, predominately oropharyngeal squamous cell carcinomas (OPSCCs) (Schiffman et al., 
2007; Dayyani et al., 2010; Sindrewicz et al., 2020). HNSCCs are known to be the sixth most 
common type of cancer with subtypes based on the locality of the tumours, such as 
nasopharyngeal, laryngeal, nasal and paranasal, oral (OSCCs), and OPSCCs (Hennessey, 
Westra & Califano, 2009; Marur et al., 2010; Beck & Golemis, 2016; Götz et al., 2016). On 
average, an estimated 500,000 new cases of HNSCCs are diagnosed each year, world-wide, 
but this increased to 600,000 in 2015 (Blons & Laurent‐Puig, 2003; Jemal et al., 2011; 
Chaturvedi et al., 2013; Pfster et al., 2015) with a 64% 5-year survival rate (Siegel, Miller & 
Jemal, 2016). Research has also found that White males are, for the first time, exhibiting higher 
rates of HNSCCs than Black males globally, indicating the potential involvement in malignant 
transformation from other risk factors (Peterson et al., 2017; Fakhry et al., 2018), with HPV 
exposure being one of them. 
 
1.3.1 HPV & HNSCCs 
In the UK, HNSCC incidence rates have increased by 92% since the late 1970s (Cancer 
Research UK, 2016). This has been suggested to be a result of increased engagement in lifestyle 
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risk behaviours for malignant transformation such as heavy smoking and heavy alcohol 
consumption (Steevens et al., 2010). Age has also shown to be a risk factor as adult males aged 
≥50 years old have been increasingly presenting with HNSCCs and more so than any other 
demographic, particularly if they engage in heavy smoking and frequent alcohol consumption 
(Marur et al., 2010; D'Souza & Dempsey, 2011; Peterson et al., 2017). Approximately 75% of 
individuals diagnosed with HNSCCs engage in one or more of these high-risk activities (Suh 
et al., 2014); and 70% of these also have an active oral HPV infection (Beck & Golemis, 2016). 
These HPV positive HNSCC cancers have also been shown to exhibit a higher survival rate 
when compared to their HPV negative HNSCC counterparts (Jung et al., 2010). HNSCC 
development, therefore, has a strong correlation with engagement in lifestyle risk behaviours 
that frequently damage the oral mucosa via etiological agents whilst harbouring an existing 
oral HPV infection. Research has also shown that a secondary oncogenic virus such as an 
Epstein-Barr virus (EBV) (causes nasopharyngeal cancer) or co-infection of HR-HPV 
subtypes, can exacerbate this further (Powles et al., 2004; Rautava et al., 2012; Chung, Bagheri 
& D’Souza, 2014). 
In contrast, in the Unites States, incidence rates of HNSCCs are in decline due to the reduction 
of heavy smokers and drinkers in the past ~10 years (Jung et al., 2017). However, incidence of 
HNSCC in oropharyngeal tissues (OPSCCs), such as the tonsils and base of the tongue, is 
increasing (Jung et al., 2017). The incidence of these OPSCCs has been continually linked to 
contraction of an oral HPV infection, leading to a 50-fold increase in the risk of malignant 
transformation (Sindrewicz et al., 2020), especially within the tonsils. Globally, HPV-related 
OPSCC incidence has been increasing by ~4-5% per year for the past ~10 years, with an 
increase of 5.3% per year in men (Hong et al., 2016; Owosho et al., 2018). In the UK, HPV-
related OSCCs and OPSCCs (mouth, tongue and tonsils) incidence is estimated to be ~30-35% 
(Cancer Research UK, 2016), with ~90% being linked to HPV-16 (Visalli et al., 2016). Current 
research has suggested that HPV-16 is, therefore, involved in the oncogenesis of OPSCCs alike 
cervical sites, particularly in tonsil epithelium (Bruni et al., 2017; Phusingha et al., 2017; Singh 
et al., 2017). However, more research is required to confirm this link and to determine the 
mechanisms in which infection would occur, as HPV-18 has also been found to be prevalent 
in OPSCCs in Asian populations (Chen et al., 2016).  
Furthermore, HPV positive OPSCCs have also been linked to lifestyle risk behaviours and 
demographics, similar to HNSCCs overall. Several studies have not only linked alcohol 
consumption and smoking (Steevens et al., 2010), but have also associated sexual practice with 
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OPSCCs (Chen et al., 2016; Visalli et al., 2016), likely to be attributed to oral HPV 
transmission. To date, this link is not fully understood as there have been many changes in 
sexual habits over the last few decades, especially within younger adults. As a result, there has 
been an increase in the numbers of younger patients presenting with HPV positive OPSCCs 
within clinics across the UK but these, oppositely to HNSCCs, are more commonly White 
males aged ≤40 years old (Gillison et al., 2012b; Fakhry et al., 2013; Owosho et al., 2018). 
This provides further evidence to suggest that oral HPV infections are likely to exacerbate oral 
damage from etiological agents, and perhaps even accelerate malignant transformation 
progression at a higher rate than in HPV negative OPSCCs (Beck & Golemis, 2016; Chen et 
al., 2016; Owosho et al., 2018).  
Furthermore, individuals with an oral HPV infection or HPV positive OPSCC have also been 
shown to have a higher risk for developing other types of HPV-associated cancer such as, 
cervical cancer, penis cancer and anus cancer (Termine et al., 2011; Doorbar et al., 2015; 
Birkeland et al., 2016). World-wide, it is predicted that 22% of individuals with an oral HPV-
associated HNSCC have another HPV-associated carcinoma of a sexual organ (Dayyani et al., 
2010). To date, it is not fully understood how HPV transmission can occur between anatomical 
sites but again, sexual practices have been linked. Further studies are necessary to explore this 
as differences in severity of infection, locality and longevity could exacerbate HPV positive 
cancer progression. This is even more pertinent as the 5-year survival rate from HPV-related 
HNSCCs is <50% due to lack of visible lesions, and therefore, late tumour presentation (Cubie, 
2013). As oral HPV is linked to HNSCCs and OPSCCs, prevalence and abundance monitoring 
in clinically healthy individuals could detect early changes before malignant transformation 
occurs, subsequently, increasing survival rates. 
 
1.4 Oral HPV 
As emerging research has started to reveal the strong links between oral HPV and OPSCC 
development, it is important to investigate prevalence and abundance of HPV within the 
general population. World-wide predictions of oral HPV prevalence rates range from 5.5-7.7% 
(Shigeishi & Sugiyama, 2016; Wood et al., 2017b; Tam et al., 2018). However, national studies 
have reported prevalence values ranging from 4.0% in Italy (Lupato et al., 2017), 5.7% in Japan 
(Cho et al., 2020), 6.8% in Peru (Rosen et al., 2016), 10.0% in Spain (Sastre-Cantón et al., 
2019), to a higher 26.0% in the Caribbean (Auguste et al., 2017), demonstrating a high degree 
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divergence depending on geographical location. This can also be seen within UK-based 
literature within the few studies that have conducted research into oral HPV prevalence rates. 
Reported oral HPV prevalence rates range from 4.0-18.7% in healthy individuals across 
England and Scotland (Conway et al., 2016; Knight et al., 2016; Mehanna et al., 2019), 
demonstrating a large national divergence more locally. Due to this large variance in oral HPV 
prevalence rates, it is important to consider what screening techniques were used within these 
studies for HPV detection, HPV subtype prevalence rates, gender differences, demographics 
and/or lifestyle risk factors. 
Firstly, age has been linked to oral HPV transmission as studies on young adults have reported 
higher prevalence rates than general population-based studies which have been commonly 
recruiting individuals up to the age of ~85 years old (Conway et al., 2016; Rosen et al., 2016; 
Mehanna et al., 2019). The few studies that have sampled young adult populations reported 
oral HPV prevalence rates ranging from 9.3-20.0% (Du et al., 2012; Edelstein et al., 2012; 
D’Souza et al., 2014). This demonstrates some disparity, similar to geographical differences, 
indicating that further research on young adult populations is necessary to determine why 
young adult populations appear to be at higher risk of oral HPV contraction than older 
populations. 
In addition, studies are also reporting differences in oral HPV prevalence between males and 
females, and different ethnic groups, similar to HPV positive HNSCCs cohorts. One recent 
study reported a 19.5% oral HPV prevalence in females and 17.4% oral prevalence in males 
(Mehanna et al., 2019) but most studies have either reported equal distributions in prevalence 
between males and females (Sastre-Cantón et al., 2019), or a higher oral HPV prevalence rate 
in males (Antonsson et al., 2014; D’Souza et al., 2014; Shigeishi & Sugiyama, 2016; Bui et 
al., 2017). It has been suggested that males are more likely to contract oral HPV and/or have 
lower clearance rates than females, especially for HR-HPV infections (Colon-López et al., 
2014; Sastre-Cantón et al., 2019; D’Souza et al., 2020). This could also explain why men are 
developing more HPV positive OPSCCs than women. However, further investigation is 
required via longitudinal studies to track and monitor oral HPV infections. This will allow for 
the determination of oral persistence, clearance and viral load differences between males and 
females for demonstrating the extent of oral HPV’s involvement in OPSCC development. 
Furthermore, research has shown that different ethnic groups may be at more risk of contracting 
oral HPV than others, similar to those presenting with HPV positive OPSCCs. The National 
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Health and Nutrition Examination Survey (NHANES) conducted a large-scale oral HPV 
screening study in the United States and found non-Hispanic White and non-Hispanic Black 
individuals exhibited higher oral HPV prevalence rates than Asian and Hispanic groups 
(Sanders, Slade & Patton, 2012; McQuillan et al., 2017). This is even more pertinent as other 
research has recently reported a higher HR-HPV type prevalence within oral cavity samples 
taken from Black ethnic groups (Pickard et al., 2012; Auguste et al., 2017; Raymond, Liu & 
Taioli, 2018), revealing White and Black Anglo-American populations may be at higher risk 
of developing HPV positive OPSCCs, but more research is required. 
Other studies have only focussed on oral HPV type-specific prevalence rates, specifically HPV-
16. Currently, there is much debate as to which HPV sub-types are the most prevalent in the 
oral population due to large variation in the screening methodologies employed to screen for 
type-specific infections and the types of populations sampled. Several studies have also found 
HPV-16 to be the most prevalent in oral cavity of healthy individuals (Wimardhani et al., 2015; 
Lupato et al., 2017; Hearnden et al., 2018), especially within White populations (Raymond, 
Liu & Taioli, 2018). For instance, one study found an oral HPV-16 prevalence rate of 4.5% in 
Australia (Sun et al., 2017), whilst only 0.15% was found in Japan (Kurose et al., 2004), again 
revealing geographical and ethnicity differences. Other studies have found HPV-18 (Seifi et 
al., 2013; Le et al., 2019), and HPV-52 (Auguste et al., 2017) to be the most prevalent in the 
oral cavity, demonstrating the need for more research to confirm global rates. Due to HR-HPV 
sub-types being linked with malignant transformation, it is important to also consider HR-HPV 
co-infection prevalence rates, abundance through viral load, and the effect on oral persistence. 
In large-scale studies in China and the United States, HR-HPV co-infection prevalence rates of 
0.1-1.5% in the general population have been reported, respectively (Hang et al., 2014; Bui et 
al., 2017). However, these rates were not comparable in already higher risk populations at 
20.4% in drug users (Ribeiro et al., 2019) and 28.1% in HIV positive individuals (Vergori et 
al., 2018). 
In fact, many studies that have limited their cohorts to HIV positive individuals, due to 
immunocompromisation being linked to the development of HPV positive OPSCCs (King et 
al., 2016; D’Souza et al., 2020; Méndez-Martínez et al., 2020; Pérez-Quintanilla et al., 2020), 
and have found significantly higher oral HPV prevalence rates and co-infection rates than 
general populations. One study found an oral HPV prevalence rate of 20.7% in HIV-positive 
men (Parisi et al., 2011), whilst another found an average point prevalence rate of oral HPV as 
high as 47.3% via a six-month sampling trial of HIV-positive men (Fakhry et al., 2010), 
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indicating an association between HIV and oral HPV. The study by Parsi et al., (2011) also 
screened anal samples for HPV and but found no concordance between anal and oral samples 
in terms of HPV subtypes prevalence. In fact, emerging research is beginning to reveal that the 
most common HR-HPV subtypes presenting in the mouth do not correlate with subtypes being 
found in genital infections. A study on oral HPV prevalence in genital HPV positive females 
(with a current/history of CIN I/II/II cervical cancer) and their male partners found that the 
male partners had a ~10% higher prevalence than the female partners, with only two subtypes 
being concurrent with genital and oral infections, and both genders; HPV-39 and HPV-42 
(Kiwerska et al., 2019). The most recently developed nine-valent HPV vaccination does not 
protect against HPV-39 (classified as high-risk) and HPV-42 (classified as low-risk) so it is 
also important to consider what HR-HPV subtypes are presenting in the mouth, in amongst 
lifestyle factors, including vaccination status. 
 
1.5 Oral HPV & Risk Factors 
As the development of OPSCCs has been found to be strongly linked with oral HPV, it is 
important to explore if there are any lifestyle risk behaviours have been linked to oral 
contraction of HPV, and development of malignant tumours. Studies have shown smoking 
(Bruni et al., 2017: Szyfter et al., 2019), heavy alcohol consumption (Kawakita & Matsuo, 
2017; Bumrungthai et al., 2019), sexual practice (King et al., 2015; Drago et al., 2016), drug 
use (Ribeiro et al., 2019), and co-infection with other viruses (Vergori et al., 2018) to be linked 
to oral HPV and OPSCC development but, alike prevalence rates, there is much disparity across 
the HPV field. 
Firstly, cigarette smoking has frequently been shown to be a main risk factors for malignant 
transformation of oral tissues (Dalla Torre et al., 2015), and has therefore also been associated 
with oral HPV prevalence and other risk factors (Rosen et al., 2016; Shigeishi & Sugiyama, 
2016; Steinau et al., 2017; Chandrupatla, Khalid & Tavares, 2019). Studies investigating oral 
HPV prevalence and smoker status have found those with an HPV positive oral infection have 
an increased are more likely to be current and former cigarette smokers (Knight et al., 2016; 
Shigeishi & Sugiyama, 2016; Steinau et al., 2017). Other studies have found no association or 
have been limited by smoker numbers (Lupato et al., 2017), as previously explained, there has 
been a significant reduction in young adult smokers in the past ~10 years due to successful 
“stop smoking” campaigns and oral health awareness (ASH, 2016; Jung et al., 2017).  
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Other studies have also investigated if smoking amount via cigarettes per day correlates with 
oral HPV and found heavy smoking to be associated with prevalence in healthy individuals 
(Gillison et al., 2012a; Farsi et al., 2017). One study oral HPV infection was highest amongst 
those who smoked more than 20 cigarettes daily (Sonawane et al., 2017). Fakhry, Gillison & 
D’Souza (2014) also investigated HR-HPV prevalence and smoking amount and found HPV-
16 linked to smoking a higher number of cigarettes per day than other HR-HPV types. It has 
been previously suggested that heavy smokers are more likely to engage in other riskier 
activities that may result in the contraction of HR-HPV, this however was in relation to genital 
HPV so more research is required for ratification with oral infections (Tanton et al., 2015). 
Furthermore, heavy drinking has also been linked to HNSCCs and OPSCCs due to frequent 
oral mucosa damage (Reidy, McHugh & Stassen, 2011; Kawakita & Matsuo, 2017). Unlike 
smoking, however, oral HPV prevalence has been frequently associated with alcohol 
consumption in those that engage in unsafe and/or dangerous level of drinking (Ortiz et al., 
2014), and therefore, studies investigating oral HPV prevalence and alcohol consumption have 
found varying rates in current drinkers (Rosen et al., 2016).  
Frequent drinking has been linked to oral HPV prevalence (Golusinski, 2017), but more often 
within individuals with pre-malignant or malignant oral lesions than healthy individuals to 
determine disease progression (Reidy, McHugh & Stassen, 2011; Kariche et al., 2018). Studies 
that have linked oral HPV prevalence in healthy young adult populations to frequent drinking 
have, instead, been investigating the effect of risk-taking behaviours whilst under the influence 
of alcohol (D'Souza & Dempsey, 2011). Research has shown that frequent (heavy) drinkers are 
more likely to take sexual risks (such as omitting barrier contraception) whilst under the 
influence of large quantities of alcohol (Vagenas et al., 2013), which can lead to oral HPV 
transmission (D'Souza & Dempsey, 2011). Binge drinking, similar to drinking frequency, has 
also been linked to higher oral and genital HPV prevalence rates due to risk-taking behaviour 
(Tanton et al., 2015; Mainous et al., 2020). Examples recently theorised to be associated with 
oral HPV include sexual risks (D'Souza & Dempsey, 2011), poor hygiene and hand washing 
practices when using public toilets (Abulizi et al., 2017; Wong et al., 2020), and drug use (Ortiz 
et al., 2014; Ribeiro et al., 2019). Research has also shown that individuals often do not know 
how many units they consume per sitting (Buykx et al., 2018), which is exacerbated whilst 
already under the influence of alcohol, leading to further dangerous levels of drinking and risk-
taking behaviour (Hingson & Zha, 2009).  
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Heavy drinking, in association with STI/STD contraction, has frequently being shown and/or 
studies in young adult populations (Jakopanec et al., 2010; Golusinski, 2017). Recent statistics 
have also shown that heavy drinking rates in young adult populations has been declining in 
recent years (Fat, Shelton & Cable, 2018). This is important as heavy alcohol consumption, 
linked to sexual risk-taking, such as increased sexual activity and associated risks like omitting 
barrier contraception and increased one-night stand frequency (Vagenas et al., 2013), may have 
reduced as well. Due to the changes in young adult drinking behaviour, it is important to 
reassess what we know about risk factors in relation to not only genital HPV, but also oral HPV 
and how they link to HPV positive OPSCC development. 
Furthermore, alike genital HPV, oral HPV also been linked to sexual practice. Traditionally, 
the contraction of HPV has had a strong correlation with individuals that have multiple 
numbers of sexual partners, frequent sexual intercourse whilst infrequently using barrier 
contraception (Mercer et al., 2013; Tanton et al., 2015). The HPV field has yet to fully explore 
this within the general population for oral HPV. Recent studies have instead linked oral HPV 
to open-mouth kissing as a transmission route due to the ability of saliva to carry HPV particles 
(Pickard et al., 2012), whilst others have suggested oral sex may increase risk (D’Souza et al., 
2014; Giuliano et al., 2015; Knight et al., 2016). As a result, many studies have started to 
investigate if HPV can be transmitted during oral-genital activity (Giuliano et al., 2015). Some 
investigations have linked cunnilingus to oral prevalence, and subsequently reported higher 
oral HPV rates in males (Sánchez-Vargas et al., 2010; D'Souza et al., 2016), and lesbian 
couples (Bartzatt, 2014), whilst others have only linked fellatio to oral HPV status (Sánchez-
Vargas et al., 2010), resulting in higher oral HPV rates in females and men who have sex with 
men (MSM) (Oliver et al., 2018). Recent investigations into the prevalence of oral HPV in the 
healthy populations have also shown that smoking and drinking alcohol combined with oral 
sex engagement, in particular, may increase the frequency of oral HR-HPV infections such as 
HPV-16 (Chaturvedi et al., 2013; D’Souza et al., 2014; Knight et al., 2016). 
Studies conducted on adult males attending sexual health clinics were also found to have higher 
oral HPV prevalence rates than the general populations (and female only populations); 37% 
were found to be HPV positive in Italy (Drago et al., 2016), whilst 13.7% were found in London 
in the UK (King et al., 2015). Both these studies indicated that sexual health may play a role 
in increasing the transmission of oral HPV, and therefore, sexual practice should also be 
considered as a risk factor for OPSCC development and oral HPV contraction.  
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Interestingly, there has been many studies conducted on sexual risk taking in young adults 
going abroad on holiday linking practices to STI/STD status (Sundbeck et al., 2016; Sundbeck, 
Agardh & Östergren, 2017), but very little has been conducted into oral HPV. Considering the 
large differences in global prevalence rates depending on geographical location, further 
investigations into young adult population recent travel history and sexual activity whilst 
abroad could be beneficial. This will allow for the determine if those engaging in sexual 
activities in countries with higher oral HPV rates to explore if this has an effect on young adult 
prevalence rates in the UK. 
 
1.6 HPV Vaccination 
In attempt to reduce the risk of developing cervical cancer caused by an acquired HPV 
infection, a bivalent vaccination programme was introduced in the UK in 2008 for 12–13-year-
old females, known as Cervarix™, produced by GlaxoSmithKline (Hilton et al., 2010; Mesher 
et al., 2013; Herrero et al., 2015; Canvin et al., 2016). This vaccination only protected 
individuals from the two most common HR-HPV subtypes, HPV-16, and HPV-18. Because of 
this, a quadrivalent vaccination known as Gardasil-4 produced by Merck replaced Cervarix™ 
in 2012 providing additional protection for the two most common LR-HPV subtypes, HPV-6, 
and HPV-11, thus protecting individuals against benign genital warts as well as genital cancers 
(Department of Health & Social Care, 2011; Herrero et al., 2015). Since, a nine-valent 
vaccination was developed and licenced in 2014 known as Gardasil-9 which protects 
individuals from a further five HR-HPV subtypes; HPV-31, HPV-33, HPV-45, HPV-52, and 
HPV-58, alongside HPV-16 and HPV-18, and LR-HPV subtypes HPV6 and HPV11 (Simms 
et al., 2016). However, this nine-valent vaccination is only available on request from GPs and 
from some private independent companies such as Superdrug and Boots UK (Francis et al., 
2010; Royal Pharmaceutical Society, 2017).  
In 2018, the Joint Committee on Vaccination and Immunisation (JCVI) recommended the 
quadrivalent HPV vaccination should also be offered to UK boys aged 12-13 years old in 
schools, alongside girls, from September 2019 (JCVI, 2018; Jo’s Cervical Cancer Trust, 2020). 
The decision to offer gender-neutral vaccination was based on several factors. Firstly, herd 
immunity was not as successful as first thought due anal and penile cancer rates in men that 
have sex with men (MSM) increasing (Stanley, 2014; JCVI, 2018). Secondly, the JCVI 
acknowledged national and international data demonstrating an increase of HPV-positive non-
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cervical cancers, such as OPSCCs. Other factors involved public opinion and push for 
vaccination equality across the whole UK population, reducing short-term fluctuations in 
uptake, improved cost-effectiveness, improved control of HR-HPVs in the population, and 
optimal protection in MSM in the long term (JCVI, 2018). 
Following the introduction of the UK HPV vaccination programme, there has been a reduction 
in HPV-16 and HPV-18 infections has been found in vulva-vaginal samples from young 
women aged 16–24 years (Mesher et al., 2013). The programme has also been shown to have 
produced a decline in genital warts diagnoses among young women and young men in the UK 
(Canvin et al., 2016). As discussed previously, the vaccination seems to have been successful 
in reducing HPV genital cases, but little is known about other anatomical sites associated with 
HPV infections, including the oral cavity. 
One study by Schlecht et al., (2019) revealed that females aged between 13-21 years old that 
had received one or more doses of the quadrivalent vaccination exhibited a lower prevalence 
of HPV-16 compared to unvaccinated females. This however does not measure the effect in 
the original population that first received the HPV vaccination. Another study, conducted in 
Columbian schools, reported an oral HPV prevalence of 0.7% in vaccinated girls, 3.2% in 
unvaccinated girls and 2.3% in unvaccinated boys, stating there had been a 72% reduction in 
HPV-16 detection in students that had been immunized (Castillo et al., 2019). However, only 
42% of the boys, 36.6% of vaccinated girls and 36.8% of unvaccinated girls stated they were 
sexually active so this does not reflect the general population and the students were unlikely to 
have come in contact with HPV, genitally or orally pre- and post-vaccination. As a result, many 
current studies seem to be screening adolescent participants to determine the effect of the HPV 
vaccination on oral infections but screening participants that have only just been vaccinated 
and that are likely to have biased sexually inactive cohort. This also suggests that sexual activity 
shown to be risk factors like oral sex cannot be compared, further indicating that these studies 
do not provide an accurate representation of the prevalence of oral HPV in the general 
population, nor an accurate measure the effect of the vaccination. Further research is required 




Page | 19  
 
1.7 Current HPV Screening Methods 
Oral HPV prevalence rates have been shown to vary locally in the UK and globally based on 
geographical location and population being sampled. This is largely thought to be as a result 
of varying sample collection methods for oral regions (Ong et al., 2014). Sample collection 
methods include rinse and gargle, swabs, sponges, biopsies, and cytology brush sampling. 
Biopsies and cytology brush sampling have been shown to yield higher cell numbers but are 
invasive and not suitable for large screening studies (Marques et al., 2015; Chikandiwa et al., 
2018). Rinse and gargle, swabs, and sponges, on the other hand, yield smaller cell numbers but 
are less invasive, can be self-administered, and are suitable for large screening studies. Further 
fluctuations in oral HPV prevalence are caused by sample locality. Rinse and gargle methods 
allow for collection of cells from the entire oral cavity; oropharyngeal and buccal alike. 
Whereas swabs and sponges target specific areas of the oral cavity for more targeted screening, 
which can either increase or inhibit detection depending on HPV infection locality. 
Furthermore, screening methods used to determine the presence and abundance of oral HPV 
also need consideration as they vary greatly in terms of sensitivity, reproducibly, sample type 
and concentration screened, and cost (Gipson et al., 2018). These factors may explain the 
fluctuations in the current screening results and lead to significant over- and under-estimations 
of oral HPV prevalence in the population being tested. 
In recent years, real-time quantitative polymerase chain reaction (qPCR) technology has 
become increasingly popular amongst virologists, especially in the oral field, due to the 
application of two useful quantitative techniques. The first, absolute quantification, is capable 
of detecting and measuring viral copy numbers within human DNA (Hall Sedlak & Jerome, 
2014), whilst the second, relative quantification, is used for determining the effect of viral 
genes on host regulatory genes, determining the changes in expression levels (Levan et al., 
2017). The sensitivity of these techniques allows for low level viral infections to be determined 
from cell samples with low concentrations, dependent on the manufacturers of the thermocycler 
being used for screening (ThermoFisher, 2014; ThermoFisher, 2016). Most real-time qPCR 
thermocyclers can detect gene copy numbers as small as present as 1-10 copies per loaded 
sample, indicating that screening would still be successful in individuals with low level 
infections of oral HPV. In comparison to traditional end point PCR, which could be considered 
a qualitative method of gene detection, this is far superior, cost-effective and highly sensitive.  
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Other viral research on HIV has also found real-time qPCR absolute quantification methods 
useful for determining the presence of HIV viral infections in comparison to the previously 
used method which was screening for antibodies (Ouédraogo, 2015). This was a significant 
development as the earliest detection possible beforehand, with antibody tests, was weeks after 
contraction (Loche & Mach, 1988). The sensitivity of real-time qPCR allowed for a standard 
curve methodology to be developed that could detect viral genome copy numbers as small as 
1 copy per cell immediately after infection (Wang et al., 2010). Similar research has been 
conducted in the HPV field, but studies are increasingly using readily available commercial 
kits for the detection of HPV in preference over establishing “home-made” assays, custom 
designed for purpose (Rosen et al., 2016; Hirth et al., 2017; Lupato et al., 2017). 
One such example used for detecting HPV DNA within samples is the Roche Linear Array® 
HPV Genotyping Test which is considered the “gold-standard” method due exhibiting a higher 
accuracy for genotyping amongst other commercially available kits (Viveka et al., 2017). This 
is a Line Probe assay which is more advance than a Reverse Line Blot test and is based on real-
time PCR and DNA sequencing. The Roche Linear Array® HPV Genotyping Test allows for 
the detection of 37 HPV genotypes, including 17 HR-HPV subtypes and 15 LR-HPV subtypes 
(Low et al., 2015). There are advantages to using this kit including, being able to determine 
co-infectivity of HPV types, being relatively straight-forward to retrieve results, and being able 
to use small concentrations of PCR products for blotting, allowing for many replicates, 
increasing reliability (Low et al., 2015). However, there are many disadvantages too including, 
timing to retrieve results, cost (especially if the kit is being used in screening a large population 
for oral HPV) (Viveka et al., 2017), and sensitivity of detection. Research has shown that 
samples with small HPV viral loads from low level infections cannot be detected unless type-
specific or multiplexing real-time qPCR methods are used (Roberts et al., 2011). Therefore, 
Roche Linear Array® HPV Genotyping Test cannot be used to quantify viral load in low level 
infections so most studies use this technique to detect HPV within transformed tumour tissue 
with proliferating HPV infections. This indicates that commercial kits, therefore, may be 
unsuitable for detecting less abundant oral HPV infections in healthy individuals, and that the 
gDNA used for screening may need to be of a high quality, which again, may not be possible 
to obtain from the oral cavity (Roberts et al., 2011). 
There are also alternative Line Probe assay kits similar to the Roche Linear Array® HPV 
Genotyping Test such as the Hybribio HPV GenoArray® kit which can detect 21 HPV 
genotypes, including 13 HR-HPV subtypes and 6 LR-HPV subtypes ((Low et al., 2015). This 
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kit is cheaper and less time-consuming to obtain the final results than Roche Linear Array® 
HPV Genotyping Test but does not allow for the detection of the same broad range of HPV 
genotypes. Some studies have also shown it to be less sensitive than the Roche Linear Array® 
HPV Genotyping Test, which therefore would result in an even larger difference in prevalence 
rates from screening with real-time qPCR. A study conducted by Low et al., (2015) used both 
the Roche Linear Array® HPV Genotyping Test and Hybribio HPV GenoArray® kit and found 
that across the 19 genotypes (detection shared across both kits), 14 genotypes were detected 
more frequently by the Roche Linear Array® HPV Genotyping Test than the Hybribio HPV 
GenoArray® kit.  
In terms of distinguishing between multiple HPV genotypes and co-infections, multiplexing 
via real-time qPCR appears to be more sensitive than Reverse Line Blot tests and Line Probe 
assays (Sun et al., 2015; Clifford et al., 2016). But multiplexing kits using real-time qPCR does 
not always allow for quantification, particularly if the same fluorophore has been tagged to 
multiple HPV types. This would allow for identification of the group of subtypes present in an 
sample but not for identification of the specific HPV subtype, and therefore, accurate 
quantification of viral load; only real-time qPCR type-specific absolute quantification assays 
have shown this ability (Seaman et al., 2010). 
Other less popular techniques for oral HPV screening include, in-situ hybridisation (ISH)-
based testing (Singhi & Westra, 2010), RNAscope DNA sequencing-based HPV genotyping 
(Mirghani et al., 2016), traditional end-point nested PCR followed by Sanger sequencing or 
DNA sequencing (either Next Generation Sequencing [NGS] or Whole Genome Sequencing 
[WGS]) (Samman et al., 2014), mate-pair sequencing (Gao et al., 2014), and HPV genotyping 
via SPF10 PCR‐DEIA‐LiPA25 system (Auguste et al., 2017). Similarly to using biopsies for 
sample collection in healthy populations, screening methods such as ISH and 
immunohistochemistry (IHC) are equally only suitable for HPV detection in tissue due to 
requiring large sample sizes. HPV genotyping methods, on the other hand, can use smaller 
samples sizes but are less specific in HPV detection so need to be combined with NGS or WGS. 
Overall, this extensive list of methods demonstrates the volume and array of screening methods 
available to use for HPV screening, indicating that not only does population demographics and 
lifestyle risk behaviours vary prevalence rates but sample type and screening tests may also be 
responsible. 
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Overall, research has shown that real-time qPCR appears to be the most sensitive and suitable 
method for oral HPV screening due to being able to establish prevalence, viral load in low-
high level infections, co-infectivity and only requiring a small sample volume for testing. 
 
1.7.1 Principles of Real-time qPCR Technology 
The basic principle of PCR is to amplify a single copy of a sequence of DNA or section of a 
gene (known as an amplicon) through temperature cycling to produce thousands of copies of 
the required sequence (Newton et al., 1997). Thermocycling stages include denaturation at 
~95°C, primer annealing (varying temperatures dependent on assay), and extension at ~72°C. 
For successful PCR, specific primers are required for the amplicon being targeted and DNA 
polymerase must be present in the mastermix along with DNA nucleotide bases and reaction 
buffers (Newton et al., 1997). In traditional end-point PCR, the presence of DNA amplification 
is detected by gel electrophoresis and immunofluorescence (with UV) after the PCR cycling 
has finished. Real-time qPCR, instead, detects the presence of DNA through reporter dye 
fluorescence throughout the thermocycling in “real-time” as amplification occurs (Arya et al., 
2014). In order to distinguish high or low levels of amplification, and therefore, high or low 
amplicon copy number, end-point PCR uses a qualitative visualisation method of level of band 
fluorescence present per sample, whilst qPCR enables the determination of the exact copy 
number concentration (relative or absolute) of the amplicon present in the reaction (Applied 
Biosystems, 2012).  
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Figure 4. Example Real-time qPCR Amplification Plot. Each cyclic stage as it should appear in non-
inhibited DNA amplification. Exponential amplification shown via Rn (fluorescence signal) per 
amplification cycle (Cq) until sample saturation occurs, represented by the plateauing effect; a) linear 
view, b) LOG view. LOG inverts the exponential phase within the linear view to more easily visualise 
sample amplification and calculate copy number (ThermoFisher, 2014). 
 
For quantification, fluorescent dyes are present within reaction mastermixes (such as SYBR 
Green) which produce signals that can be monitored throughout the thermocycling (Nygard et 
al., 2007). The amount of fluorescence released during amplification is directly proportional to 
the amount of amplified DNA (ThermoFisher Scientific, 2016). This means that the higher the 
initial number of DNA copies that are present within the sample being tested, the quicker the 
fluorescence will be detected, indicating the presence of a higher original copy number (Nygard 
et al., 2007). Real-time qPCR amplification is detected through exponential phases of 
fluorescence dye being released as doubling of the product (amplicon) occurs every cycle. A 
pre-determined threshold is used to produce a Quantification Cycle (Cq) value when the 
exponential amplification fluorescent signals crosses over. Cq values, therefore, increase as the 
DNA amplicon copy number decreases (Bunce et al., 2012). The exponential amplification 
then plateaus out for the remainder of the cycling which is caused by all of the reagents being 
used up within the reaction (Figure 4). At this stage, the amplification becomes “saturated” 
with excess products (Bustin, 2010) so no longer produces a signal.  
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Figure 5. Example Copy Number Standard Curve. Cq vs LOG copy number curve using 8 known 
standards (10-fold dilutions) to reveal expected slope, R2 value and efficiency (%) (Bio-Rad, 2013). 
 
For absolute quantification, the Cq values recorded during amplification can be used to create 
a standard curve (Cq vs LOG copy number) of serially diluted stocks of positive DNA for the 
amplicon in question, each containing known a copy number of the desired target (Lee et al., 
2006) (Figure 5). This standard curve can be used to determine the absolute copy number of 
the desired target within a positive unknown sample (Applied Biosystems, 2012), providing 
the reaction efficiency is 100% ±10%, the R2 (correlation coefficient) value is >0.99 ±0.1, the 
standard deviation from the mean of the Cq difference between standard replicates is <0.169 
±0.1 and the graph slope value (m in y=mx+c) is -3.32 ±10% (ThermoFisher Scientific, 2014; 
ThermoFisher Scientific, 2016). This makes this method suitable for screening samples for 
viral targets as well as quantifying viral load for determination of severity of infection. It is 
important to note that if any of the measurements of efficiency, accuracy or precision (known 
as Accuracy Indicators) are outside of the acceptable range, then the standard curve cannot be 
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1.8 Project Aim & Objectives 
The aim of the study was to establish oral HPV prevalence and abundance within the UK young 
adult population and to determine if either were influenced by demographics, HPV type, 
vaccination status, and lifestyle choices of an individual. The objectives of the research project 
were as follows;  
 To collect mucosal epithelial cell samples from the oral cavity of clinically healthy 
young adults recruited at University of Derby, to determine prevalence of HPV 
infection within the clinically healthy population. 
 To obtain questionnaire data from the cohort during sample collection for information 
on lifestyle choices, demographics and vaccination status to establish cohort risk factors 
for contraction of oral HPV and OPSCC development. 
 To establish and optimise a novel and reproducible real-time PCR methodology using 
consensus primers for the screening of oral samples for multiple types of HPV to detect 
viral DNA presence. 
 To establish a real-time PCR house-keeping gene method for use in screening oral 
samples for beta-actin as a reference gene for DNA viability and use as a copy number 
control to calculate cell number from downstream HPV quantification assays. 
 To establish and optimise real-time qPCR methodologies using type-specific HPV 
DNA primers to enable the detection and quantification of HPV-6, HPV-11, HPV-16 
and HPV-18 viral DNA within the oral samples via absolute quantification. 
 To compare oral HPV prevalence rates in the study cohort with questionnaire data on 
lifestyle risk factors for the contraction of HPV and OPSCC development, to determine 
if smoking, alcohol consumption and sexual practice influences HPV status. 
 To compare oral HPV abundance in the study cohort with questionnaire data on lifestyle 
risk factors for the contraction of HPV and OPSCC development, to determine if 
smoking, alcohol consumption and sexual practice influences HPV viral load. 
 To compare oral HPV prevalence, abundance and type in the vaccinated and 











 HeLa (ATCC® CCL-2™) Cells [American Type Culture Collection; ATCC] 
 SiHa (ATCC® HTB-35™) Cells [American Type Culture Collection; ATCC] 
 Ltk-11 (ATCC® CRL-10422™) Cells [American Type Culture Collection; ATCC] 
 A549 (ATCC® CCL-185™) Cells [American Type Culture Collection; ATCC] 
 MCF7 (ATCC® HTB-22™) Cells [American Type Culture Collection; ATCC] 
 White-clawed Crayfish (CR) (Austropotamobius pallipes) gDNA (non-manufactured) 
 Dulbecco's Modified Eagle Medium (DMEM) [ThermoFisher Scientific – 11885-084] 
 Fetal Bovine Serum (FBS), E.U.-approved [ThermoFisher Scientific – 10270-106] 
 Penicillin-Streptomycin (10,000 U/mL) [ThermoFisher Scientific – 15140122] 
 L-Glutamine (200 mM) [ThermoFisher Scientific – 25030081] 
 Trypsin-EDTA (0.25%), phenol red [ThermoFisher Scientific – 25200056] 
 Sub-cloning Efficiency™ DH5α™ Competent E.coli [Invitrogen – 18265-017] 
 Ampicillin (100mg/mL) [Sigma-Aldrich – A5354] 
 Disposable Sterile Petri Dishes [Sigma-Aldrich – SIAL506CC0CRNV] 
 UltraPure™ DNase/RNase-free ddH2O [Invitrogen – 11538646] 
 HiSpeed® Plasmid Maxi Kit [Qiagen – 12662] 
 DNeasy Blood & Tissue Extraction Kit [Qiagen – 69506]  
 BrightWhite qPCR 96-well Plates for ABI FAST Machines and StepOnePlus™ 
[Primerdesign Ltd – BW-FAST] 
 8-Strip Cap Seals for BrightWhite 96-well Plates [Primerdesign Ltd – BW-8STRIP] 
 PrecisionFAST qPCR Master Mix [Primerdesign Ltd – PFAST-machine type-20ML] 
 PrecisionFAST qPCR Master Mix with SYBR Green [Primerdesign Ltd – PFAST-R-
SY-10ML] 
 SensiFAST™ SYBR® Hi-ROX Kit [Bioline – BIO-92005] (Chapter 3) 
 Human double dye probe-based reference gene detection kit [ACTB] [Primerdesign Ltd 
– HK-DD-hu-600] 
 Custom-designed Real-time PCR Assays (Other Species) Primer and Double-dye 
(Taqman-style) Kit for HPV6, E6/E7 [Primerdesign Ltd – DD-any-600] 
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 Custom-designed Real-time PCR Assays (Other Species) Primer and Double-dye 
(Taqman-style) Kit for HPV11, E6/E7 [Primerdesign Ltd – DD-any-600] 
 GelRed™ Nucleic Acid Gel Stain [10,000X in DMSO] [Biotium – 41002] 
 DirectLoad™ PCR 100bp Low Ladder [Sigma-Aldrich – D3687] 
 HyperLadder™ 25bp [Bioline – BIO-33031] 
 DNA Loading Buffer [Sigma-Aldrich – G2526] 
 GP5/GP6+ Primers & Oligonucleotide Synthesis Report (de Roda Husman et al., 1995) 
[Eurofins Genomic – APPENDIX E, Figure 54] 
 MY09/MY11 Primers & Oligonucleotide Synthesis Report (Husnjak et al., 2000) 
[Eurofins Genomic – APPENDIX E, Figure 55] 
 HPV-16 (Moberg et al., 2003) & HPV-18 E7 (Gravitt et al., 2003) Primers & 
Oligonucleotide Synthesis Report [Eurofins Genomic – APPENDIX E, Figure 56] 
 HPV-6b E6/E7 Primer Data Sheet [Primerdesign Ltd – APPENDIX E, Figure 57] 
 HPV-11 E6/E7 Primer Data Sheet [Primerdesign Ltd – APPENDIX E, Figure 58] 
 pBRHPV-6b (-6) Plasmid (Karolinska Institutet) & Map [APPENDIX D, Figure 49] 
 pBRHPV-11 (-11) Plasmid (Karolinska Institutet) & Map [APPENDIX D, Figure 50] 
 pBRHPV-16 (-16) Plasmid (Collins et al., 2009) & Map [APPENDIX D, Figure 51] 
 pGEMII18-WT (-18) Plasmid (Collins et al., 2009) & Map [APPENDIX D, Figure 52] 
 
2.2 Equipment & Software 
 Captair®flow 321Class II laminar flow hood [Erlab] 
 AB® StepOnePlus™ Real-Time PCR System & Software [ThermoFisher Scientific] 
 NanoDrop 2000 & Software [ThermoFisher Scientific] 
 ChemiDoc XRS+ System & Software [Bio-Rad] 
 Primer-BLAST tool (uses Primer3 & BLAST software) (Ye et al., 2012) [NCBI] 
 Beacon Designer™ Free Edition Online qPCR Design Tool [PremierBiosoft] 
 uMeltSM Online Software v2.0.2 (Dwight, Palais & Wittwer, 2011) [Wittwer Lab] 
 IBM SPSS Statistics v26 [IBM Corp] (Chapter 5) 
 Microsoft 365 Packages; Excel & Word [Microsoft] (Chapter 3 & 5) 
 
 





The first aim of the study was to establish a reproducible and sensitive HPV consensus screen 
for the detection of multiple HPV types in samples taken from the oral cavity of healthy 
individuals. This chapter describes the establishment and optimisation of this screening 
methodology, enabling the detection of HPV for establishment of oral prevalence within a UK-
based young adult healthy population. From this, oral HPV prevalence can be compared to 
participant demographics and lifestyle choices associated with risk factors for OPSCC 
development and HPV contraction. All materials used for this methodology establishment are 
detailed in Chapter 2. 
 
3.1 Sample Collection 
The first methodological aspect to be determined was sample type. In order to assess the most 
appropriate sample type for oral screening, a pilot test was conducted using samples collected 
via foam-applicators swabs (SW) and oral rinses (OR) from 22 healthy student volunteers. For 
the SW samples, volunteers were asked to gently brush the inside of both cheeks with the foam-
tipped applicators whilst repeatedly turning the applicator 360° in a clockwise motion for 
approximately 20-30 seconds. For the OR samples, volunteers were asked to take in 10 mL of 
sterile ddH2O from a sterile tube and rinse the inside of their mouths for 20-30 seconds before 
expelling back into the sterile tube. DNA was extracted from all samples using a DNeasy Blood 
& Tissue Extraction Kit [Qiagen] for comparison of DNA yield and purity using NanoDrop 
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Table 1. Pilot Sample Collection Comparison. DNA concentrations (ng/µL) from NanoDrop 2000 
software [ThermoFisher Scientific] and sample purities recorded via the 260:280 ratio and 260:230 ratio 
(n=22), with values of ~1.8 and between >1.5 denoting purity, respectively (O'neill et al., 2011). 
 
SW = foam-applicator swab sample; OR = oral rinse sample. 
 
The SW sample collection method produced a higher average DNA concentration and purity 
ratios than the OR sample collection (Table 1). This was thought to be due to the direct brushing 
of layers of mucosal epithelium, collecting a higher number of cells for DNA extraction. Using 
SW samples would also allow for localised screening whilst OR samples do not, which is 
important as HPV has been shown to infect different sites in the oral cavity (Sindrewicz et al., 
2020). As such, the decision was made to move forward collecting foam-applicator swab 
samples from participants for screening within the study. 
 
3.2 Development of HPV Consensus Screening Method  
In order to develop an HPV consensus screening assay for detecting multiple HPV types in 
samples taken from the oral cavity, which would compete with commercial assays, there were 
many factors that required consideration. The screening method needed to; 1) allow for 
screening of HPV viral DNA, 2) reliably detect a broad range of HPV types, 3) be sensitive 
enough to detect HPV in oral samples with low DNA concentrations, 4) give an estimate of 
HPV abundance as well as prevalence, 5) be more cost-effective than kit-based assays, and 6) 
be reproducible and novel. To ensure all of these objectives were met, every stage of the 
screening assay was meticulously designed and optimised using HPV positive plasmids (HPV-
16 and HPV-18) and control samples that were positive (HeLa and SiHa gDNA) and negative 
(MCF7, A549, Ltk-11 and White-clawed Crayfish (CR) [Austropotamobius pallipes] gDNA) 
for HPV (further details are provided in Section 4.3, Chapter 4). 
As discussed in the introduction, real-time PCR has frequently been used for viral screening as 
it allows for the detection and amplification of a desired target amplicon which can be 
visualised in “real-time” (Applied Biosystems, 2012). End-point PCR, on the other hand, can 
only be used in conjunction with a secondary visualisation technique of gel electrophoresis to 
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measure the estimated size (bp) of the amplified product, and only at the final phase (plateau 
phase or “end-point”) of the PCR reaction (Schmittgen et al., 2000). Real-time PCR is therefore 
faster, allows for immediate determination of amplicon presence, and allows for a dissociation 
(melt) curve to be added to the end of cycling to determine the number of amplified products 
present (Bookout et al., 2006). This dissociation (melt) curve can either be used instead of gel 
electrophoresis visualisation or used in conjunction to confirm the presence of the desired target 
amplicon (Sharma & Dasgupta, 2012).  
However, traditional HPV screening methods have previously been developed using end-point 
PCR, including consensus primers which detect a broad range of HPV types. Consensus primer 
screening have traditionally been avoided in real-time PCR due to high levels of self-annealing 
(primer dimerisation) which can affect amplification signals (Bookout et al., 2006), but Seo et 
al., (2016) has previously shown it to work for GPM7 consensus primers. Therefore, a 
combination approach of both methods was theorised to meet all six previously set out 
objectives for assay development. However, this required many stages of optimisation as 
combining a real-time PCR assay with end-point PCR primers and visualisation techniques had 
not been described previously in the oral HPV field. 
 
3.2.1 HPV Consensus Primers 
The HPV consensus primer set chosen for the assay needed to detect a broad range of HPV 
types due to the large type variance being found in oral samples, but also maintain good 
specificity to the four HPV subtypes targeted by the quadrivalent vaccination (Gardasil-4), 
HPV-6, HPV-11, HPV-16 and HPV-18, to align to the study objectives. Therefore, the two 
most used HPV consensus primer sets for HPV L1 (MY09/11 and GP5/GP6+) in previous HPV 
screening studies were compared via alignments for sequence mismatches to multiple HPV 
subtypes (de Roda Husman et al., 1995; Husnjak et al., 2000). Both primers sets were 
compared against 14 of the most common HPV subtypes, including HPV-6, HPV-11, HPV-16 
and HPV-18, via alignments for sequence mismatches to HPV subtype L1 sequences and 
between each other (Gravitt et al., 2000; Saini et al., 2009) (APPENDIX C, Table 32). 
Out of the 14 HPV subtype sequence alignments, the GP5/GP6+ primer set had a higher 
number of nucleotide mismatches than the MY09/11 primers due to lack of degenerative bases. 
GP5+ (forward primer) revealed 34 nucleotide mismatches in total and GP6+ (reverse primer) 
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revealed 31 nucleotide mismatches in total, whilst MY11 (forward primer) revealed 19 
nucleotide mismatches and MY09 (reverse primer) revealed 24 nucleotide mismatches. In 
comparison to each other, MY11 exhibited higher specificity to 9 subtypes, equal numbers of 
mismatches in 3 subtypes and less specificity to 2 subtypes in comparison to GP5+. MY09 
exhibited higher specificity to 7 subtypes, equal numbers of mismatches in 3 subtypes less 
specificity to 4 subtypes in comparison to GP6+. Overall, the alignments provided evidence to 
suggest that the MY09/11 primer set would be better suited for use in screening for multiple 
types of HPV than GP5/GP6+. The degenerative bases appeared to decrease the number of 
mismatches to the 14 HPV subtype L1 sequences but also increased non-specificity of the 
primer set. To confirm HPV amplification and determine level of non-specificity, both primer 
sets were subjected to preliminary real-time PCR screening. 
 
3.2.2 Preliminary Primer Testing 
To assess the level of non-specificity in the HPV consensus primer sets and determine which 
was the most suitable for real-time PCR HPV screening, preliminary testing was carried out 
using AB® StepOnePlus™ Real-Time PCR System [ThermoFisher Scientific]. BrightWhite 
qPCR 96-well Plates for ABI FAST Machines and StepOnePlus [Primerdesign Ltd] were used 
to run total of 7 HPV plasmid standards (HPV-16 or HPV-18), 1 no-template  control (NTC), 
1 positive controls (HeLa or SiHa gDNA), and 4 negative controls in triplicate (APPENDIX 
B, Figure 48). Each well of the plate allowed a total volume of 20 µL, which was made up of 
15 µL of real-time PCR mastermix (including primers) and 5 µL of template DNA or 
UltraPure™ DNase/RNase-free ddH2O.  
For this initial assay, the composition of the real-time PCR mastermix per well was as follows; 
10 µL of SensiFAST™ SYBR® Hi-ROX Kit [Bioline], according to manufacturer’s 
instructions, 0.8 µL of each primer, forward and reverse (400 nM), and 3.4 µL UltraPure™ 
DNase/RNase-free ddH2O. The 400 nM primer concentration was chosen as an average of a 
selection  previously used in end-point PCR HPV screening for both primer sets (Snijders et 
al., 1990; Qu et al., 1997; Gravitt et al., 2000; Haws et al., 2004; Evans et al., 2005; Venceslau 
et al., 2014; Erhart et al., 2016). Thermocycling conditions used for this assay were also chosen 
as a combination of approaches from previous studies and SensiFAST™ SYBR® Hi-ROX Kit 
[Bioline] manufacturer instructions. The cycling conditions were as follows; a hot start for 
enzyme activation at 95°C for 3 mins, followed by 45 cycles of denaturation at 95°C for 20 
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secs, annealing at 50°C for 30 secs, and extension at 72°C for 45 secs. Due to the use of SYBR 
Green as the fluorophore indicating dsDNA amplification, a dissociation (melt) curve followed 
amplification to determine number of PCR products present per sample, with the following 




Figure 6. GP5/GP6+ Initial Real-time PCR Screen. Data generated by AB® StepOnePlus™ Real-
Time PCR System and software using GP5/GP6+ primers and cycling conditions previously described 
in Section 3.2.2. A HPV18 plasmid 10-fold dilution series (1x106 copies/5µL to 1 copies/5µL) was run 
using HPV +ve and –ve controls [all 10 ng/5µL] to assess the reliability and efficiency of the L1 assay 
(n = 3). a) GP5/GP6+ Dissociation curve – Derivative reporter signal data (-Rn) per plasmid standard 
(3 replicates) vs temperature (°C). b) GP5/GP6+ Amplification Plot – Raw fluorescence signal data 
(ΔRn) per plasmid standard (3 replicates) vs cycle number and threshold (0.52 ΔRn). c) GP5/GP6+ 
1% Agarose Gel - Determining the number of amplification products present for each standard and 
NTC (left to right; 1x106 copies/5µL to 1x103 copies/5µL, NTC). Methods described in Section 4.7, 
Chapter 4. d) HPV-18 Copy Number Standard Curve –quantification cycle (Cq) values (3 replicates) 
and LOG copy number per HPV-18 plasmid standard (1x106 copies/5µL to 1 copies/5µL).  
 
The GP5/GP6+ initial real-time PCR screen confirmed the primer set would not be suitable for 
real-time PCR screening due to high levels of non-specific binding to products other than the 
HPV L1 target that was visible in the dissociation (melt) curve and corresponding gel (Figure 
6). The GP5/GP6+ primers were designed to amplify a ~150 bp product but the real-time PCR 
screen revealed three different products had amplified during thermocycling from the three 
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dissociation peaks with alternative melting temperatures (Tm) and corresponding different 
sized products (including ~150 bp target) visible via gel electrophoresis. The uneven 
amplification signals and variation in Cq values per replicate on the estimated copy number 




Figure 7. MY09/11 Initial Real-time PCR Screen. Data generated by AB® StepOnePlus™ Real-
Time PCR System and software using MY09/11 primers and cycling conditions previously described 
in Section 3.2.2. A HPV18 plasmid 10-fold dilution series (1x106 copies/5µL to 1 copies/5µL) was run 
using HPV +ve and –ve controls [all 10 ng/5µL] to assess the reliability and efficiency of the L1 assay 
(n = 3). a) MY09/11 Dissociation curve – Derivative reporter signal data (-Rn) per plasmid standard 
(3 replicates) vs temperature (°C). b) MY09/11 Amplification Plot – Raw fluorescence signal data 
(ΔRn) per plasmid standard (3 replicates) vs cycle number and threshold (0.52 ΔRn). c) MY09/11 1% 
Agarose Gel - Determining the number of amplification products present for each standard and NTC 
(left to right; 1x106 copies/5µL to 1x101 copies/5µL, NTC). Methods described in Section 4.7, Chapter 
4. d) HPV-18 Copy Number Standard Curve –quantification cycle (Cq) values (3 replicates) and 
LOG copy number per HPV-18 plasmid standard (1x106 copies/5µL to 1 copies/5µL).  
 
The MY09/11 initial real-time PCR screen confirmed the primer set, in comparison to the 
GP5/GP6+ primer set, would be suitable for real-time PCR screening due to a high level of 
specificity to the HPV L1 target (Figure 7). The MY09/11 primers were designed to amplify a 
~450 bp product of which was confirmed by one large dissociation peak with a Tm of ~83.5°C 
and corresponding correct sized products visible via gel electrophoresis. The amplification 
signals per standard and small variation in Cq values per replicate on the estimated copy 
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number curve also confirmed specificity to the ~450 bp product. There was, however, a large 
quantity of primer dimers present per standard tested, represented by the large dissociation 
peaks around ~65-75°C and products sized <100 bp on the gel. These primer dimers required 
reduction to ensure optimal amplification of target products (Sahdev et al., 2007). There was 
also some minor non-specific binding/unknown dissociation present on the melt curve with a 
Tm of ~90.5°C. This required further investigation to determine the cause and if it would affect 
optimisation of the primer set. 
Overall, the alignments and initial real-time PCR screening tests confirmed the MY09/11 
primers were more suited than GP5/GP6+ for HPV consensus screening using real-time PCR, 
so were chosen for assay development.  
 
3.3 MY09/11 Assay Optimisation 
Following the decision to use MY09/11 primers for HPV consensus screening using real-time 
PCR, the assay required optimisation to increase sensitivity of target detection and reaction 
efficiency. By doing so, the screen would be able to distinguish if samples originating from the 
oral cavity were HPV positive and estimate abundance of infection via comparison to known 
copy number plasmid standards. Due to the broad specificity of the primers, the amplified 
products produced during screening could not be quantified as the amplicon fluorescence 
signal, used to produce Cq values for copy number calculations (Chapter 4), could have been 
comprised of the doubling of other dsDNA products. Other products include multiple HPV 
targets due to coinfections of more than one HPV genotype in the samples, primer dimers due 
to the non-specificity of the degenerative bases in the MY09/11 primers, or non-specific 
binding of other non-HPV DNA sequences. Therefore, this assay was developed to only use as 
an indication of HPV prevalence in the oral cavity. 
The next step was to adapt the cycling conditions to suit real-time PCR conditions to reduce 
non-specific binding/unknown fluorescence and primer dimerisation, as evident in the melt 
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3.3.1 Adapting Cycling Conditions 
The AB® StepOnePlus™ Real-Time PCR System [ThermoFisher Scientific] allows for “fast” 
cycling which reduces enzyme activation time, cycle number, denaturation time, and 
annealing/extension periods. It has been shown that the larger the amplicon size, the longer the 
extension period is required (ThermoFisher Scientific, 2014), yet real-time PCR has seen the 
removal of this step via combination of annealing and extension periods for quicker reactions 
(ThermoFisher Scientific, 2016). The MY09/11 amplicon was ~450 bp so was larger than the 
recommended real-time PCR amplicon size of ~80-150 bp (Thornton & Basu, 2011), requiring 
an extension step. Yet, including long extension steps can also increase the chance of non-
specific binding so it was important to maintain a balance between optimising the conditions 
and the consensus primer set’s ability to anneal to the correct L1 target. Following the discovery 
of non-specific binding/unknown dissociation in the initial test screen of the MY09/11 primers, 
the decision was made to incrementally decrease the extension period by 10-15 secs from 45 
seconds until the final duration of 10 secs was selected.  
 
Table 2. Accuracy Indicators per Extension Time Change. Changes in reaction efficiency (%), mean 
Cq difference between 10-fold standards, and standard deviation (STDEV) between replicates for every 
incremental reduction in extension time (n = 3). Ideal mean Cq difference = ~3.32 cycles; ideal reaction 




For each decrease in extension time, the dissociation (melt) curve was examined to determine 
the effect on the non-specific binding peak/unknown dissociation. The decrease in extension 
time appeared to increase the reaction efficiency and reduce some of the primer dimerisation 
(Table 2) but had no effect on the dissociation Tm peak of ~90.5°C, so further investigations 
were necessary. These results also indicated that further assay adaptations were necessary as 
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the reaction efficiency for a 10 sec extension time was still outside of the “ideal” parameters of 
100% ± 10% (ThermoFisher Scientific, 2016). 
 
3.3.2 PCR Reaction Mastermix  
Following the optimisation of the extension time, it was theorised that the unknown 
dissociation peak, primer dimerisation and reaction efficiency could be improved by testing 
different commercial PCR mastermixes. Research has shown that efficiency of DNA 
polymerase enzymes found in mastermixes and buffer compositions effect real-time PCR 
efficiency and vary primer affinity with target sequences (Wolffs et al., 2004; Tesena et al., 
2017). As a result, a second commercially available mastermix, PrecisionFAST qPCR Master 
Mix with SYBR Green [Primerdesign Ltd], was purchased and tested in comparison to 
SensiFAST™ SYBR® Hi-ROX Kit [Bioline]. 
To help establish which mastermix produced the most efficient results, the voluntary SW 
samples were screened alongside plasmid DNA and the HPV positive and negative controls to 
represent screening participant samples following establishment. Samples taken from the oral 
cavity are widely recognised to be problematic for effective screening due to originating from 
an unstable environment with numerous impurities (Dziurkowska & Wesolowski, 2018). 
Therefore, it was important to consider the effect of assay changes on HPV detection in “real” 
samples for the remaining development steps. 
For this stage of the assay development, the composition of the real-time PCR mastermix per 
well was as follows; 10 µL of SensiFAST™ SYBR® Hi-ROX Kit [Bioline] or PrecisionFAST 
qPCR Master Mix with SYBR Green [Primerdesign Ltd], according to manufacturer’s 
instructions, 0.8 µL of each primer, forward and reverse (400 nM), and 3.4 µL UltraPure™ 
DNase/RNase-free ddH2O. The cycling conditions were as follows; a hot start for enzyme 
activation at 95°C for 3 mins, followed by 40 cycles of denaturation at 95°C for 20 secs, 
annealing at 50°C for 30 secs, and extension at 72°C for 10 secs. The number of cycles was 
reduced by 5 cycles as the initial screening indicated that samples would be unlikely to amplify 
>35 cycles using the NTC amplification signal (due to primer dimers) as a threshold. Due to 
the use of SYBR Green as the fluorophore indicating dsDNA amplification, a dissociation 
(melt) curve followed amplification to determine number of PCR products present per sample, 
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Figure 8. SensiFAST™ Bioline Mastermix Testing. Data generated by AB® StepOnePlus™ Real-
Time PCR System and software using MY09/11 primers and cycling conditions previously described 
in Section 3.3.2. A HPV18 plasmid 10-fold dilution series (S1-S7; 1x106 copies/5µL to 1 copies/5µL) 
was run using HPV +ve (S = SiHa – HPV-16 +ve) and –ve controls (CR = Crayfish; LC = A549 lung 
cells; LTK = Ltk-11 mouse cells) [all 10 ng/5µL] to assess the reliability and efficiency of the L1 assay, 
alongside an oral SW sample (P) (n = 3). a) Bioline Dissociation curve – Derivative reporter signal 
data (-Rn) per template (3 replicates) vs temperature (°C). b) Bioline 1% Agarose Gel - Determining 
the number of amplification products present for each template and NTC (left to right; 1x106 copies/5µL 
to 1x100 copies/5µL, NTC, P, LC, LTK, CR, S). Methods described in Section 4.7, Chapter 4. 
 
The SensiFAST™ Bioline mastermix was found to promote non-specificity of the MY09/11 
HPV consensus primer set in most of the genomic DNA positive and negative controls, evident 
from the multiple dissociation peaks in the dissociation (melt) curve and product bands on the 
1% agarose gel (Figure 8). It was likely that the MY09/11 primers were amplifying non-HPV 
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related DNA sequences in the control genomes. However, HPV was detected in the SiHa 
control (HPV-16 positive cell line), due to the presence of a ~450 bp DNA fragment, but the 
non-specific product peaks masked the template peak within the dissociation curve. This was 
deemed problematic as samples with HPV positive infections could be overlooked using the 
dissociation (melt) curve, and via gel electrophoresis, should the samples have HPV copy 
numbers lower than 1x103 copies/5µL. This was determined by 10-fold plasmid dilution series 
of known copy number standards (S1-S7) as they could not be visualised from 1x103 
copies/5µL or less. This would potentially further lead to HPV samples being falsely deemed 
negative, should the primer set have a higher affinity to an alternative sequence than the L1 
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Figure 9. PrecisionFAST Primerdesign Mastermix Testing. Data generated by AB® StepOnePlus™ 
Real-Time PCR System and software using MY09/11 primers and cycling conditions previously 
described in Section 3.3.2. A HPV18 plasmid 10-fold dilution series (S1-S7; 1x106 copies/5µL to 1 
copies/5µL) was run using HPV +ve (S = SiHa – HPV-16 +ve) and –ve controls (CR = Crayfish; LC = 
A549 lung cells; LTK = Ltk-11 mouse cells) [all 10 ng/5µL] to assess the reliability and efficiency of 
the L1 assay, alongside an oral SW sample (P) (n = 3). a) Primerdesign Dissociation curve – 
Derivative reporter signal data (-Rn) per template (3 replicates) vs temperature (°C). b) Primerdesign 
1% Agarose Gel - Determining the number of amplification products present for each template and 
NTC (left to right; 1x106 copies/5µL to 1x100 copies/5µL, NTC, P, LC, LTK, CR, S). Methods 
described in Section 4.7, Chapter 4. 
 
The PrecisionFAST Primerdesign Ltd mastermix, on the other hand, seemed to reduce 
MY09/11 non-specificity and increase reaction efficiency due to a reduction in non-specific 
binding and primer dimerisation, evident from the dissociation (melt) curve and 1% agarose 
gel (Figure 9). The controls (LC, LTK and SiHa gDNA) that exhibited multiple product peaks 
and DNA fragment bands within SensiFAST™ Bioline mastermix testing appeared 
significantly reduced with the PrecisionFAST Primerdesign Ltd mastermix. This would allow 
for more reliable sample determination during HPV consensus screening using the MY09/11 
primer set. However, the assay still required optimisation as there was high prevalence of 
primer dimers in all controls and plasmid standards, evident from the dissociation peaks around 
Page | 40  
 
~65-75°C and highly exposed products sized <100 bp on the gel. Using this data, the decision 
was made to use PrecisionFAST qPCR Master Mix with SYBR Green [Primerdesign Ltd] for 
screening. 
 
3.3.3 Adapting Primer Annealing Temperature  
The next stage of the method optimisation, in attempt to improve HPV specificity and reduce 
primer dimerisation, was to test the effect of changing the MY09/11 primer set annealing 
temperature on reaction efficiency and other indicators of real-time PCR accuracy. As 
described in the introduction, “ideal” accuracy indicator values can be used to assess how 
accurate a real-time PCR assay is for detection of the target amplicon and, if using absolute 
quantification, how well the known copy number standard curve can predict sample copy 
number of the target gene. Accuracy indicators include; the slope value (m in y=mx+c) of -
3.32 ± 10%, R2 (correlation coefficient) value of >0.99 ± 0.1, and reaction efficiency value of 
100% ± 10% (calculated by formula C in Section 4.9, Chapter 4) (ThermoFisher Scientific, 
2016). Mean difference in Cq between standards (~3.32 cycles for 10-fold dilutions) and 
standard deviation of replicates can also be used in conjunction.  
For this stage of the assay development, the composition of the real-time PCR mastermix per 
well was as follows; 10 µL of PrecisionFAST qPCR Master Mix with SYBR Green 
[Primerdesign Ltd], according to manufacturer’s instructions, 0.8 µL of each primer, forward 
and reverse (400 nM), and 3.4 µL UltraPure™ DNase/RNase-free ddH2O. The cycling 
conditions were as follows; a hot start for enzyme activation at 95°C for 3 mins, followed by 
40 cycles of denaturation at 95°C for 20 secs, annealing from 48-62°C for 30 secs (tested in 
increments of 2°C), and extension at 72°C for 10 secs. Due to the use of SYBR Green as the 
fluorophore indicating dsDNA amplification, a dissociation (melt) curve followed 
amplification to determine number of PCR products present per sample, with the following 
conditions; 95°C – 15 secs, 60°C – 30 secs to 95°C increasing by increments of +0.3°C. The 
AB® StepOnePlus™ Real-Time PCR System [ThermoFisher Scientific] allows for gradient 
PCR thermocycling via the VeriFlex™ block system, where every 2 out of 12 columns of wells 
in the BrightWhite qPCR 96-well Plates for ABI FAST Machines and StepOnePlus 
[Primerdesign Ltd] can be heated to a different temperature per stage of thermocycling. Using 
this technology eight different primer annealing temperatures were tested with two different 
HPV plasmids for creating 10-fold copy number standard curves (1x106 copies/5µL to 1 
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copies/5µL). Both HPV-16 and HPV-18 plasmids were used to test if there were also any 
differences in reaction efficiency between HPV genotypes amplified using the MY09/11 
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Table 3. HPV-18 MY09/11 (400 nM) Annealing Temperature Accuracy Indicators. Data generated by AB® StepOnePlus™ Real-Time PCR System and 
differences in “ideal” accuracy values calculated in Microsoft Excel. VeriFlex™ block system technology was used for running 8 different temperatures, in 2°C 
increments. Data shown for estimated standard curves made of 6 & 5 copy number standards per temperature (n = 3). Accuracy indicators include; the slope 
value (m in y=mx+c) of -3.32 ± 10%, R2 (correlation coefficient) value of >0.99 ± 0.1, reaction efficiency value of 100% ± 10% (calculated by formula C in 
Section 4.9, Chapter 4), difference in Cq between standards (~3.32 cycles) and standard deviation (STDEV) of replicates (ThermoFisher Scientific, 2016). 
Differences from “ideal” values calculated for each indicator, with a colour system representing order of closest value; Green = 1st/2nd; Orange = 3rd/4th; Blue = 
5th/6th. Each temperature was given a score based the number of accuracy indicators close to their ideal values; Light Green = 1st; Light Orange = 2nd. 
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Estimated known copy number standard curves using the HPV-18 plasmid Cq values were 
created and differences from “ideal” values were calculated in Excel [Microsoft] for each 
indicator. A colour system was used to represent order of the closest values; Green = 1st/2nd; 
Orange = 3rd/4th; Blue = 5th/6th. Each temperature was then given an overall score based on 
the number of accuracy indicators close to their ideal values; Light Green = 1st; Light Orange 
= 2nd. The annealing temperature with the highest score out of the 8 annealing temperatures 
tested, via having the highest number of collective “ideal” accuracy values, was determined to 
be the optimal. For HPV-18 detection using MY09/11 primers, gradient PCR thermocycling 
determined the most accurate and efficient annealing temperature using 400 nM with 
Primerdesign Ltd mastermix was 54°C (Table 3), with 52°C coming in second place.  
 In order to test if this was the same for other HPV genotypes using MY09/11 primers, HPV-
16 was deemed important to test due to it being a high-risk (HR-HPV) genotype, commonly 
found in the oral cavity. Furthermore, if young adult female participants (aged 18-25 years old) 
were screened using the final version of this MY09/11 HPV consensus screening method, they 
would be likely to have received the bivalent vaccination which covered HPV-16 and HPV-
18. As a result, another 10-fold known copy number HPV-16 plasmid dilution series was used 
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Table 4. HPV-16 MY09/11 (400 nM) Annealing Temperature Accuracy Indicators. Data generated by AB® StepOnePlus™ Real-Time PCR System and 
differences in “ideal” accuracy values calculated in Microsoft Excel. VeriFlex™ block system technology was used for running 8 different temperatures, in 2°C 
increments. Data shown for estimated standard curves made of 6 & 5 copy number standards per temperature (n = 3). Accuracy indicators include; the slope 
value (m in y=mx+c) of -3.32 ± 10%, R2 (correlation coefficient) value of >0.99 ± 0.1, reaction efficiency value of 100% ± 10% (calculated by formula C in 
Section 4.9, Chapter 4), difference in Cq between standards (~3.32 cycles) and standard deviation (STDEV) of replicates (ThermoFisher Scientific, 2016). 
Differences from “ideal” values calculated for each indicator, with a colour system representing order of closest value; Green = 1st/2nd; Orange = 3rd/4th; Blue = 
5th/6th. Each temperature was given a score based the number of accuracy indicators close to their ideal values; Light Green = 1st; Light Orange = 2nd. 
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Estimated known copy number standard curves using the HPV-16 plasmid Cq values were 
created and differences from “ideal” values were calculated in Excel [Microsoft] for each 
indicator. A colour system was used to represent order of the closest values; Green = 1st/2nd; 
Orange = 3rd/4th; Blue = 5th/6th. Each temperature was then given an overall score based on 
the number of accuracy indicators close to their ideal values; Light Green = 1st; Light Orange 
= 2nd. The annealing temperature with the highest score out of the 8 annealing temperatures 
tested, via having the highest number of collective “ideal” accuracy values, was determined to 
be the optimal. For HPV-16 detection using MY09/11 primers, gradient PCR thermocycling 
determined the most accurate and efficient annealing temperature using 400 nM with 
Primerdesign Ltd mastermix was also 54°C (Table 4), with 52°C coming in second place.  
However, even after adapting the annealing temperature of the real-time PCR cycling 
conditions, the HPV-18 and HPV-16 assays were still producing a large quantity of primer 
dimers which could be visualised via associated dissociation (melt) curves and 1% agarose gels 
(data not shown). Unfortunately, due to the consensus nature of the primers using degenerative 
bases, primer dimerisation was guaranteed but attempts could still be made to reduce the 
quantity even further to ensure reliable downstream screening. 
 
3.3.4 Adapting Primer Concentration 
The final stage of the method optimisation, in attempt to reduce primer dimerisation, was to 
test the effect of changing the MY09/11 primer concentration on reaction efficiency and other 
indicators of real-time PCR accuracy. The same “ideal” accuracy indicators were used as the 
previous development stage; the slope value (m in y=mx+c) of -3.32 ± 10%, R2 (correlation 
coefficient) value of >0.99 ± 0.1, and reaction efficiency value of 100% ± 10% (calculated by 
formula C in Section 4.9, Chapter 4) (ThermoFisher Scientific, 2016). Mean difference in Cq 
between standards (~3.32 cycles for 10-fold dilutions) and standard deviation of replicates were 
also used.  
For this stage of the assay development, the composition of the real-time PCR mastermix per 
well was as follows; 10 µL of PrecisionFAST qPCR Master Mix with SYBR Green 
[Primerdesign Ltd], according to manufacturer’s instructions, 0.2-0.8 µL of each primer, 
forward and reverse (100 nM to 400 nM), and 3.4-4.6 µL UltraPure™ DNase/RNase-free 
ddH2O. The cycling conditions were as follows; a hot start for enzyme activation at 95°C for 3 
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mins, followed by 40 cycles of denaturation at 95°C for 20 secs, annealing from 52-54°C for 
30 secs (tested in increments of 1°C), and extension at 72°C for 10 secs. Due to the use of 
SYBR Green as the fluorophore indicating dsDNA amplification, a dissociation (melt) curve 
followed amplification to determine number of PCR products present per sample, with the 
following conditions; 95°C – 15 secs, 60°C – 30 secs to 95°C increasing by increments of 
+0.3°C.  
This methodology development step also used the AB® StepOnePlus™ Real-Time PCR 
System [ThermoFisher Scientific] gradient PCR VeriFlex™ block system for testing three 
different primer annealing temperatures (52°C, 53°C and 54°C) at the same time as testing four 
different primer concentrations (100 nM, 200 nM, 300 nM and 400 nM). An additional 
temperature of 53°C was added as there was little variation between the accuracy indicator 
values for 52°C and 54°C. Furthermore, both HPV-16 and HPV-18 plasmids were also used 
for creating 10-fold copy number standard curves (1x106 copies/5µL to 1 copies/5µL), 
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Table 5. HPV-18 MY09/11 Primer Concentration & Annealing Temperature Accuracy Indicators. Data generated by AB® StepOnePlus™ Real-Time 
PCR System and differences in “ideal” accuracy values calculated in Microsoft Excel. VeriFlex™ block system technology was used for running 3 different 
temperatures, in 1°C increments per 4 different primer concentrations. Data shown for estimated standard curves made of 6 & 5 copy number standards per 
temperature/concentration (n = 3). Accuracy indicators include; the slope value (m in y=mx+c) of -3.32 ± 10%, R2 (correlation coefficient) value of >0.99 ± 
0.1, reaction efficiency value of 100% ± 10% (calculated by formula C in Section 4.9, Chapter 4), difference in Cq between standards (~3.32 cycles) and 
standard deviation (STDEV) of replicates (ThermoFisher Scientific, 2016). Differences from “ideal” values calculated for each indicator, with a colour system 
representing order of closest value; Green = 1st/2nd; Orange = 3rd/4th; Blue = 5th/6th. Each temperature was given a score based the number of accuracy indicators 
close to their ideal values; Light Green = 1st; Light Orange = 2nd. 
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Estimated known copy number standard curves using the HPV-18 plasmid Cq values were 
created and differences from “ideal” values were calculated in Excel [Microsoft] for each 
indicator. Identical to the previous method development section, a colour system was used to 
represent order of the closest values; Green = 1st/2nd; Orange = 3rd/4th; Blue = 5th/6th. Each 
temperature/primer concentration was then given an overall score based the number of 
accuracy indicators close to their ideal values; Light Green = 1st; Light Orange = 2nd. The 
annealing temperature/primer concentration combination with the highest score out of all the 
combinations tested, via having the highest number of collective “ideal” accuracy values, was 
determined to be the optimal. For HPV-18 detection using MY09/11 primers, gradient PCR 
thermocycling determined the most accurate and efficient annealing temperature/primer 
concentration combination using Primerdesign Ltd mastermix was 53°C using either 200 nM 
and 300 nM concentrations (Table 5), with 52°C and 54°C at 300 nM coming in second place. 
There were two options per rating as the scores were calculated to be equal for the conditions 
in question. 
 In order to test if this was the same for other HPV genotypes using MY09/11 primers, a 10-
fold known copy number HPV-16 plasmid dilution series was used and subjected to the same 
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Table 6. HPV-16 MY09/11 Primer Concentration & Annealing Temperature Accuracy Indicators. Data generated by AB® StepOnePlus™ Real-Time 
PCR System and differences in “ideal” accuracy values calculated in Microsoft Excel. VeriFlex™ block system technology was used for running 3 different 
temperatures, in 1°C increments per 4 different primer concentrations. Data shown for estimated standard curves made of 6 & 5 copy number standards per 
temperature/concentration (n = 3). Accuracy indicators include; the slope value (m in y=mx+c) of -3.32 ± 10%, R2 (correlation coefficient) value of >0.99 ± 
0.1, reaction efficiency value of 100% ± 10% (calculated by formula C in Section 4.9, Chapter 4), difference in Cq between standards (~3.32 cycles) and 
standard deviation (STDEV) of replicates (ThermoFisher Scientific, 2016). Differences from “ideal” values calculated for each indicator, with a colour system 
representing order of closest value; Green = 1st/2nd; Orange = 3rd/4th; Blue = 5th/6th. Each temperature was given a score based the number of accuracy indicators 
close to their ideal values; Light Green = 1st; Light Orange = 2nd. 
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Estimated known copy number standard curves using the HPV-16 plasmid Cq values were 
created and differences from “ideal” values were calculated in Excel [Microsoft] for each 
indicator. Identical to the previous method development section, a colour system was used to 
represent order of the closest values; Green = 1st/2nd; Orange = 3rd/4th; Blue = 5th/6th. Each 
temperature/primer concentration was then given an overall score based the number of 
accuracy indicators close to their ideal values; Light Green = 1st; Light Orange = 2nd. The 
annealing temperature/primer concentration combination with the highest score out of all the 
combinations tested, via having the highest number of collective “ideal” accuracy values, was 
determined to be the optimal. For HPV-16 detection using MY09/11 primers, gradient PCR 
thermocycling determined the most accurate and efficient annealing temperature/primer 
concentration combination using Primerdesign Ltd mastermix was 52°C using either 200 nM 
and 400 nM concentrations (Table 6), with 53°C and 54°C at 300 nM and 400 nM, respectively, 
coming in second place. As with HPV-18, there were two options per rating as the scores were 
calculated to be equal for the conditions in question. 
For both HPV-16 and HPV-18, the gradient PCR development steps found the optimal 
annealing temperatures for MY09/11 real-time PCR using Primerdesign Ltd mastermix to be, 
on average, either 52°C 53°C, whilst optimal primer concentrations were found to be either 
200 nM or 300 nM. The final stage in determining the optimal combination of conditions was 
to examine the real-time PCR raw data (data not shown) and corresponding 1% agarose gels to 
qualitatively analyse the effect on primer dimerisation (Figure 10). 
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Figure 10. Comparison of Primer Dimerisation From Gradient PCR. Real-time PCR products run on 1% agarose gels from HPV-16 MY09/11 (a) 52°C 
and (b) 53°C runs, revealing the difference in primer dimerisation and product amplification per temperature and per primer concentration (x3; 300 nM, 200nM 
and 100nM) tested (n = 3). Left to right; 1x106 copies/5µL to 1x100 copies/5µL, NTC, S, CR, P, LTK, LC. Methods described in Section 4.7, Chapter 4.
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From the real-time PCR raw data and 1% agarose gels, it was determined that, on average 
across the two HPV genotypes, the optimal annealing temperature was 53°C, whilst the optimal 
primer concentration was 200 nM (Figure 10b). Visually, there was less primer dimer products 
on the dissociation (melt) curve and gel, especially within the highest known copy number 
standard (1x106 copies/5µL). This indicated that this annealing temperature and primer 
concentration combination encouraged optimal annealing of the MY09/11 primers to HPV L1 
target sequences, rather than non-specific products (evident by the reduction of the ~100-150 
bp product amplified in LTK) and the primers themselves. Due to this, an annealing 
temperature of 53°C and primer concentration of 200 nM were deemed to be the most suitable 
to move forward with for HPV screening of oral samples, concluding the HPV MY09/11 
consensus assay development. 
 
3.3.5 Optimisation of Sample DNA Concentration 
The final stage of testing before using the established HPV consensus assay to screen 
participant oral samples was to optimise the amount of sample DNA that could be screened. 
Due to the high sensitivity of real-time PCR, high DNA concentrations of gDNA have been 
shown to overload the system, resulting in poor efficiency and inaccurate results. Therefore, it 
was important to determine what the optimal concentration of sample DNA was for the 
designed assay, to ensure the method was not compromised following optimisation. 
Using the final mastermix composition and cycling conditions devised for the MY09/11 assay, 
a range of different standardised DNA concentrations of the HPV positive controls (HeLa 
gDNA) and a known HPV positive tonsil sample (T), obtained from an additional research trial 
at the same institute as the researcher, were screened. Simple dilutions were made to create 
working stocks of the following concentrations per control; 1.0 ng/µL, 1.2 ng/µL, 1.4 ng/µL, 
1.6 ng/µL, 1.8 ng/µL and 2.0 ng/µL. HeLa and tonsil DNA were used to represent participant 
oral samples. 
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Figure 11. Optimal DNA Concentration Testing. Data generated by AB® StepOnePlus™ Real-Time PCR System and software using MY09/11 primers and 
final HPV cycling conditions described (n = 3). HeLa gDNA (H) and HPV positive tonsil DNA (T) dilutions were screened to determine optimal DNA 
concentration (1.0 ng/µL, 1.2 ng/µL, 1.4 ng/µL, 1.6 ng/µL, 1.8 ng/µL and 2.0 ng/µL which were equivalent to 5 ng/5µL, 6 ng/5µL, 7 ng/5µL, 8 ng/5µL, 9 
ng/5µL, 10 ng/5µL). a) MY09/11 Amplification Plot – Raw fluorescence signal data (ΔRn) per template (3 replicates) vs cycle number. b) MY09/11 
Dissociation Curve – Derivative reporter signal data (-Rn) per template (3 replicates) vs temperature.
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Both the 1.8 ng/µL and 2.0 ng/µL (9 ng/5µL and 10 ng/5µL) DNA concentrations of tonsil 
DNA (T) and Hela gDNA (H) overloaded the system suggesting that lower concentrations will 
be needed when screening the participant samples, evident from the sigmoid curves on the 
amplification plot (Figure 11a). If this assay were being used for quantification, this would 
affect the ability to generate accurate Cq values, which would then affect the ability of a copy 
number standard curve to accurately predict gene copy number. However, for the purpose of 
determining HPV status via consensus screening, this does not affect the dissociation curve 
which can be used for determination HPV presence (Figure 11b). In contrast, 1.0 ng/µL and 
1.2 ng/µL (5 ng/5µL and 6 ng/5µL) DNA concentrations of tonsil DNA (T) and Hela gDNA 
(H) did not overload the system but the amplification signal and associated dissociation peak 
signal were relatively weak. The dissociation (melt) curve, however, did reveal the high 
sensitivity of real-time PCR as the dissociation of the amplified L1 target sequence could still 
be visualised. Therefore, the HPV consensus screen was validated in terms of use in sample 
screening; with evidence of successful HPV detection in low concentrations of gDNA. 
However, the optimal DNA concentration for sample screening was determined to be 1.6 ng/µL 
(8 ng/5µL) by the strong amplification and dissociation peak signals present in the real-time 
PCR raw data (Figure 11). Therefore, the decision was made to standardise all participant oral 
sample DNA concentrations to 8 ng/5µL via simple dilutions for successful HPV screening. 
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3.4 Interpretation of HPV Screening Results 
The DNA concentration optimisation method development run revealed that samples with low 
concentrations could be visualised using the real-time PCR dissociation (melt) curve, but the 
product peak signals were weak. Therefore, there was a possibility that samples could be easily 
misinterpreted as either false positives or negatives, dependent on position and size of the peak. 
This, combined with the evidence to suggest samples with HPV copy numbers lower than 
1x103 copies/5µL could not be visualised on an agarose gel, indicated that an HPV 
interpretation strategy was necessary when determining the HPV status of an oral sample. 
The strategy devised involved using a combined approach of interpreting sample dissociation 
(melt) curve product peaks alongside gel electrophoresis to confirm presence of the L1 target 
amplicon, further collating newer real-time PCR methods with traditional end-point PCR 
visualisation techniques. 
 
Figure 12. HPV Consensus Assay Dissociation Curve Interpretation. Example data generated by 
AB® StepOnePlus™ Real-Time PCR System and software using MY09/11 primers and final HPV 
cycling conditions described (n=6). Derivative reporter signal data (-Rn) per template (2 replicates) vs 
temperature has been plotted to demonstrate how oral samples were deemed HPV +ve, 
Borderline/Unknown or HPV –ve. Stars = Tm for two different product peaks. 
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To determine the presence of HPV in samples using the HPV consensus screening assay 
devised, the HPV positive and negative controls and HPV-16 and HPV-18 plasmids were used 
for comparison (Figure 12).  
If a sample exhibited a product peak on the dissociation (melt) curve following thermocycling 
that had a strong signal (approximately >2.0 -Rn) and a Tm value matching the Tm value for 
the HPV positive controls, represented by “HPV +ve” (Figure 12), then the sample was deemed 
HPV positive. The sample was also run on a 1% agarose gel, alongside the controls, to 
determine if a corresponding ~450 bp product was present. Furthermore, sample dissociation 
peak profiles were also compared to online software, uMeltSM Version 2.0.2 (Dwight, Palais & 
Wittwer, 2011) [Wittwer Lab], predicted L1 target profiles to compare the sample Tm with 
calculated Tm values.  
If a sample exhibited a product peak on the dissociation (melt) curve following thermocycling 
that had a weak signal (approximately <0.7 -Rn), as represented by “BD/Unknown” (Figure 
12) but matched the Tm value for the HPV positive controls, then the sample was deemed 
borderline HPV positive/unknown. The sample was also run on a 1% agarose gel, alongside 
the controls, to determine if a corresponding ~450 bp product was present. If a product of a 
different size was present, the sample was deemed HPV negative. If there was no product 
present, the sample remained borderline HPV positive/unknown. Similarly, if a sample 
exhibited a product peak on the dissociation (melt) curve following thermocycling that had a 
moderate-strong signal (approximately >0.7 -Rn), as represented by “BD/Unknown” (Figure 
12) but did not match the Tm value for the HPV positive controls, then the sample was deemed 
borderline HPV positive/unknown. The sample was also run on a 1% agarose gel, alongside 
the controls, to determine if a corresponding ~450 bp product was present. If a product of a 
different size was present, the sample was deemed HPV negative. If there was no product 
present, the sample remained borderline HPV positive/unknown.  
Finally, if a sample exhibited a product peak on the dissociation (melt) curve following 
thermocycling that had a signal, as represented by “HPV –ve” (Figure 12), that did not match 
the Tm value for the HPV positive controls but matched the NTC Tm, then the sample was 
deemed HPV negative. The sample was also run on a 1% agarose gel, alongside the controls, 
to determine if a corresponding <100 bp product representing primer dimers was present. If 
primer dimers were present or an alternative product to the target ~450 bp was present, the 
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sample was deemed HPV negative. If there was no product present, the sample remained HPV 
negative. 
In summary, this chapter described the successful establishment of an HPV consensus 
screening method for the detection of multiple HPV types in oral samples with low DNA 
concentrations. Every aspect of the method was considered and optimised from sample type to 
primer and DNA concentration. Success was deemed when all objectives set out prior to 
establishment were met, ensuring the described method was fit for purpose. Overall, the final 
method allowed for screening of HPV viral DNA, reliably detected a range of HPV types, 
exhibited a high level of sensitivity for the detection of HPV in oral samples with low DNA 
concentrations, was able to give an estimate of HPV abundance as well as prevalence due to 
the use of plasmid copy number standard curves, was cost-effective, and finally, was 
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Chapter 4:  
ORAL HPV LABORATORY SCREENING METHODS 
 
4.1 Cohort Sample Collection  
The inclusion criteria for the cohort of this study was healthy adults, aged 18 years old or older, 
residing in the East Midlands of the UK. All participants were enrolled on a course at 
University of Derby, studying for an undergraduate or postgraduate degree (in multiple 
disciplines). A predominately student-based cohort was chosen as the participants needed to be 
representative of the wider healthy UK young adult population. This student-based cohort was 
also chosen as the female participants, if UK-native, should have received the bivalent 
Cervarix™ or quadrivalent Gardasil® HPV vaccination during secondary school education 
(from 2008 onwards) before sexual maturity, or received it as part of the HPV vaccination catch 
up programme, dependent on age. 
For recruitment, the study was advertised in postgraduate research offices whilst undergraduate 
students were approached at the end of revision or independent study lectures, with prior 
written permission from the course and module leaders, to ask for voluntary participation. This 
interaction involved a 5-minute talk introducing the research, explaining the purpose of the 
project and what participation would entail, before asking for volunteers. If any individual 
wished to participate, they were required to fill out a consent form (APPENDIX G) first, 
attached to an information sheet (APPENDIX F), before completing a questionnaire 
(APPENDIX H & APPENDIX I) and undergoing sample collection.  
The participant information sheet contained information on the study rationale, data handling 
and storage, confidentiality assurances, and withdrawal rights, to ensure participants were 
consenting to participate in the study on an informed basis. The participants were also required 
to create a unique identification number prior to sample collection to ensure anonymity 
throughout the study. This unique identification number provided the only link between the 
consent form, questionnaire and donated sample. 
The questionnaire(s) was designed for collecting data on cohort demographics, HPV 
vaccination status, and lifestyle factors associated with the contraction of oral HPV and linked 
to HPV positive OPSCCs progression, such as smoking status, alcohol consumption, and 
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sexual practice. The questionnaire(s) used closed dichotomous and multiple-choice questions, 
and very few open-response questions, designed to collect quantitative categorical data for ease 
of statistical analysis. There were two questionnaires for two sample collection periods within 
the study; Phase 1 (P1) was in September/October 2016 and Phase 2 (P2) was in March/April 
2017. The second questionnaire (P2) was an improved version of the pilot questionnaire (P1), 
which included updated questions on smoking frequency and amount for calculation of pack 
years, and updated questions on alcohol consumption frequency and amount for determining 
binge drinking and NHS/NICE health risk status. For more information on questionnaire design 
and analysis, please see Chapter 5. 
For sample collection, the participants were required to use self-administered foam-tipped 
applicators to brush the inside of their cheeks for the collection of oral mucosal cells (squamous 
epithelial cells). The sample collection process (sampling technique and timing) was explained 
and demonstrated to those who volunteered, at the time of recruitment, to ensure 
standardisation of technique across the cohort. The participants were asked to gently brush the 
inside of both cheeks with the foam-tipped applicators whilst repeatedly turning the applicator 
360° in a clockwise motion for approximately 20-30 seconds. Following this, the foam-tipped 
applicators were placed back in their sleeves, labelled with participants’ unique identification 
numbers and stored at -80°C for a maximum of 7 days before being processed into acellular 
format. All matching documentation was stored onsite in two securely locked storage cabinets 
(one for consent, one for questionnaires) until processing for analysis. 
 
4.2 Sample Preparation & DNA Extraction  
In preparation for DNA extraction, the foam-tipped applicators containing the mucosal cell 
samples were defrosted on ice and washed in 2 mL of 1 x phosphate-buffered saline (PBS) [10 
mM PO4
3−, 137 mM NaCl, 2.7 mM KCl] to suspend the cells in solution. Following transfer to 
microcentrifuge tubes, the cell samples were subjected to centrifugation at 350 xg for 10 
minutes for cell pellet collection. The supernatant was removed via pipetting and all cell pellets 
were placed back on ice for 5 mins before adding 200 μL of 1 x PBS ready for DNA extraction. 
A DNeasy Blood & Tissue Kit [Qiagen] was used for DNA extraction from the cell samples, 
according to manufacturer’s quick start protocol (for cultured cells, beginning at part 1d). All 
extracted genomic (g)DNA was eluted using the kit AE buffer [10 mM Tris-HCl, pH 9.0; 0.5 
mM EDTA] ready for quantification. 
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4.3 HPV Positive & HPV Negative Controls  
To determine if the donated samples were HPV positive, a series of gDNA HPV positive and 
HPV negative controls were prepared, ready for use in subsequent consensus and type-specific 
real-time PCR screening assays alongside the participant samples for comparison. 
For HPV positive controls, HeLa (ATCC® CCL-2™) cells and SiHa (ATCC® HTB-35™) 
cells were obtained from the American Type Culture Collection (ATCC®) for culturing and 
extraction. SiHa cells are derived from a HPV-16 positive human cervical grade II squamous 
cell carcinoma and are reported to contain 1-2 integrated copies of HPV-16/cell, whilst HeLa 
cells are derived from a HPV-18 positive human cervical adenocarcinoma and are reported to 
contain 10-50 integrated copies of HPV-18/cell.  
For HPV negative controls, MCF7 (ATCC® HTB-22™) cells, A549 (ATCC® CCL-185™) 
cells, and Ltk-11 (ATCC® CRL-10422™) cells were obtained from the American Type 
Culture Collection (ATCC®) for culturing and extraction. MCF7 cells are derived from a 
human breast adenocarcinoma, whilst A549 cells are derived from a human lung epithelial cell 
carcinoma, making them suitable (via cell type and structure) HPV negative controls for direct 
comparisons to HeLa and SiHa cells. Ltk-11 cells, alternatively, are mouse fibroblasts, which 
were selected to be a non-human but mammal-derived HPV negative control from a non-
diseased origin. White-clawed Crayfish (CR) (Austropotamobius pallipes) gDNA was also 
obtained from an internal environmental science research group at the university, selected to 
be a non-mammal HPV negative control from a non-diseased origin. 
 
4.3.1 Cell Culture of Control Cell Lines 
To create stocks of HPV positive and HPV negative gDNA, the cell lines underwent cell 
culturing. For this, all obtained cell lines were thawed using a water bath set at 37°C and 
transferred to separate T75 flasks per cell type under aseptic conditions in a Captair®flow 
321Class II laminar flow hood [Erlab], according to manufacturers’ instructions. All cell lines 
were then grown and maintained at 37°C with 5% CO2, using separate incubators for the HPV 
positive and HPV negative controls. The cell lines were treated every other day with high 
glucose Dulbecco's Modified Eagle Medium (DMEM) [ThermoFisher Scientific] containing 
10% Fetal Bovine Serum (FBS) [ThermoFisher Scientific], 1% Penicillin-Streptomycin 
(10,000 U/mL) [ThermoFisher Scientific], and 1% L-glutamine (200 mM) [ThermoFisher 
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Scientific] and passaged at ~90-100% confluency. Passaging allowed for splitting (1:10 split 
ratios) into new T75 flasks, harvesting for DNA extraction, or detaching for liquid nitrogen 
storage; liquid phase (-196°C) for future use.  
To split and harvest the cells for DNA extraction, the culture medium was removed, and cells 
were washed with 1 x PBS. Cells were detached using 2 mL of 1 x 0.25% phenol red Trypsin-
EDTA [5. 3mM KCl; 0.4 mM KH₂PO₄; 4.2 mM NaHCO3; 137.9 mM NaCl; 0.3 mM Na₂HPO₄-
7H2O, 5.6 mM D-Glucose (Dextrose); 0.91 mM EDTA; 0.025 mM phenol red, and 0.105 mM 
Trypsin] [ThermoFisher Scientific] and subsequently transferred into 10 mL sterile tubes for 
cell pellet production via centrifugation at ~163 xg for 10 mins. The media supernatant was 
removed to leave the cell pellet and 500 µL PBS was added on wet ice ready for DNA 
extraction.  
 
4.3.2 DNA Extraction of Control Cell Lines 
Similar to participant cell sample extraction, a DNeasy Blood & Tissue Kit [Qiagen] was used 
for DNA extraction from all HPV positive and HPV negative cell lines, according to 
manufacturer’s quick start protocol (for cultured cells, beginning at part 1d). All extracted 
gDNA was eluted using the kit AE buffer [10 mM Tris-HCl, pH 9.0; 0.5 mM EDTA] ready for 
quantification. 
 
4.4 Plasmid Constructs 
Five different plasmid constructs were used within this study to establish copy number standard 
curves for sample screening via absolute quantification using real-time PCR technology; four 
HPV genotype specific plasmids and one human beta-actin plasmid from a human double dye 
probe-based reference gene detection kit [ACTB] [Primerdesign Ltd]. The four HPV genotype 
specific plasmids contained whole HPV genome inserts for HPV-6, HPV-11, HPV-16 and 
HPV-18, corresponding to the four types targeted for by quadrivalent Gardasil® HPV 
vaccination. The HPV-6 and HPV-11 plasmids were kind gifts from the International HPV 
Reference Centre at the Karolinska Institutet in Stockholm, Sweden (APPENDIX D, Figure 49 
& 50), whilst the HPV-16 and HPV-18 plasmids were kind gifts from Dr Sally Roberts (Collins 
et al., 2009) at University of Birmingham in the UK (APPENDIX D, Figure 51 & 52).  
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The pBRHPV-6b plasmid contained the complete HPV-6 genome (7902 bp), isolated from a 
genital wart and sub-cloned in backbone vector of pBR322 at BamHI site (de Villiers, 
Gissmann & zur Hausen, 1981). The pBRHPV-11 plasmid contained the complete HPV-11 
genome (7931 bp), isolated from a laryngeal papilloma and sub-cloned in backbone vector of 
pBR322 at BamHI site (Gissmann et al., 1982). The pBRHPV-16 plasmid contained the 
complete HPV16 genome (7905 bp), derived from a cervical carcinoma, that was cloned in λ 
L47, a bacteriophage first, and then subsequently sub-cloned in backbone vector of pBR322 
(Dürst et al., 1983). The pGEMII18-WT plasmid contained the complete wild type HPV18 
genome (7857 bp) which was cloned as an EcoRI fragment into the backbone vector of pGEMII 
(Karstensen et al., 2006); genome isolation origin is unknown as data is not available.  
 
4.4.1 Plasmid Elution & Preparation 
To create stocks of the HPV plasmids for use in screening and quantifying HPV viral load in 
samples, the plasmids underwent bacterial transformation and bulk-up processes. For this, one 
more plasmid (pUC19) was required as a control to ensure and measure if the transformation 
and bulk-up processes were successful. The pUC19 plasmid (empty DNA backbone control) 
was derived from a kit containing Sub-cloning Efficiency™ DH5α™ Competent E.coli 
[Invitrogen], which was used for the subsequent bacterial transformations of all HPV plasmids 
and the pUC19 control. All HPV plasmids and pUC19 contained an ampicillin-resistance gene 
(ampR) as a selection marker (APPENDIX D, Figure 53). 
In preparation for bacterial transformation, 1 L of nutrient lysogeny broth (LB) and 1 L nutrient 
agar were made up and sterilised, before splitting the 1 L of nutrient LB into two 500 mL 
bottles and adding 500 µL of ampicillin (100 mg/mL) [Sigma-Aldrich] to one of the two 500 
mL bottles. Ampicillin (100 mg/mL) was also added to the 1 L bottle of nutrient agar (1 mL), 
which was transferred into disposable sterile petri dishes [Sigma-Aldrich] (~25 mL per plate; 
final ampicillin concentration of 100 µg/mL). All plates and LB bottles were incubated at 37°C 
ready for transformation. 
DH5α E.coli were also defrosted on wet ice alongside the pUC19 control plasmid suspended 
in TE (Tris-EDTA) buffer [100 pg/µL in 5 mM Tris-HCl, pH 8.0; 0.5m M EDTA] and 
UltraPure™ DNase/RNase-free ddH2O [Invitrogen]. During defrosting, a heating block was 
set to 42°C and HPV-16 and HPV-18 plasmids were eluted from the filter papers they were 
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suspended on (the HPV-6 and HPV-11 plasmids were already suspended in ~100 µL of TE). 
For elution, ~1-2 cm in diameter of filter paper was placed in 100 µL of UltraPure™ 
DNase/RNase-free ddH2O, centrifuged at 2000 xg, and placed on wet ice for 30 mins. 
 
4.4.2 Bacterial Transformation 
For the bacterial transformation, 100 µL of DH5α E.coli was added to each of the four HPV 
plasmid suspensions (volumes varying between 10-25 µL for 1-10 ng per suspension), and to 
2.5 µL of the pUC19 TE solution. The bacterial transformation and plating of transformed 
cultures was completed according to the Sub-cloning Efficiency™ DH5α™ Competent E.coli 
kit protocol instructions, using the previously prepared LB and ampicillin agar plates. All plates 
were incubated at 37°C for 24 hours to encourage transformant colony growth. The use of 
ampicillin prevented growth of non-transformed DH5α E.coli due to the ampR selection 
marker in all plasmid backbones. 
 
4.4.3 Colony Picking & Pellet Production 
Following the 24-hour incubation period, a single colony pick was performed for each plasmid 
type by gently scrapping one of the transformed DH5α E.coli colonies from the surface of the 
agar using a sterile pipette tip. The pipette tips were transferred into conical flasks containing 
200 mL of ampicillin LB (previously prepared), one per plasmid. These were incubated on an 
orbital shaker for another 24 hours at 37°C to encourage further colony growth.  
After a further 24 hours of incubation, transformant suspensions within the conical flasks were 
split into 100 mL sterile tubes for centrifugation at ~3400 xg for 20 mins for the collection of 
bacterial pellets. Following centrifugation, the broth supernatant was removed, leaving the 
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4.4.4 Plasmid DNA Extraction 
A HiSpeed® Plasmid Maxi Kit [Qiagen] was used for plasmid DNA extraction from each 
transformed bacterial pellet, according to manufacturer’s quick start protocol. Prior to 
extraction, all kit buffers were also prepared according to manufacturer’s instructions, 
including making up 100 mL stock solution of 70% (v/v) ethanol. As instructed, RNase A was 
added to kit Buffer P1 [50 mM Tris-HCl, pH 8.0; 10 mM EDTA] to produce a final 
concentration of RNase A of 100 µg/mL, which was chilled at 4-5°C for 4 hours alongside kit 
Buffer P3 [110 mL of 3 M Potassium acetate, pH 5.5]. Following plasmid DNA extraction 
using the kit, all extracted plasmid DNA was eluted in TE buffer, ready for quantification. 
 
4.5 DNA Quantification & Dilutions 
Following extraction processes, all participant DNA samples, controls and plasmids were 
quantified to determine DNA concentrations (ng/µL) using a NanoDrop 2000 [ThermoFisher 
Scientific]. Sample purity was also recorded via the 260:280 ratio and 260:230 ratio, with 
values of ~1.8 and between >1.5 denoting purity, respectively (O'neill et al., 2011). 
In preparation for usage in HPV consensus screening, following the establishment of the novel 
screening real-time PCR methodology (Chapter 3), all participant DNA samples, controls and 
plasmids were subjected to a series of dilutions. The participant DNA samples were diluted 
using UltraPure™ DNase/RNase-free ddH2O to produce new working stocks of 1.6 ng/µL (8 
ng/5µL), according to the optimum concentration devised in Chapter 3. For direct comparison 
to the samples, the HPV positive and HPV negative gDNA controls were also diluted using 
UltraPure™ DNase/RNase-free ddH2O to produce new working stocks of 1.6 ng/µL (8 
ng/5µL). 
 
4.5.1 Plasmid Dilution 
As the HPV plasmids were used for creating known copy number standard curves for estimated 
quantification in consensus screening and absolute quantification in type-specific screening,  
serial dilutions were made based on copy number rather than simple dilutions based on 
concentration similar to the samples and controls. Using the determined plasmid DNA 
concentrations following extraction, gene copy number/ng of DNA was calculated using 
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formula A in Section 4.9. Using these copy number values; dilution factors were calculated per 
HPV plasmid stock in order to produce new working stocks of 2.00x109 copies/µL. From the 
working stocks, ten 10-fold serial dilutions (10µL of DNA stock and 90µL ddH2O) were 
performed per plasmid, creating a series of HPV positive 10-fold standards for creation of copy 
number standard curves in subsequent real-time PCR experiments. The highest copy number 
standard used in quantification was 2x105 copies/µL (1x106 copies/5µL) and the lowest was 
0.2x10-1 copies/µL (1x100 copies/5µL), providing a range which would allow for quantification 
of all samples of all levels of infection severity. 
The human beta-actin plasmid from a human double dye probe-based reference gene detection 
kit [ACTB] was prepared and diluted according to manufacturer’s instructions, producing an 
identical copy number range for screening and quantification of reference gene, beta-actin, in 
samples for calculations of cell number and viral copy number per million cells (see Section 
4.8.1). 
 
4.6 Real-time PCR Screening  
Sample screening assays were established using real-time PCR on an AB® StepOnePlus™ 
Real-Time PCR System [ThermoFisher Scientific]. BrightWhite qPCR 96-well Plates for ABI 
FAST Machines and StepOnePlus [Primerdesign Ltd] were used, allowing for total of 
approximately 7 standards, 1 no-template  control (NTC), 2 positive controls, 2 negative 
controls and 20 DNA samples, in triplicate, to be run each time (APPENDIX B, Figure 48). 
Each well of the plate allowed a total volume of 20 µL, which was made up of 15 µL of real-
time PCR mastermix (including primers) and 5 µL of template DNA or UltraPure™ 
DNase/RNase-free ddH2O. The composition of the real-time PCR mastermix varied dependent 
on the primer set and use of hydrolysis probes (Table 7), and whether home-made assays or 
kits were used for screening samples. Thermocycling conditions also varied dependent on the 
assay and primer set, however a dissociation (melt) curve analysis (95°C – 15 secs, 60°C – 30 
secs to 95°C increasing by increments of +0.3°C) always followed amplification with the use 
of SYBR Green in the mastermix. All specific screening assay information is detailed in the 
following Sections; 4.6.1, 4.6.2, 4.6.3, 4.6.4, 4.6.5 and 4.6.6. 
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Table 7. Primers & Probes Used for Real-time PCR Screening. Details of each primer set and corresponding hydrolysis probe (including fluorophore(s) and 
quencher(s)), if applicable, used within the study for real-time PCR consensus and type-specific screening.  
 
*Probes were also provided but the sequences are unknown as they were not provided following manufacturing. 
†Degenerative sequence codes: M = A or C, W = A or T, Y = C or T, and R = A or G. 
‡Tagged with fluorescence probes; fluorophore (FAM) & quencher (TAMRA)
Content removed for copyright purposes 
Content removed for copyright purposes 
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Six different primer sets, and corresponding hydrolysis probes, if applicable, were used within 
the study (Table 7) (APPENDIX E). GP5/GP6+ (de Roda Husman et al., 1995) were used for 
preliminary HPV consensus assay testing but not for HPV screening of the cohort (Chapter 3), 
whilst MY09/11 (Husnjak et al., 2000) were used for the final established HPV consensus 
screening assay, used to estimate HPV prevalence within the cohort. All other primer/probe sets 
were used for type-specific screening and absolute quantification of HPV subtypes, HPV-6 
[Primerdesign Ltd], HPV-11 [Primerdesign Ltd], HPV-16 (Moberg et al., 2003) and HPV-18 
(Gravitt et al., 2003). Before use in screening assays, all primer sets were aligned to the HPV 
positive plasmids using Primer-BLAST Online Tools [NCBI] and analysed for secondary 
structures (self-dimerization), hairpinning, and cross-dimerization of the primers and probes 
using Beacon Designer™ Free Edition Online qPCR Design Tool [PremierBiosoft], to assess 
their efficiency and specificity in detection of HPV in samples. Alignments of the HPV-6 and 
HPV-11 primers revealed both target amplicons to be viral oncogene E6 (APPENDIX B, Figure 
45), rather than spanning both E6 and E7 oncogenes, as the kits suggested. For beta-actin 
screening, the primers and hydrolysis probe were taken from the human double dye probe-based 
reference gene detection kit [ACTB] from Primerdesign (along with the plasmid). As the 
primer/probe sequences were not custom-designed alike HPV-6 and HPV-11 sets, they were 
not provided by the manufacturer. 
 
4.6.1 Beta-actin (ACTB) Screening 
All participant DNA samples were tested for DNA integrity using a beta-actin (ACTB) 
housekeeping gene screening assay. For this assay, the composition of the real-time PCR 
mastermix per well was as follows; 10 µL of PrecisionFAST qPCR Master Mix [Primerdesign 
Ltd], 1 µL of ACTB primers (300 nM)/hydrolysis probe mix (100 nM), and 4 µL of UltraPure™ 
DNase/RNase-free ddH2O. The remaining 5 µL of well volume was used for pure stock 
participant DNA, despite concentration. The thermocycling conditions established for this 
assay, using PrecisionFAST qPCR Master Mix and the human double dye probe-based 
reference gene detection kit [ACTB] protocols for reference, were as follows; a hot start for 
enzyme activation at 95°C for 2 mins, followed by 40 cycles of denaturation at 95°C for 5 secs 
and annealing at 60°C for 20 secs. Due to the use of a FAM-tagged hydrolysis probe, there was 
no dissociation (melt) curve required.  
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For absolute quantification, the beta-actin plasmid provided in the human double dye probe-
based reference gene detection kit [ACTB] was used for an ACTB positive copy number 
standard curve. The standards followed a 10-fold serial dilution of copy number, according to 
manufacturer’s instructions, with the highest copy number standard being 2x105 copies/µL 
(1x106 copies/5µL) and the lowest being 0.2x10-1 copies/µL (1x100 copies/5µL). Samples that 
amplified between the highest and lowest known standard copy numbers could be quantified 
(Section 4.8.1). This also allowed for the calculation of sample cell number, and subsequently, 
viral copy number/million cells, if found to be HPV positive. If beta-actin was detected in the 
participant samples, confirming DNA viability, and subsequent calculations made, the samples 
were taken forward for HPV consensus screening. 
 
4.6.2 HPV Consensus Screening 
For determination of an estimated HPV prevalence within the cohort, the established novel 
screening methodology (Chapter 3) was used for screening the participants’ DNA samples 
following beta-actin screening. The final method utilised traditional end-point PCR consensus 
primers, MY09/11, specific to the HPV L1 region of the viral genome (Table 7). These were 
chosen as they were shown to anneal to a large range of HPV subtypes by alignment, including 
the quadrivalent vaccination genotypes of HPV-6. HPV-11, HPV-16 and HPV-18, as well as 
exhibiting less non-specific binding than GP5/GP6+ during preliminary testing. However, due 
to this broad specificity of the primers, the amplified products produced during screening could 
not be quantified as the amplicon fluorescence signal, used to produce Cq values for copy 
number calculations, could have been comprised of doubling other dsDNA other than one HPV 
target. Other variables include, multiple HPV targets due to coinfections of more than one HPV 
genotype in the samples, primer dimers due to the non-specificity of the degenerative bases in 
the MY09/11 primers, or non-specific binding of other non-HPV DNA sequences. Therefore, 
this assay was only used as an indication of HPV prevalence. 
For this assay, the final determined composition of the real-time PCR mastermix per well was 
as follows; 10 µL of PrecisionFAST qPCR Master Mix with SYBR Green [Primerdesign Ltd], 
0.4 µL of each primer, forward and reverse (200 nM), and 4.2 µL UltraPure™ DNase/RNase-
free ddH2O. The remaining 5 µL of well volume was used for the working stocks of participant 
DNA, all with a concentration of 1.6 ng/µL. The final thermocycling conditions established for 
this assay (Chapter 3), were as follows; a hot start for enzyme activation at 95°C for 3 mins, 
followed by 40 cycles of denaturation at 95°C for 20 secs, annealing at 53°C for 30 secs, and 
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extension at 72°C for 10 secs. Due to the use of SYBR Green as the fluorophore indicating 
dsDNA amplification, a dissociation (melt) curve followed amplification to determine number 
of PCR products present per sample, with conditions as described in Section 4.6.  
All samples were screened alongside HPV positive controls (HeLa and SiHa gDNA), HPV 
negative controls (NTC, MCF7, A549 and Ltk-11 gDNA) and either the HPV-16 or HPV-18 
plasmid, for direct comparison of amplification and dissociation curve data. Online software, 
uMeltSM Version 2.0.2 (Dwight, Palais & Wittwer, 2011) [Wittwer Lab], was also used to 
compare dissociation curve data and predict HPV status based on HPV subtype melt curve 
profiles (Chapter 3). Samples identified as HPV positive or borderline/unknown from the 
MY09/11 screen using the method previously described (Chapter 3) were taken forward for 
type-specific HPV screening and quantification for HPV-6, HPV-11, HPV-16 and HPV-18. 
 
4.6.3 HPV6 E6 Type-Specific Screening 
All participant DNA samples identified as HPV positive or borderline/unknown were screened 
using the following HPV-6 detection and quantification assay. For this assay, the composition 
of the real-time PCR mastermix per well was as follows; 10 µL of PrecisionFAST qPCR Master 
Mix [Primerdesign Ltd], 1 µL of custom-designed HPV-6 E6 primers (300 nM)/hydrolysis 
probe mix (100 nM) (Table 7), and 4 µL of UltraPure™ DNase/RNase-free ddH2O. The 
remaining 5 µL of well volume was used for pure stock participant DNA, despite concentration. 
The thermocycling conditions established for this assay, using PrecisionFAST qPCR Master 
Mix and Custom-designed Real-time PCR Assays (Other Species) Primer and Double-dye 
(Taqman-style) kit for HPV6, E6/E7 [Primerdesign Ltd] protocols for reference, were as 
follows; a hot start for enzyme activation at 95°C for 2 mins, followed by 50 cycles of 
denaturation at 95°C for 5 secs and annealing at 60°C for 20 secs. Due to the use of a hydrolysis 
probe, there was no dissociation (melt) curve required.  
For absolute quantification, the pBRHPV-6b (HPV-6) plasmid (Karolinska Institutet) was used 
for an HPV-6 positive copy number standard curve. The standards followed a 10-fold serial 
dilution of copy number, as previously described (Section 4.4.1), with the highest copy number 
standard being 2x105 copies/µL (1x106 copies/5µL) and the lowest being 0.2x10-1 copies/µL 
(1x100 copies/5µL) (7 standards). Samples that amplified between the highest and lowest 
known standard copy numbers could be quantified (Section 4.8.2). 
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4.6.4 HPV11 E6 Type-Specific Screening 
All participant DNA samples identified as HPV positive or borderline/unknown were also 
screened using the following HPV-11 detection and quantification assay. For this assay, the 
composition of the real-time PCR mastermix per well was as follows; 10 µL of PrecisionFAST 
qPCR Master Mix [Primerdesign Ltd], 1 µL of custom-designed HPV-11 E6 primers (300 
nM)/hydrolysis probe mix (100 nM) (Table 7), and 4 µL of UltraPure™ DNase/RNase-free 
ddH2O. The remaining 5 µL of well volume was used for pure stock participant DNA, despite 
concentration. The thermocycling conditions established for this assay, using PrecisionFAST 
qPCR Master Mix and Custom-designed Real-time PCR Assays (Other Species) Primer and 
Double-dye (Taqman-style) kit for HPV11, E6/E7 [Primerdesign Ltd] protocols for reference, 
were as follows; a hot start for enzyme activation at 95°C for 2 mins, followed by 50 cycles of 
denaturation at 95°C for 5 secs and annealing at 60°C for 20 secs. Due to the use of a hydrolysis 
probe, there was no dissociation (melt) curve required.  
For absolute quantification, the pBRHPV-11 (HPV-11) plasmid (Karolinska Institutet) was 
used for an HPV-11 positive copy number standard curve. The standards followed a 10-fold 
serial dilution of copy number, as previously described (Section 4.4.1), with the highest copy 
number standard being 2x105 copies/µL (1x106 copies/5µL) and the lowest being 0.2x10-1 
copies/µL (1x100 copies/5µL) (7 standards). Samples that amplified between the highest and 
lowest known standard copy numbers could be quantified (Section 4.8.2). 
 
4.6.5 HPV-16 E7 Type-Specific Screening 
All participant DNA samples identified as HPV positive, or borderline/unknown were also 
screened using the following HPV-16 detection and quantification assay. For this assay, the 
composition of the real-time PCR mastermix per well was as follows; 10 µL of PrecisionFAST 
qPCR Master Mix [Primerdesign Ltd], 0.6 µL of forward and reverse HPV-16 E7 primers (300 
nM), 0.2 µL of hydrolysis probe (100 nM) (Table 7), and 3.6 µL of UltraPure™ DNase/RNase-
free ddH2O. The remaining 5 µL of well volume was used for pure stock participant DNA, 
despite concentration. The thermocycling conditions established for this assay, using the 
PrecisionFAST qPCR Master Mix protocol and the conditions published by Moberg et al., 
(2003) for reference, were as follows; a hot start for enzyme activation at 95°C for 3 mins, 
followed by 50 cycles of denaturation at 95°C for 5 secs and annealing at 60°C for 30 secs. Due 
to the use of a hydrolysis probe, there was no dissociation (melt) curve required.  
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For absolute quantification, the pBRHPV-16 (HPV-16) plasmid (Collins et al., 2009) was used 
for an HPV-16 positive copy number standard curve. The standards followed a 10-fold serial 
dilution of copy number, as previously described (Section 4.4.1), with the highest copy number 
standard being 2x105 copies/µL (1x106 copies/5µL) and the lowest being 0.2x100 copies/µL 
(1x101 copies/5µL) (6 standards). Samples that amplified between the highest and lowest 
known standard copy numbers could be quantified (Section 4.8.3). 
 
4.6.6 HPV-18 E7 Type-Specific Screening 
All participant DNA samples identified as HPV positive or borderline/unknown were also 
screened using the following HPV-18 detection and quantification assay. For this assay, the 
composition of the real-time PCR mastermix per well was as follows; 10 µL of PrecisionFAST 
qPCR Master Mix [Primerdesign Ltd], 0.6 µL of forward and reverse HPV-18 E7 primers (300 
nM), 0.2 µL of hydrolysis probe (100 nM) (Table 7), and 3.6 µL of UltraPure™ DNase/RNase-
free ddH2O. The remaining 5 µL of well volume was used for pure stock participant DNA, 
despite concentration. The thermocycling conditions established for this assay, using the 
PrecisionFAST qPCR Master Mix protocol and the conditions published by Gravitt et al., 
(2003) for reference, were as follows; a hot start for enzyme activation at 95°C for 3 mins, 
followed by 50 cycles of denaturation at 95°C for 5 secs and annealing at 60°C for 30 secs. Due 
to the use of a hydrolysis probe, there was no dissociation (melt) curve required.  
For absolute quantification, the pGEMII18-WT (HPV-18) plasmid (Collins et al., 2009) was 
used for an HPV-18 positive copy number standard curve. The standards followed a 10-fold 
serial dilution of copy number, as previously described (Section 4.4.1), with the highest copy 
number standard being 2x105 copies/µL (1x106 copies/5µL) and the lowest being 0.2x10-1 
copies/µL (1x100 copies/5µL) (7 standards). Samples that amplified between the highest and 
lowest known standard copy numbers could be quantified (Section 4.8.3). 
 
4.7 Gel Electrophoresis 
Following consensus and type-specific screening via real-time PCR, PCR products were 
electrophoresed on either 1% or 2% agarose gel using 1 x TBE (Tris-borate-EDTA) running 
buffer [89 mM Tris; 89 mM Boric acid; 2 mM EDTA] to separate DNA fragments based on 
size and charge. GelRedTM Nucleic Acid Gel Stain [10,000X in DMSO] [Biotium] was added 
to the agarose to permit band visualisation via UV fluorescence. 
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To run the gels, 10-15 µL of the PCR products was added to 5 µL of DNA loading buffer 
[0.05% (w/v) bromophenol blue; 40% (w/v) sucrose; 0.1 M EDTA, pH 8.0; 0.5% (w/v) sodium 
lauryl sulphate (SDS)] [Sigma-Aldrich], vortexed and then loaded to the agarose gel wells. As 
a comparison, a DirectLoad™ PCR 100bp Low Ladder [Sigma-Aldrich] was loaded on the 1% 
gels and a HyperLadder™ 25bp [Bioline] on the 2% gels (dependent on expected amplicon 
size), according to manufacturer’s instructions. The 1% gels ran for ~40-60 mins at a range of 
75–100 volts, whilst the 2% gels ran for ~2-2.5 hours at a range of 60–80 volts. Both were 
visualised using a ChemiDoc XRS+ System [Bio-Rad]. This allowed for comparison of band 
fluorescence and real-time PCR amplification and dissociation (melt) curves, for confirmation 
of HPV status per sample screened. 
 
4.8 Sample Analysis  
Real-time PCR data and gel electrophoresis results were interpreted to determine whether the 
participant samples contained beta-actin gDNA, HPV viral DNA, and if screened with HPV 
type-specific assays, HPV-6, HPV-11, HPV-16 and HPV-18 subtype viral DNA. Overall HPV 
prevalence was determined by the final HPV consensus screening methodology previously 
described in Chapter 3. Alternatively, beta-actin and all four HPV subtypes prevalence were 
determined via amplification fluorescence signal, whilst gene copy number/HPV viral load was 
determined via absolute quantification due to the use of hydrolysis probes for amplicon 
specificity. The following section(s) presents all type-specific methodologies for the 
interpretation of screening results. 
 
4.8.1 Beta-actin (ACTB) Quantification 
Using the previously described real-time PCR conditions in Section 4.6.1, all participant 
samples were screened for beta-actin for DNA integrity and to calculate cell number per sample 
for downstream viral load calculations, should the samples test HPV positive. In order to test 
for DNA integrity and calculate cell number, a beta-actin plasmid was used to create a known 
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Figure 13. Final ACTB Real-time qPCR Analysis Method. Data generated by AB® StepOnePlus™ 
Real-Time PCR System and software using established primer and cycling conditions previously 
described in Section 4.6.1 (n = 3). a) ACTB Amplification Plot – Raw fluorescence signal data (ΔRn) 
per known copy number standard (3 replicates) vs cycle number and threshold (0.5 ΔRn). b) ACTB 
Copy Number Standard Curve – Generated in Microsoft Excel using the mean ± standard deviation 
(error bars) quantification cycle (Cq) values (9 replicates) and LOG copy number per ACTB plasmid 
standard (1x106 – 1 copy/5µL).  
 
If beta-actin was detected in a participant DNA sample, the real-time PCR amplification plot 
revealed this via amplification fluorescence signal (ΔRn) data which was visually compared to 
the beta-actin plasmid dilutions of known copy numbers (Figure 13a). The earlier the 
amplification fluorescence signal was detected in the cycling, the higher the beta-actin gene 
copy number was in the participant sample, represented by the 1x106 copies standard at ~20.13 
cycles. Once the amplification fluorescence signal surpassed the quantification cycle (Cq) 
threshold, a Cq value was produced which could be used for quantifying an exact beta-actin 
gene copy number per sample using the equivalent beta-actin plasmid known copy number 
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standard curve (Figure 13b). Due to the amplification fluorescence signal being measured on a 
logarithm scale by the AB® StepOnePlus™ Real-Time PCR System [ThermoFisher 
Scientific], known copy numbers for the beta-actin plasmid standards were converted to 
logarithm values (LOG copy number) for plotting against Cq. Therefore, the copy number 
standard curve presented a negative linear regression line because the high Cq values 
corresponded to low copy numbers. The beta-actin copy number standard curve was considered 
a good predictor of beta-actin copy number in the samples due to exhibiting “ideal” accuracy 
indicators values, such as a slope value (m in y=mx+c) of -3.32 ± 10%, an R2 (correlation 
coefficient) value of >0.99 ± 0.1 and a reaction efficiency value of 100% ± 10% (calculated by 
formula C in Section 4.9) (ThermoFisher Scientific, 2016). 
Using formula B described in Section 4.9 and the established beta-actin standard curve (Figure 
13b), the exact copy number/5µL of beta-actin within all participant samples was calculated, 
providing the Cq values did not exceed the parameters of the standard curve (20.13 Cq – 38.65 
Cq). Any participant that exhibited an average Cq that was <20.13 was subjected to a 1:10 
dilution and measured again, whilst those that exhibited an average Cq that was >38.65 (or did 
not amplify or reach the threshold) were classified as “undetermined” and were therefore not 
viable for further screening. 
Following the calculation of exact copy number/5µL per sample replicate, cell number was 
calculated for downstream viral load calculations and to assess how effectiveness of the oral 
brushing collection technique. The average exact copy number/5µL per sample was calculated 
before being dividing by two, as there are only two copies of genomic beta-actin per human 
cell, for calculation of sample cell number/5µL. The exact copy number/5µL of any diluted 
samples was multiplied by 10 to reverse the dilution factor before averaging and dividing by 
two, for calculation of sample cell number/5µL. 
 
4.8.2 HPV-6 & HPV-11 Quantification 
Using the previously described real-time PCR conditions in Sections 4.6.3 and 4.6.4, all 
participant samples deemed to be HPV positive or borderline/unknown from the MY09/11 
consensus screen were screened for low-risk (LR) HPV types, HPV-6 and HPV-11. In order to 
test for both LR-HPV types and calculate viral load from viral gene (E6) copy number, the 
HPV-6 and HPV-11 plasmids was used to create known copy number standard curves (Figure 
14 & 15). 
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Figure 14. Final HPV-6 Real-time qPCR Analysis Method. Data generated by AB® StepOnePlus™ 
Real-Time PCR System and software using established primer and cycling conditions previously 
described in Section 4.6.3 (n = 3). a) HPV-6 Amplification Plot – Raw fluorescence signal data (ΔRn) 
per known copy number standard (3 replicates) vs cycle number and threshold (0.25 ΔRn). b) HPV-6 
Copy Number Standard Curve – Generated in Microsoft Excel using the mean ± standard deviation 
(error bars) quantification cycle (Cq) values (3 replicates) and LOG copy number per HPV-6 plasmid 
standard (1x106 – 1 copy/5µL).  
 
If HPV-6 was detected in a participant DNA sample via amplification fluorescence signal (ΔRn) 
data, alike beta-actin, it was visually compared to the HPV-6 plasmid dilutions of known copy 
numbers (Figure 14a). The Cq values produced by the amplification plot for all HPV-6 positive 
samples were also used for quantifying an exact HPV-6 E6 copy number using the established 
HPV-6 plasmid known copy number standard curve (Figure 14b). The HPV-6 copy number 
standard curve was considered a good predictor of HPV-6 copy number in the samples due to 
exhibiting “ideal” accuracy indicators values, such as a slope value (m in y=mx+c) of -3.32 ± 
10%, an R2 (correlation coefficient) value of >0.99 ± 0.1 and a reaction efficiency value of 
100% ± 10% (calculated by formula C in Section 4.9) (ThermoFisher Scientific, 2016). 
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Using formula B described in Section 4.9 and the established HPV-6 standard curve (Figure 
14b), the exact copy number/5µL of HPV-6 within all participant samples was calculated, 
providing the Cq values did not exceed the parameters of the standard curve (17.35 Cq – 37.49 
Cq). Any participant that exhibited an average Cq that was >37.49, or did not amplify, or if the 
signal did not reach the threshold were classified as “undetermined” and were therefore deemed 
HPV-6 negative. 
Following the calculation of exact copy number/5µL per sample replicate, HPV-6 viral load 
was calculated. First, the average exact copy number/5µL per sample was calculated before 
being dividing by sample cell number/5µL, determined from beta-actin screening. This gave 
HPV-6 copy number/cell, which was then multiplied by 1x106 cells to standardise the results 






















Figure 15. Final HPV-11 Real-time qPCR Analysis Method. Data generated by AB® StepOnePlus™ 
Real-Time PCR System and software using established primer and cycling conditions previously 
described in Section 4.6.4 (n = 3). a) HPV-11 Amplification Plot – Raw fluorescence signal data (ΔRn) 
per known copy number standard (3 replicates) vs cycle number and threshold (0.12 ΔRn) [1 copy 
standard not shown]. b) HPV-11 Copy Number Standard Curve – Generated in Microsoft Excel using 
the mean ± standard deviation (error bars) quantification cycle (Cq) values (3 replicates) and LOG copy 
number per HPV-11 plasmid standard (1x106 – 1 copy/5µL).  
 
If HPV-11 was detected in a participant DNA sample via amplification fluorescence signal 
(ΔRn) data, alike beta-actin and HPV-6, it was visually compared to the HPV-11 plasmid 
dilutions of known copy numbers (Figure 15a). The Cq values produced by the amplification 
plot for all HPV-11 positive samples were also used for quantifying an exact HPV-11 E6 copy 
number using the established HPV-11 plasmid known copy number standard curve (Figure 
15b). The HPV-11 copy number standard curve was considered a good predictor of HPV-11 
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copy number in the samples due to exhibiting “ideal” accuracy indicators values, such as a slope 
value (m in y=mx+c) of -3.32 ± 10%, an R2 (correlation coefficient) value of >0.99 ± 0.1 and a 
reaction efficiency value of 100% ± 10% (calculated by formula C in Section 4.9) 
(ThermoFisher Scientific, 2016). 
Using formula B described in Section 4.9 and the established HPV-11 standard curve (Figure 
15b), the exact copy number/5µL of HPV-11 within all participant samples was calculated, 
providing the Cq values did not exceed the parameters of the standard curve (17.56 Cq – 37.19 
Cq). Any participant that exhibited an average Cq that was >37.19, or did not amplify, or if the 
signal did not reach the threshold were classified as “undetermined” and were therefore deemed 
HPV-11 negative. 
Following the calculation of exact copy number/5µL per sample replicate, HPV-11 viral load 
was calculated. First, the average exact copy number/5µL per sample was calculated before 
being dividing by sample cell number/5µL, determined from beta-actin screening. This gave 
HPV-11 copy number/cell, which was then multiplied by 1x106 cells to standardise the results 
using the universal units of viral copy number/million cells, representing HPV-11 viral load. 
 
4.8.3 HPV-16 & HPV-18 Quantification 
Using the previously described real-time PCR conditions in Sections 4.6.5 and 4.6.6, all 
participant samples deemed to be HPV positive or borderline/unknown from the MY09/11 
consensus screen were screened for high-risk (HR) HPV types, HPV-16, and HPV-18. In order 
to test for both HR-HPV types and calculate viral load from viral gene (E7) copy number, the 
HPV-16 and HPV-18 plasmids was used to create known copy number standard curves (Figure 












Figure 16. Final HPV-16 Real-time qPCR Analysis Method. Data generated by AB® StepOnePlus™ 
Real-Time PCR System and software using established primer and cycling conditions previously 
described in Section 4.6.5 (n = 3). a) HPV-16 Amplification Plot – Raw fluorescence signal data (ΔRn) 
per known copy number standard (3 replicates) vs cycle number and threshold (0.5 ΔRn). b) HPV-16 
Copy Number Standard Curve – Generated in Microsoft Excel using the mean ± standard deviation 
(error bars) quantification cycle (Cq) values (3 replicates) and LOG copy number per HPV-16 plasmid 
standard (1x106 – 10 copies/5µL).  
 
If HPV-16 was detected in a participant DNA sample via amplification fluorescence signal 
(ΔRn) data, alike beta-actin and LR-HPV types, it was visually compared to the HPV-16 
plasmid dilutions of known copy numbers (Figure 16a). The Cq values produced by the 
amplification plot for all HPV-16 positive samples were also used for quantifying an exact 
HPV-16 E7 copy number using the established HPV-16 plasmid known copy number standard 
curve (Figure 16b). The HPV-16 copy number standard curve was considered a good predictor 
of HPV-16 copy number in the samples due to exhibiting “ideal” accuracy indicators values, 
such as a slope value (m in y=mx+c) of -3.32 ± 10%, an R2 (correlation coefficient) value of 
 
Page | 80  
 
>0.99 ± 0.1 and a reaction efficiency value of 100% ± 10% (calculated by formula C in Section 
4.9) (ThermoFisher Scientific, 2016). 
Using formula B described in Section 4.9 and the established HPV-16 standard curve (Figure 
16b), the exact copy number/5µL of HPV-16 within all participant samples was calculated, 
providing the Cq values did not exceed the parameters of the standard curve (20.35 Cq – 37.76 
Cq). Unlike LR-HPV type-specific screening, the HPV-16 assay required addition analysis for 
determine of HPV-16 status per sample due to primer design. Upon analysis with the Beacon 
Designer™ Free Edition Online qPCR Design Tool [PremierBiosoft], the HPV-16 
primer/probe set was found to exhibit some high ΔG scores, indicating problematic self-
dimerization (APPENDIX B, Figure 46), which could result in false positive samples. Without 
the ability to run a dissociation (melt) curve for product visualisation due to the use of 
hydrolysis probes, an additional analysis strategy was developed in order to determine which 
samples were indeed HPV-16 positive or negative. For standardisation, the same strategy was 
also employed within the HPV-18 sample assay, despite the primer analysis indicating a lack 
of secondary structures (APPENDIX B, Figure 47).  
Initially, all participant samples were run in triplicate whilst screening for HPV-16 and HPV-
18 to correspond to the HPV-16 (SiHa gDNA) and HPV-18 (HeLa gDNA) positive controls, 
negative controls and the plasmid standards. Dependent on the amplification results, repeat 
screens were performed on a selection of samples, resulting in six replicates being run in total. 
Repeat screening occurred if the sample fit one or more of the following criteria; late 
amplification in the cycling (>37 Cq), large standard deviations between the replicates (>0.3 
Cq) and/or the amplification signal of one or two replicates failing to reach the threshold. 
Following the repeat screening, samples were deemed negative if a definite positive status for 
HPV-16 or HPV-18 could not be determined, despite combining the two sets of replicates. If 
the second set of replicates appeared positive and/or exhibited one or more of the following 
criteria: earlier amplification in the cycling (<37 Cq), minimal standard deviation between the 
replicates (<0.3 Cq) and/or the amplification signal of two or all three replicates appeared to 
reach the threshold, the screening assay was run for a third time, resulting in nine replicates 
being run in total. If a definite HPV-16 or HPV-18 status could not be determined after this 
third and final repeat screening, the samples from the previous two were run on 2% agarose 
gels to determine band presence; 78 bp for HPV-16 and 137 bp for HPV-18. 
Following the analysis and calculation of exact copy number/5µL per sample replicate, HPV-
16 viral load was calculated. First, the average exact copy number/5µL per sample was 
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calculated before being dividing by sample cell number/5µL, determined from beta-actin 
screening. This gave HPV-16 copy number/cell, which was then multiplied by 1x106 cells to 
standardise the results using the universal units of viral copy number/million cells, representing 




Figure 17. Final HPV-18 Real-time qPCR Analysis Method. Data generated by AB® StepOnePlus™ 
Real-Time PCR System and software using established primer and cycling conditions previously 
described in Section 4.6.6 (n = 3). a) HPV-18 Amplification Plot – Raw fluorescence signal data (ΔRn) 
per known copy number standard (3 replicates) vs cycle number and threshold (0.2 ΔRn) [1 copy 
standard not shown]. b) HPV-18 Copy Number Standard Curve – Generated in Microsoft Excel using 
the mean ± standard deviation (error bars) quantification cycle (Cq) values (3 replicates) and LOG copy 
number per HPV-18 plasmid standard (1x106 – 1 copy/5µL).  
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If HPV-18 was detected in a participant DNA sample via amplification fluorescence signal 
(ΔRn) data, alike all other type-specific assays, it was visually compared to the HPV-18 plasmid 
dilutions of known copy numbers (Figure 17a). The Cq values produced by the amplification 
plot for all HPV-18 positive samples were also used for quantifying an exact HPV-18 E7 copy 
number using the established HPV-18 plasmid known copy number standard curve (Figure 
17b). The HPV-18 copy number standard curve was considered a good predictor of HPV-18 
copy number in the samples due to exhibiting “ideal” accuracy indicators values, such as a slope 
value (m in y=mx+c) of -3.32 ± 10%, an R2 (correlation coefficient) value of >0.99 ± 0.1 and a 
reaction efficiency value of 100% ± 10% (calculated by formula C in Section 4.9) 
(ThermoFisher Scientific, 2016). 
Using formula B described in Section 4.9 and the established HPV-18 standard curve (Figure 
17b), the exact copy number/5µL of HPV-18 within all participant samples was calculated, 
providing the Cq values did not exceed the parameters of the standard curve (17.94 Cq – 37.69 
Cq). The additional analysis strategy previously described for HPV-16 screening, was also 
employed for HPV-18 status determination. 
Following the analysis and calculation of exact copy number/5µL per sample replicate, HPV-
18 viral load was calculated. First, the average exact copy number/5µL per sample was 
calculated before being dividing by sample cell number/5µL, determined from beta-actin 
screening. This gave HPV-18 copy number/cell, which was then multiplied by 1x106 cells to 
standardise the results using the universal units of viral copy number/million cells, representing 




(A) Formula for calculating plasmid DNA copy number; used to quantify the four plasmid 
DNA stocks (HPV6, HPV11, HPV16 & HPV18) and create diluted solutions for use as 
standards in real-time qPCR standard curves: 
 
( 𝑿 𝒏𝒈 ×  𝟔. 𝟎𝟐𝟐𝟏 × 𝟏𝟎𝟐𝟑 𝒎𝒐𝒍𝒆𝒄𝒖𝒍𝒆𝒔 ∕ 𝒎𝒐𝒍𝒆)
((𝑵 × 𝟔𝟓𝟎 𝒈 𝒎𝒐𝒍𝒆⁄ )  ×  𝟏 × 𝟏𝟎𝟗 𝒏𝒈 𝒈⁄ )




Page | 83  
 
𝑿 = amount of DNA amplicon (ng) 
𝑵 = length of dsDNA amplicon (bp) 
𝑪 = number of copies of amplicon (molecules) 
 
 
(B) Formula of regression lines in copy number standard curves and how it was used to 
calculate the copy number of positive participant samples (absolute quantification): 
𝒚 = 𝒎𝒙 + 𝒄 
 
Rearranged to calculate LOG copy number: 
 
𝒙 = 𝒚 − 𝒄 ∕ −𝒎 
 
Then, LOG copy number is inverted to produce the real copy number value: 
                                     
𝟏𝟎^(𝑳𝑶𝑮 𝑪𝒐𝒑𝒚 𝑵𝒖𝒎𝒃𝒆𝒓) 
 
𝒚 = Quantification Cycle (Cq) of samples 
𝒙 = LOG Copy Number 
𝒄 = y-intercept 
𝒎 = slope of regression line 
 
 
(C) Formula for calculating qPCR reaction efficiency (%) (to measure the rate of amplicon 
generation) using the standard curve slope (m) value; used to assess if there were any 
problems with the qPCR reaction (e.g. cycling conditions, inhibitors, and incorrect copy 
numbers): 
 
                          𝑬 = ( 𝟏𝟎^(-1 ÷ 𝒎) -1 ) × 𝟏𝟎𝟎% 
 
  𝑬 = Efficiency (%) 
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Chapter 5:  
ORAL HPV QUESTIONNAIRE ANALYSIS METHODS 
 
To explore cohort identity and determine if prevalence and abundance of infection was 
influenced by HPV type, vaccination status, and lifestyle choices of an individual, HPV 
screening results were analysed against questionnaire data on factors associated with the 
contraction of oral HPV and linked to HPV positive OPSCCs progression, such as smoking 
status, alcohol consumption, and sexual practice.  The following chapter will describe how the 
questionnaire data was handled prior to statistical analysis and during statistical analysis, whilst 
comparing gender (Chapter 6) and HPV prevalence and abundance (Chapter 7). 
 
5.1 Questionnaire Design & Data Handling 
The questionnaire(s) was designed to include closed dichotomous and multiple-choice 
questions, and very few open-response questions, for the collection of quantitative categorical 
data. As previously described in Chapter 4, there were two questionnaires for two different 
sample collection periods within the study; Phase 1 (P1) was in September/October 2016 and 
Phase 2 (P2) was in March/April 2017. P1 participants filled out an older pilot version of the 
study questionnaire than P2 participants (Chapter 4) who filled out an improved version with 
updated questions on smoking and alcohol consumption [APPENDIX H & I]. The P1 
questionnaire also asked participants about family history of cancer, current medical conditions, 
and sunbed use, which was used for another study on a Merkel Cell Polyomavirus (MCPyV), 
therefore, these questions were omitted from the HPV study analysis. In total, there were six 
key (baseline) overarching research themes within the questionnaire which required exploration 
within this study including, cohort demographics, smoking characteristics, alcohol 
consumption characteristics, relationship information, sexual behaviour, and HPV-related data. 
Due to the use of two questionnaires, the collected participant data was combined, where 
possible, and organised in Excel [Microsoft] for full cohort analysis. For successful statistical 
exploration, all questionnaire data was also cleansed, which involved identifying missing 
responses and cleaning up the database. Before finally being transferred to an IBM SPSS 
Statistics v26 [IBM Corp] database for statistical analysis, all variables were numerically coded 
to ensure the data could be “read” by SPSS. 
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5.1.1 Demographic Data 
The first key research theme of the questionnaire(s) that required cleansing and organising of 
data for analysis was cohort demographics including gender (self-identified), age and ethnicity. 
For gender and age, participants were provided with multiple-choice options to select, whilst 
ethnicity was an open-response question, giving the participants the option to state their own 
ethnic identity. For analysis, ethnicity responses were categorised into five overarching groups 
(White, Mixed/Multiple Ethnic Groups, Asian/Asian British, Black/African/Caribbean/Black 
British, and Other Ethnic Groups/Unknown), according to Office for National Statistics 
recommendations (Office for National Statistics, 2009a). For ease of further statistical analyses 
(2 x 2 crosstabulations), ethnicity was also categorised into two overarching groups (White 
British and Other White, BAME & Unknown). 
 
5.1.2 Smoking Data 
The second key research theme of the questionnaire(s) was cohort smoking characteristics 
including status, frequency, amount, other tobacco-based substances and non-tobacco related 
substances. Smoker status was determined by asking participants if they currently smoked or 
previously smoked. If participants did not provide a response and moved onto the next set of 
questions as instructed, they were classified as “never-smokers”. For “current-smokers” or 
“former-smokers”, data on mean number of cigarettes smoked per sitting was also collected 
alongside frequency as measures of smoking intensity and amount. The P2 questionnaire also 
asked smokers about how many years they had engaged in smoking (absent in P1), which could 
be combined with number of cigarettes per sitting and frequency to calculate pack years – a 
gold standard clinical measure of smoking frequency and intensity (De Vita et al., 2019).  
Pack years was calculated by first, determining how many cigarettes each participant smoked 
per day using the amount and frequency provided. For instance, the number of cigarettes 
smoked in each sitting for “3-5 times/week” smokers were multiplied by 4, as an average 
number of days spent smoking, and then divided by 7, a full week’s duration. Mean number of 
cigarettes per day were then divided by 20 (cigarette pack size) and multiplied by the number 
of years smoked to calculate pack years (Khan et al., 2006; Masters & Tutt, 2010). As pack 
years could only be calculated for P2 participants, both pack years and cigarettes per day were 
used as measures of smoking intensity and amount to ensure the full smoker cohort underwent 
comparative analyses. Those individuals who were calculated to have smoked <100 cigarettes 
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in their lifetime were also categorised as “never-smokers”, in accordance with the literature 
(CDC, 2020; NHS Digital, 2020) but recorded for recognition of potential “social-smokers”. 
Participants that smoked were also asked if they engaged in any other tobacco-based smoking 
such as tobacco pipes, cigars and shisha/water-pipes. If participants answered “yes” in response, 
they were asked to specify and provide the amount and frequency of said substance, similar to 
cigarette smoking. As these were tobacco-based products, and heavy engagement could 
contribute to OPSCC development alike cigarette smoking (Szyfter et al., 2019), the equivalent 
number of cigarettes per day was calculated, alongside pack years if duration of smoking was 
known, using literature and NHS clinical guidelines for healthcare staff. To calculate the 
equivalent number of cigarettes per sitting (and per day) from other tobacco-based products, 
the following guidelines were used; 1 cigar = 4 cigarettes, 1 bowl of a pipe = 2.5 cigarettes 
(Masters & Tutt, 2010; NHS Scotland, 2014), 1 water-pipe session (~45 minutes) = 10 
cigarettes (Jawad, Khaki & Hamilton, 2012; Masters, Tutt & Yaseen, 2012).  
Alongside tobacco-based smoking, participants were also able to offer information on non-
tobacco-based smoking such as vaping/e-cigarettes and cannabis smoking. If participants 
answered “yes” in response, they were asked to specify and provide the amount and frequency 
of said substance. Vaping/e-cigarettes usage was more difficult to quantify than tobacco-based 
products due to the many variables involved with refillable e-liquids, such as cartridge sizes, 
flavourings, and batteries (Cooper, Harrell & Perry, 2016), therefore frequency and amount 
were omitted from the analysis. For cannabis smoking, amount could be compared via number 
of cannabis cigarettes per day, whilst frequency sub-levels mirrored that of cigarette smoking. 
Cannabis smokers were also given a smoker status, even if they did not smoke cigarettes, as 
cannabis cigarettes almost always contain tobacco mixed with cannabis (Macleod et al., 2015). 
Ideally, quantity would have been measured by calculating the amount of cannabis (in grams) 
smoked across the cohort but due to large variations in cannabis cigarette sizes and types, this 
was not possible. Instead, number of cannabis cigarettes per day was used as a measure of 
quantity with the same calculation used for tobacco cigarettes.  
 
5.1.3 Alcohol Consumption Data 
The third key research theme of the questionnaire(s) was cohort alcohol consumption 
characteristics including status, frequency, amount, type, and NHS/NICE health risk status 
linked to drinking behaviour. Alcohol consumption status was determined by asking 
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participants if they currently or previously drank alcohol. If participants did not provide a 
response and moved onto the next set of questions as instructed, they were classified as “never-
drinkers”. Alternatively, to smoker status, “never-drinkers” only encompassed those that had 
never drunk alcohol rather than a minimal lifetime amount (CDC, 2018). 
Similar to smoking characteristics, participants were asked about drinking frequency and 
amount. The P2 questionnaire included a question for “current-drinkers” only, asking if they 
previously engaged in heavier drinking than their current behaviour due to the link between oral 
mucosa damage and long-term heavy drinking, past or present (Kawakita & Matsuo, 2017), but 
this was omitted from the analysis due to the small number of responses. For amount, 
participants were asked what types of alcohol they drank (multiple-choice) and how many 
drinks were consumed per frequency level selected (numerical open-response). The purpose of 
this was to determine how many units on average were consumed per sitting as research has 
shown that the average person does not know how many units they consume per week or how 
many are in their favourite alcoholic drinks (Buykx et al., 2018). The P2 questionnaire gave 
participants two extra categories to choose from for alcohol types – cider and alcopops – as 
these were frequent responses for the “other” category in the P1 questionnaire cohort.  
Using NHS guidelines and the information on type and amount provided, each participants’ 
average unit intake per sitting was calculated (NHS, 2018; Alcohol Change UK, 2020). As an 
example, four bottles of beer/cider/lager (330ml, ABV 5%) at 1.7 units were calculated to be 
6.8 units in total. This information combined with frequency was then used to calculate weekly 
units which could be compared across the entire cohort. To calculate weekly units, the number 
of units consumed in each sitting was multiplied/divided by the frequency. For instance, 6.8 
units per sitting was multiplied by 4, as an average number of days spent drinking, for those 
that drank “3-5 times/week”, whilst 6.8 units per sitting was divided by 4 for those that drank 
“once a month”. This information was used to determine if participants drank more than the 
recommended maximum weekly 14 units for both men and women (NICE, 2010; Department 
of Health & Social Care, 2016). 
As heavy frequent drinking has been shown to be a risk factor for the development of OPSCCs, 
binge drinking prevalence was determined using calculated units per sitting and NHS guidelines 
(van Monsjou et al., 2013). Participants that drank ≥7 units in one sitting were classified as 
binge drinkers which was calculated by averaging ≥8 units for men and ≥6 units for women 
(NICE, 2010; Office for National Statistics, 2017).  
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Weekly consumption data was also used to determine overall health risk related to drinking 
behaviour via NHS/NICE health risk status; a clinical risk indicator system for the likelihood 
of developing health problems/conditions based on levels of alcohol consumption (NICE, 2010; 
NHS Digital, 2016b). Participants were categorised according to the five levels of the NHS risk 
assessment; “no-risk” participants were “never-drinkers” or “former-drinkers” that used to 
consume <35 units per week; “pre-risk” participants were “former-drinkers” but used to 
consume  ≥35 units per week; “lower-risk” participants consumed <14 units per week (under 
the recommended weekly limit); “increasing-risk” participants consumed between 14-35 units 
per week; whilst “higher-risk” participants consumed ≥35 units per week. The NHS guidelines 
do provide higher thresholds per risk level for men (for instance, “higher-risk” = ≥50 units per 
week) but due to the weekly recommended number of units changing to 14 units for both men 
and women in 2016 (Department of Health & Social Care, 2016), the thresholds per risk level 
for women were used for standardisation of all participants in this study and to allow direct 
comparison between genders. 
 
5.1.4 Relationship Data 
The fourth key research theme of the questionnaire(s) was cohort relationship characteristics 
including status, length of relationship, type and sexual orientation. For relationship status, type 
and sexual orientation, participants were provided with multiple-choice options to select, whilst 
length of relationship was a numerical open-response question. For this theme, there were only 
minor revisions required during data cleansing in comparison to smoking characteristics, 
alcohol consumption characteristics and sexual practice.  
Firstly, participants were asked if they were in a relationship and if so, how long they had been 
in that relationship (“short-term” = <1 year; “long-term” = ≥1 year). All relationship lengths 
were converted to months, which also lead to the recategorisation of some participants’ 
relationship status responses for those participants that selected the incorrect option for the 
length of their relationship. There were also no responses for the option of “divorced/widowed” 
so it was omitted from the data analysis. For type, those in relationships were asked if they 
engaged in monogamy or would describe their relationship as monogamous. Some “single” 
participants answered the question, so their responses were recategorised to “N/A”, whilst those 
that stated they were in “short-term” or “long-term” relationships but selected “N/A” were 
recategorised to “Unknown”. 
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5.1.5 Sexual Practice Data 
The fifth key research theme of the questionnaire(s) that required cleansing and organising of 
data for analysis was sexual practice including general descriptors (such as, open-mouth 
kissing, sexual intercourse/activity in last year and sexually transmitted disease/infection 
[STD/STI] status), number of sexual partners, sexual activity, one-night stand (ONS) frequency 
and condom usage. The questionnaire(s) was designed to include a variety of quantitative 
questions on factors linked to oral HPV transmission and genital HPV transmission to allow for 
the exploration of sexual practice data in relation to differences in type, prevalence, and 
abundance of HPV. 
All questions on general descriptors were dichotomous and required little data cleansing, unless 
participants had not provided a response despite being sexually active, which was classed as 
missing data and was recategorised to “unknown”. The multiple-choice sexual practice 
questions required more data cleansing than the dichotomous questions due to multiple sub-
levels and changes to the structure of some questions between the P1 and P2 questionnaires. 
For example, P1 questionnaire gave five options to choose from for total number of sexual 
partners, whilst P2 gave seven to break down the higher range of “21-39” sexual partners into 
two categories. Due to lack of responses and ease of statistical analysis, both P1 and P2 datasets 
were reduced to four options and combined. The two options of “6-10” and “11-20” were 
consistent across both questionnaires, whilst those that had “less than 5” (P1) sexual partners 
were grouped with “1-5” (P2) sexual partners and all options succeeding 20 sexual partners 
were combined into a final fourth option (“21-39” and “≥40” in P1; “21-30”, “31-40”, “41-50” 
and “>50” in P2) of “>20” sexual partners. 
For sexual activity, participants were asked to select all activities that applied to them including, 
vaginal sex, anal sex, oral sex, foreplay (sexual activity with a partner) and masturbation (sexual 
activity without a partner). This allowed for each activity to be compared separately across the 
cohort as each were treated as five separate dichotomous variables. The number of sexual 
activities engaged in per participant was also calculated to determine level of sexual diversity, 
creating a new variable for statistical analysis. 
Furthermore, both ONS frequency and condom usage data was gathered using multiple-choice 
questions but included scales to produce ranked ordinal responses for analysis. Both variables 
also required combining of responses for full cohort analysis as there were differences between 
the P1 and P2 questionnaires. ONS frequency revisions allowed for data from two P1 questions 
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(Q18 & Q18a) to be combined in one using the new P2 scale of 1-5 (1 = None; 2 = Some 
[~25%]; 3 = Half [~50%]; 4 = Most [~75%]; 5 = All). Condom usage within the P2 
questionnaire also used a new 1-5 scale (1 = Always; 2 = Sometimes [~25%]; 3 = 50/50; 4 = 
Mostly [~75%]; 5 = Never), allowing for combining of equivalent P1 categories. The “50/50” 
category, however, was omitted from the analysis due to lack of responses. Those that selected 
“never”, were asked to specific why as an open-response question within both questionnaires. 
Each participant response was coded according to the reason stated and grouped to calculate 
prevalence for those reasons within the cohort (for example, OC = oral contraception). This 
data was then used to give an indication of those in the cohort that possibly were not protected 
against HPV, such as those that gave no reason (NR) for not using barrier contraception. 
 
5.1.6 HPV-Related Information 
The sixth and final key research theme of the questionnaire(s) that required cleansing and 
organising of data for analysis was HPV-related information including previously diagnosed 
HPV infection(s), previously diagnosed HPV-related precursor/cancer(s) and HPV vaccination 
status (including healthcare provider). Similar to relationship information, there were only 
minor revisions required during data cleansing due to the use of largely dichotomous questions. 
For those that had been previously diagnosed with an HPV infection(s), participants were asked 
when they were diagnosed for calculation of the length of time between diagnosis and 
participation in the study (2016 or 2017). For those that had been previously diagnosed with an 
HPV precursor/cancer(s), participants were asked about their specific diagnosis. Both sets of 
questions were included to 1) determine if those participants presented an oral HPV infection 
alongside another, indicating multi-site infection, and 2) determine if those participants 
exhibited persistent HPV infections, should they have tested positive for oral HPV in this study 
as well. 
 
5.2 Statistical Analysis 
Following data cleansing and grouping, a new equivalent coded database was created for 
inputting data into SPSS to ensure the data could be read by the programme. For categorical 
data, a series of numbers were used to represent each possible response per question under each 
variable. For example, “Yes” responses were coded as 1 and “No” responses were coded as 2, 
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whilst continuous numerical data, such as copy number, was directly input into SPSS. By doing 
so, variables could be classified as “Numerical” and values could be classified as “Nominal”, 
allowing non-parametric tests to be conducted. In total, regrouping, and converting the 
participant data into a coded format condensed the original database from 166 columns of data 
down to a more manageable 73. 
Most of the statistical analysis performed within this study was via Pearson’s Chi-square test, 
used to determine if there was any statistically significant relationship between two categorical 
variables with two or more categorical, independent sub-levels. Statistical significance was 
determined via p-values in comparison to threshold alpha (α) values of * p ≤ .05 (95% CI), ** 
p ≤ .01 (99% CI), *** p ≤ .001 (99.9% CI) for acceptance or rejection of null hypotheses of no 
difference between variables. All three α values were used for comparisons to reduce the chance 
of type I (false positives) and type II errors (false negatives) within the analysis for a robust and 
reliable exploration, especially when cross-comparing individual sub-levels (2 x 2) within a 
larger crosstabulation; 2 x 6, for instance. A large proportion of the lifestyle data comparisons 
between gender (Chapter 6) and HPV prevalence (Chapter 7) was performed by Chi-square 
analysis due to the relatively large sample size but with smaller sample sizes, such as within the 
HPV positive cohort only, comparisons were made using Fisher’s Exact test. This test was used 
when any of the variable sub-levels had expected counts <5. There is a common misconception 
that Fisher’s Exact tests cannot be used on crosstabulations larger than 2 x 2, as traditionally 
these analyses were conducted by hand, but SPSS is capable of the statistical calculations 
required by analysis so Fisher’s Exact could be used (Kim, 2017). 
Despite both Chi-square and Fisher’s Exact tests being used for determination of significance 
in relationships between two categorical variables, both are known to be influenced by sample 
size and do not express how significantly associated differences are (effect size). To test for 
effect size/strength of association, regardless of sample size, the Cramer’s V test was used 
following the discovery of a statistically significant result as a measure of data reliability. 
Cramer’s V test was chosen as it can be used with crosstabulations larger than 2 x 2 and 
successfully measure strength of association within datasets of all sizes. Interpretation of the 
Cramer’s V effect size results varied dependent on the number of degrees of freedom from the 
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Table 8. Interpretation of Cramer’s V Effect Size. Strength of association threshold values for a 
small, medium or large effect size (≥) dependent on the number of degrees of freedom from the 
significance test performed (Kim, 2017). 
 
 
The remaining ordinal or continuous questionnaire data such as frequency scales, pack years, 
mean number of cigarettes or alcohol units, and copy number, were subjected to normality and 
homogeneity of variance tests (assumption testing) to determine if parametric analyses was 
appropriate for each variable. For normality, the Shapiro-Wilk test was used as it was most 
suitable for distribution testing in datasets with <2000 values being tested (Yap & Sim, 2011). 
For homogeneity of variance, the Levene’s test was used as it was able to compare the variance 
via means and medians with adjusted degrees of freedom, which could be used for continuous 
and ordinal data, respectively (Gastwirth, Gel & Miao, 2009). Both tests used a threshold α 
value of * p ≤ .05 to determine statistical significance; any values that were p ≤ .05 indicated 
that the data was not normally distributed (per sub-level) and/or that there was heterogeneity of 
variance in the dataset. Where the ordinal or continuous variables were not normally distributed 
but did exhibit homogeneity of variance, non-parametric testing was deemed the most 
appropriate in the form of Mann-Whitney U or Kruskal-Wallis H tests, depending on the 
number of sub-levels within the independent comparison variable. Where the ordinal or 
continuous variables were not normally distributed but exhibited heterogeneity of variance, 
alternative non-parametric tests (such as Chi-square or Fisher’s Exact test) were performed 
(dependent on sample size), or the data was omitted from the analysis due to the lack of any 
other analysis options. None of the variables tested were normally distributed so only non-
parametric tests were used throughout the study. 
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Following assumption testing, either the Mann-Whitney U test or Kruskal-Wallis H test was 
used to determine if there were any statistically significant differences between two or more 
independent sub-levels when the dependent variable was ordinal or continuous. The Mann-
Whitney U test was used for testing only two independent sub-levels, such as gender, whilst the 
Kruskal-Wallis H test was used for testing more than two independent sub-levels, such as 
smoking and alcohol consumption status. Both tests also used a threshold α value of * p ≤ .05 
to determine statistical significance of mean ranks. 
In summary, a combination of statistical approaches were used to analyse the questionnaire and 
screening data within the study. Most variables were categorical and therefore required Chi-
square or Fisher’s Exact testing, whilst others were ordinal or continuous so required Mann-
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Chapter 6:  
COHORT IDENTITY OF ORAL HPV STUDY 
 
The aim of the study was to establish oral HPV infection rates and viral load within the UK 
young adult population to determine if prevalence and abundance of infection was influenced 
by HPV type, vaccination status, and lifestyle choices of an individual. Questionnaire data was 
collected for analysis of lifestyle data alongside an oral swab for HPV screening. Each stage of 
data collection (combining P1 and P2) and sample exclusion was recorded, including the 
number of samples taken forward per methodology step (Figure 18). 
 
 
Figure 18. Study Selection. ACTB = Beta-actin housekeeping screening and real-time PCR absolute 
quantification for sample viability and cell number; HPV = Human papillomavirus consensus screening 
with MY09/11 primers and HPV-6, HPV-11, HPV-16 & HPV-18 type-specific probe-primers. 
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In order to make comparisons between HPV infection, viral load and lifestyle, cohort identity 
was established first. In total, 452 participants were recruited for the study but 3.09% (n = 
14/452) were excluded due to 1) illegible consent forms or lack of signature, or 2) one of three 
required data collection components (questionnaire, consent, or oral swab) not being returned 
to the research team (Figure 18). As a result, the total study cohort was 438 participants, with 
408 oral swabs taken forward for HPV consensus screening after testing with b-actin primers 
to assess the viability of the DNA samples.  
 
6.1 Cohort Demographics & Characteristics 
The study cohort’s questionnaire data (n = 438) was recorded in Microsoft Excel for cleansing 
to remove missing data, grouping, and organising into six key research themes, and coding for 
subsequent statistical analysis using SPSS. The first theme to be explored was cohort 
demographics, to investigate how representative the cohort was of the young adult UK 
population (Table 9). 
 
Table 9. Study Cohort Demographics. Total participant counts (n) and cohort percentages (%) per age 
range (in years), gender (M = male, F = female; no participants stated alternative gender identities) and 
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Overall, a higher proportion of participants identified as female (59.36%, n = 260/438) than 
male (40.64%, n = 178/438) within the study cohort, with 92.01% aged between 18-25 years 
old (Table 9). This age bias was to be expected due to the student inclusion criteria of the study, 
but also meant the cohort was not representative of the entire population of England and Wales 
compared to the 2011 Census which revealed 29.50% of the population were aged between 18-
39 years old (Office for National Statistics, 2018). Therefore, only 7.99% of the study cohort 
were >26 years old so were categorised as mature students due to being older than the average 
age of undergraduate students attending university. For gender, however, the study cohort was 
comparable to England and Wales’ gender distribution in the 2011 Census (M = 49.00%; F = 
51.00%) and Natsal-3 (M = 41.51%; F = 58.49%) (Mercer et al., 2013; Office for National 
Statistics, 2018), which were both used as comparative datasets for this study. 
Cohort ethnicity was also biased with the largest proportion identifying as “White” at 86.76% 
(n = 380/438), which was considerably higher than the national average of 29.50% attending 
universities across the UK (Universities and Colleges Admissions Service, 2019), with 82.65% 
(n = 362/438) identifying more specifically as “White British” (Table 9). This was, however, 
comparable with Natsal-3 as 87.50-87.80% of their study cohort, dependent on gender, 
identified as “White” (Mercer et al., 2013). 
 
6.1.1 Baseline Smoking Characteristics 
To further identify if the cohort was representative of the wider young adult UK population and 
those within the cohort at risk of developing OPSCCs and/or engaging in practices associated 
with contracting an oral HPV infection, data on lifestyle characteristics in terms of smoking, 
alcohol consumption, sexual practice, HPV vaccination status and HPV-related information 
was also collected and collated (Tanton et al., 2015; Paquette et al., 2017). The first to be 
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Table 10. Baseline Smoking Characteristics. Participant counts (n), cohort percentages (%) or means 
± standard deviation per smoking characteristic including determined smoker status (CDC, 2020; NHS 
Digital, 2020), frequency, calculated data (incl. cigarettes/day and pack years), other tobacco and non-
tobacco substances.  
 
a Data shown for n = 111 (total smoker count; former and current) rather than entire cohort of n = 438. 
b Only calculated for P2 participants; smoking history unavailable for P1 participants (Chapter 5, Section 5.1.2). 
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In terms of smoker status, 18.72% (n = 82/438) of the cohort were classified as “current-
smokers”, 6.62% (n = 29/438) were classified as “former-smokers” whilst the largest proportion 
at 74.66% (n = 327/438) were classified as “never-smokers” according to NHS and CDC 
guidelines (CDC, 2020; NHS Digital, 2020) (Table 10). Overall, 25.34% (n = 111/438) of the 
cohort had smoked at some point in their lifetimes which was ~10% higher than the national 
average (Office for National Statistics, 2019a) but comparable to NHS data on young adults 
and “non-risky” categorised males and females aged 16-24 years old involved in the Natsal-3 
study (Khadr et al., 2016; NHS Digital, 2016a). However, 16.21% (n = 53/327) of the “never-
smokers” had smoked before, but less than 100 cigarettes in their lifetimes, increasing overall 
cohort smoking frequency by 12.10% to 37.44% (n = 164/438).   
Of the participants that smoked (current and former, n = 111), the mean number of cigarettes 
smoked per day was 5.58 ± 5.40, with a range of 19.97 (0.03-20.00 cigarettes per day) and a 
modal value of 10.00 cigarettes per day (Table 10). The highest proportion of the cohort 
smokers smoked “Daily” at 45.05% (n = 50/111), which would change to a “Few times a year” 
(n = 60/164) when taking social “never-smokers” (those who had smoked previous but less than 
100 cigarettes in their lifetimes) into account. Pack years could not be calculated for the whole 
smoking cohort, only those involved in P2 of the study. The mean pack years for P2 participants 
was 1.83 ± 3.75 years, with a range of 26.98 (0.02-27.00) pack years, and a modal value of 0.02 
pack years (Table 10). This could not be compared with recent national statistics due to the data 
being unavailable. 
Furthermore, of the participants that smoked (current and former), 18.92% (n = 21/111) also 
smoked/had smoked other-tobacco-based products other than cigarettes (Table 10). In total, 
5.41% (n = 6/111) stated that they smoked/had smoked cigars; 0.90% (n = 1/111) stated that 
they smoked/had smoked pipes, whilst 13.51% (n = 15/111) stated that they used/had used 
water pipes (shisha pipes). Use of these alternative tobacco-based products was notably less 
frequent than that of cigarette smoking with the modal frequency being “Few times a year” as 
opposed to “Daily” for cigarette smoking. No other types of tobacco-based smoking were 
reported.  
Alongside tobacco-based smoking, cannabis smoking and vaping/e-cigarette usage data was 
also recorded. In total, 13.47% (n = 59/438) of the entire cohort were smokers of cannabis, with 
a mean of 1.16 ± 2.50 cannabis cigarettes per day and a range similar to tobacco-based cigarette 
smoking at 14.99 (0.01-15.00) cannabis cigarettes per day (Table 10). The frequency of 
cannabis smokers was only slightly lower than the national average of 17.30% in young adults 
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aged between 16-24 years old (Office for National Statistics, 2019b). For vaping/e-cigarette 
usage, 1.37% (n = 6/438) stated that they frequently used these alternatives to tobacco-based 
smoking (Table 10), which again, was slightly lower than the national average of 6.3% (Office 
for National Statistics, 2019a). It was not, however, recorded if vaping/e-cigarette usage was in 
replacement to cigarettes or coinciding. 
 
6.1.2 Baseline Alcohol Consumption Characteristics 
To further identify those within the cohort at risk of developing OPSCCs and/or engaging in 
practices associated with contracting an oral HPV infection and if the cohort was representative 
of the wider young adult UK population, questionnaire data on alcohol consumption was then 
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Table 11. Baseline Alcohol Consumption Characteristics. Participant counts (n), cohort percentages 
(%) or means ± standard deviation per alcohol drinking characteristic. These included status, frequency, 
type, calculated data (incl. units/week, binge drinking status, and number of types consumed, if 
available), and NHS/NICE health risk status (NICE, 2010; Department of Health and Social Care, 2016; 
NHS Digital, 2016b). 
 
a Data shown for n = 401 (total alcohol drinker count; former and current). 
b Only calculated for those participants that provided data on alcohol amount, type and frequency. 
c Calculated using units/week according to NHS/NICE health risk classification system (Chapter 5, Section 5.1.3). 
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Most of the cohort, at 88.58% (n = 388/438), were current alcohol drinkers (Table 11), which 
was comparable to the Health Survey for England 2015 which estimated 83% of the population 
engaged in alcohol consumption (NHS Digital, 2016b). Of the participants that consumed 
alcohol (current and former, n = 401), the mean number of units consumed per week was 14.5 
± 15.67, with a large range of 78.6 (1.0-79.6 units/week) and a modal frequency of  “1-2 
times/week” exhibited by 34.41% (n = 138/401) of the drinking cohort (Table 11). These 
findings were also concurrent with data from the Health Survey for England 2015, especially 
unit consumption, as an estimated mean of 11.90 units per week was reported (NHS Digital, 
2016b). 
The most popular type of alcoholic drink amongst the drinking cohort was “Spirits & Mixer” 
at 68.08% (n = 273/401) whilst the least popular type was “Alcopops” at 11.72% (n = 47/401), 
with 65.09% (n = 261/401) consuming more than one different type of alcohol per sitting (Table 
11). Conversely, these findings were not comparable with national NHS data as beer and wine 
were reported to be the types most regularly drank in England, especially within those 
exceeding the weekly unit guidelines (NHS Digital, 2017). 
Furthermore, a large proportion of the drinking cohort at 37.91% (n = 152/401) were also 
classified as binge-drinkers (≥7 units in each sitting; see Chapter 5, Section 5.1.3); 33.92% (n 
= 136/401) were not; 28.18% (n = 113/401) did not provide the appropriate information for this 
to be calculated (Table 11). The prevalence of binge drinking within the study cohort was ~10% 
higher than the national average but equal to levels for 16-24-year-olds (Office for National 
Statistics, 2017). 
By utilising the units per week data and NHS/NICE guidelines, an overall indicator of health 
related to drinking behaviour was determined (NHS/NICE Health Risk Status) per participant, 
for the entire cohort (n = 438) (see Chapter 5, Section 5.1.3). Overall, 9.82% (n = 43/438) 
exhibited no-risk (including never-drinkers), 0.23% (n = 1/438) were determined to have a “Pre-
risk” status, 41.32% (n = 181/438) were “Lower-risk”, 15.98% (n = 70/438) were “Increasing-
risk”, whilst only 6.85% (n = 30/438) were “Higher-risk” (Table 11). The cohort proportions 
for “Increasing-risk” and “Higher-risk” were comparable NHS data for 16–24-year-olds but 
“Lower-risk” was 20% lower due to not including underage drinkers (<18 years old) like the 




Page | 102  
 
6.1.3 Baseline Relationship Characteristics 
The fourth theme from the questionnaire data to be explored was relationship characteristics 
(Table 12). It was important to include such data for cohort comparisons to Natsal-3 (Mercer et 
al., 2013), to assess how representative and similar the study cohort was to national datasets for 
sample validity. 
 
Table 12. Baseline Relationship Characteristics. Participant counts (n), cohort percentages (%) or 
means ± standard deviation per relationship characteristic including status, descriptors and sexual 
orientation. 
 
a Data shown for relationship cohort; n = 248 (short-term (<1 year) and long-term/married (≥1 year) cohort). 
 
For relationship status, the highest proportion of the cohort, at 43.38% (n = 190/438), stated 
they were “Single” which was only 3.28% higher than those in “Long-term/Married” 
relationships (>1 year in length) at 40.18% (n = 176/438) (Table 12). These findings were 
comparable to Natsal-3 as the highest proportion of 16-24-year-olds within their study were 
also “Single” but ~40% higher, as non-marital or non-cohabiting short and long-term 
relationships were included in this category (Mercer et al., 2013). Of the 56.62% (n = 248/438) 
in relationships, 91.13% (n = 226/248) stated they were monogamous and reported a mean 
relationship length of 30.12 ± 36.80 months (Table 12). These findings could not be compared 
to Natsal-3 as they did not collect and/or publish such data (Mercer et al., 2013). 
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Information on sexual orientation was also collected for comparisons to Natsal-3. The largest 
proportion of the study cohort at 81.05% (n = 355/438) identified as “Heterosexual”, whilst 
3.20% (n = 14/438) identified as “Homosexual” and 8.45% (n = 37/438) as “Bisexual” (Table 
12). The remaining 7.31% (n = 32/438) either selected “Other”, but did not give details, or 
withheld the information altogether. Interestingly, there was a larger variation in sexual 
orientation data within this study than Natsal-3, which reported a ~15% higher proportion of 
self-identified heterosexual individuals in both the male and female cohorts (Mercer et al., 
2013). 
 
6.1.4 Baseline Sexual Practice Characteristics 
To further identify those within the cohort engaging in practices associated with contracting an 
oral HPV infection, data on sexual behaviour (including general descriptors, partners and 
practices) was explored (Table 13, Table 14 & Figure 19), whilst comparing to the Natsal-3 
dataset for sample validity (Mercer et al., 2013; Khadr et al., 2016; Woodhall et al., 2016). 
 
Table 13. Baseline Sexual Practice Descriptors & Sexual Partners. Participant counts (n) and cohort 
percentages (%) per sexual practice characteristic including open-mouth kissing, sexual intercourse 
(incl. within the last year and sexually transmitted diseases/infections status), and number of sexual 
partners (4 groups). 
 
a Data shown for sexually active cohort; n = 369. 
b Missing data has been omitted; may not total n = 369. 
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Overall, 85.39% (n = 374/438) of the cohort reported engaging in open-mouth kissing and 
84.25% (n = 369/438) had engaged in sexual intercourse; 91.87% (n = 339/369) of which, stated 
that it was within the last year of participating in the study (Table 13). Open-mouth kissing 
findings could not be compared to Natsal-3 as it was not measured within their study, but sexual 
intercourse prevalence correlated at ~81% within 16-24-year-olds (Khadr et al., 2016). 
Only 6.78% (n = 25/369) of those who were sexually active reported having had a sexually 
transmitted disease/infection (STD/STI) (Table 13); 72.00% (n = 18/25) of which were 
diagnosed with chlamydia (4.11% for entire cohort, n = 18/438), 8.00% (n = 2/25) had genital 
warts, 4.00% (n = 1/25) had HPV, 4.00% (n = 1/25) had gonorrhoea, whilst 12.00% (n = 3/25) 
did not specify the STD/STI type. The overall prevalence of STD/STIs, and more specifically 
chlamydia, within the cohort was comparable with 16-24-year-olds in Natsal-3 which reported 
an ~8% and ~3% prevalence, respectively (Khadr et al., 2016; Woodhall et al., 2016). 
Most of the sexually active cohort, at 67.75% (n = 250/369), reported engaging in sexual 
intercourse with 1-5 sexual partners (Table 13). The second and third highest proportions were 
for those that reported having 6-10 sexual partners, at 18.43% (n = 68/369,) and 11-20 sexual 
partners, at 7.32% (n = 27/369), respectively. These findings were comparable with the 5-9 
(~19% prevalence) and >10 (~18% prevalence) sexual partners sub-levels for 16-24-year-olds 
reported in Natsal-3, if 11-20 and >20 sub-levels were considered as one category equating to 
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Table 14. Baseline Sexual Activity & One-Night Stand (ONS) Practice. Participant counts (n) and 
cohort percentages (%) per sexual practice characteristic including sexual activities engaged in and ONS 
frequency (scaled; from total number of sexual partners per participant). 
 
a Data shown for sexually active cohort; n = 369. 
b Missing data has been omitted; may not total n = 369. 
 
Furthermore, participants were also asked what types of sexual activity they engaged in. Most 
of the sexually active cohort engaged in vaginal sex, at 97.02% (n = 358/369), whilst only 
27.37% (n = 101/369) engaged in anal sex (Table 14). Oral sex was the second most popular at 
88.35% (n = 326/369), with foreplay third at 87.53% (n = 323/369) and masturbation fourth at 
69.11% (n = 255/369). As a result, 65.85% (n = 243/369) of the sexually active cohort engaged 
in four or more different types of sexual activity. The prevalence for vaginal sex, anal sex and 
oral sex were ~10-20% higher than the data for heterosexual 16-24-year-olds within the Natsal-
3 study, resembling the data for the 25-34-year olds categories more than the younger adults 
(Mercer et al., 2013; Natsal-3, 2019). 
Over half of the sexually active cohort, at 55.56% (n = 205/369), stated that none of their sexual 
partners were one-night stands (ONS), which was considerably higher than those that stated 
that all of their sexual partners were ONS at 2.17% (n = 8/369) (Table 14). These findings 
cannot be compared to Natsal-3 as only attitudes to ONS, rather than engagement, was 
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Figure 19. Baseline Condom Usage. Figure generated in Microsoft Excel for sexually active cohort, n 
= 369. a) Frequency of Cohort Condom Usage - Participant counts (n) and cohort percentages (%) per 
sub-level of condom usage frequency scale (ranging from “Never” to “Always”). Missing data excluded, 
n = 1. b) Reasons for “Never” Usage - Participant counts (n) and cohort percentages (%) from “Never” 
cohort, n = 111. Codes for reasons; NR = no reason stated, LR = lesbian relationship, OC = other 
contraception used (not specified), NTBR = negative STI test results before relationship, OP = only one 
sexual partner (all parties in relationship), S = sterilization, LTR = long-term relationship. 
“Combination” refers to a combination of coded reasons given. 
 
 
As condoms are known to prevent STD/STIs (including HPV) as they are a form of barrier 
contraception (Tanton et al., 2015), participants were asked how frequently they used them in 
reference to all sexual activity with all partners. In total, 17.34% (n = 64/369) of sexually active 
participants stated they “Always” used condoms during sexual intercourse, whilst 30.08% (n = 
111/369) stated they “Never” used condoms, equating to a difference of 12.74% (Figure 19a). 
The second largest proportion was “Sometimes” (equivalent to ~25% of the time), at 30.62% 
(n = 112/369), revealing that the two “riskier” sub-levels were selected the most within the 
study cohort. Due to a difference in questionnaire design between this study and Natsal-3, these 
findings could not be directly compared but their data did suggest that condom usage with new 
sexual partners within young adults had notably decreased within ten years (from Natsal-2 data) 
(Mercer et al., 2013; Khadr et al., 2016). 
Participants that stated they “Never” used condoms were asked to give more details (Figure 
19b). The majority, at 35.14% (n = 39/111), stated they used another form of contraception 
instead of condoms, but type was not specified (i.e. oral, barrier, hormone). The second largest 
proportion at 34.23% (n = 38/111) gave no reason for why condoms were not used, possibly 
indicating no protective measures being taken during sexual intercourse. Using the information 
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provided about condom usage, it was then estimated that 58.81% (n = 217/369) of sexually 
active participants were possibly not protected against STD/STIs, including HPV, during sexual 
activity due to a lack of barrier contraception.  
 
6.1.5 Baseline HPV-Related Characteristics 
The final cohort theme to be explored was HPV-related characteristics (Table 15), to identify 
those within the cohort at risk of developing OPSCCs from either having a diagnosed HPV 
infection prior to screening within this study or from non-vaccination (Tanton et al., 2015; 
Paquette et al., 2017). 
 
Table 15. Baseline HPV-Related Characteristics. Participant counts (n) and cohort percentages (%) 
or means ± standard deviation per HPV-related characteristic including diagnoses (incl. time since 
diagnosis), vaccination status and which healthcare service provided the HPV vaccination. 
 
a Data shown for those diagnosed with an HPV infection but only calculated using data available; n = 5. 
b Data shown for those diagnosed with an HPV-related cancer/precursor; n = 3. 
c Data shown for vaccinated cohort; n = 180. 
d The category of “Overseas Private Healthcare” has been excluded due to zero uptake. 
 
 
Only a small proportion of the cohort, at 1.83% (n = 8/438), had previously been diagnosed 
with an HPV infection (unknown type or area of infection), with a mean number of years since 
diagnosis of 7.6 ± 11.06 years and a large range of 27 years. A further 0.68% (n = 3/438) of the 
cohort had been previously diagnosed with an HPV cancer and/or precursor; one participant 
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(33.33%) was diagnosed with CIN II, one participant (33.33%) was diagnosed with CIN III and 
cervical cancer, whilst the last participant did not specify their diagnosis (Table 15). These 
findings could not be directly compared to Natsal-3 as their participants were not asked if they 
had been previously diagnosed with HPV and/or an HPV-related precursor/cancer (Tanton et 
al., 2015; Tanton et al., 2017). 
Study participants were also asked if they had received an HPV vaccination (Table 15). The 
largest proportion of the cohort, at 49.32% (n = 216/438), stated they had not received the 
vaccination which resulted in 41.10% (n = 180/438) indicating they had and 9.59% (n = 42/438) 
being unsure. Of those that were vaccinated in this study, 96.67% (n = 174/180) had received 
the vaccination via the NHS in the UK, leaving 2.22% (n = 4/180) having received it via 
overseas public healthcare and 1.11% (n = 2/180) having received it privately in the UK.  
 
6.1.6 Summary of Baseline Cohort Characteristics 
In summary, the exploration of the baseline characteristics in conjunction with national 
statistical databases (Office for National Statistics, NHS Digital and Natsal-3) indicated that the 
study cohort was a good representative for the wider UK young adult (student) population. 
Many characteristics explored were concurrent with lifestyle and practices of 16-24-year-olds 
including smoker status, binge drinking, NHS/NICE health risk status, sexual intercourse 
frequency, STD/STI prevalence, numbers of sexual partners and condom usage (Mercer et al., 
2013; Khadr et al., 2016; NHS Digital, 2016b; Woodhall et al., 2016; NHS Digital, 2017; Office 
for National Statistics, 2017). The baseline characteristics to differ from the findings in the 
comparative databases were relationship status, due to questionnaire design, types of sexual 
activity, sexual orientation and vaccination status (Mercer et al., 2013; Tanton et al., 2017; 
Natsal-3, 2019). 
Furthermore, demographics and characteristics such as gender distribution, ethnicity, cannabis 
smoking, vaping/e-cigarette usage, alcohol consumption status and average units per week were 
also similar to overall UK adult population data (Mercer et al., 2013; NHS Digital, 2016b; 
Office for National Statistics, 2018; Office for National Statistics, 2019a; Office for National 
Statistics, 2019b), further indicating that the study cohort could be used to represent the wider 
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6.2 Gender Comparisons of Lifestyle Data 
To explore the study cohort and the lifestyle questionnaire data further, gender comparisons 
were made using statistical analyses to determine which population engaged with riskier 
behaviours associated with HPV infections and OPSCCs development, in accordance with 
national statistical data from Office for National Statistics, NHS Digital and Natsal-3. Firstly, 
the two main risk factors for oral mucosa damage, alcohol consumption status and smoker 
status, were explored and compared between the male and female cohorts (Figure 20). 
 
 
Figure 20. Gender Comparisons of Alcohol Consumption & Smoker Status. Statistically analysed 
in SPSS using Chi-square tests for nominal categorical data (M/F = 2 x 3 crosstabulation; Smoker vs 
Alcohol = 3 x 3 crosstabulation). Figure generated in Microsoft Excel. M = 178; F = 260.  
 
All sub-levels of alcohol consumption status and smoker status responses (current, former. and 
never) were similar proportionally between males and females (Figure 20), with 4.43% more 
males being current smokers (M = 21.35%; F = 16.92%, p = .762) and 1.25% more males being 
current drinkers (M = 89.33%; F = 88.08%, p = .435) compared to females. These findings were 
concurrent with national statistics, confirming that males aged 16-24 years old smoke and drink 
~2-4% more than females in the UK (Office for National Statistics, 2017; Office for National 
Statistics, 2018). When cross-examining the risk factors themselves, ~60% more participants 
(from both genders) consumed alcohol than did smoke (p = .357). These findings were also 
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similar to national statistics as ~40% more people drink alcohol than smoke in the UK (Office 
for National Statistics, 2017; Office for National Statistics, 2018). 
 
6.2.1 Smoking vs Gender 
Despite smoker status revealing little difference between males and females, it was important 
to explore and compare all smoking characteristics including smoking frequency, amount 
(tobacco-based cigarettes), and pack years (Table 16). 
 
Table 16. Smoking Frequency & Amount per Gender. Number of responses (n) and percentage (%) 
of smoking cohort (current and former) per gender. Statistically analysed in SPSS using Mann-Whitney 
U tests for non-parametric continuous or ordinal ranked data unless otherwise indicated. 
 
a Missing or unknown data has been omitted; may not total n = 111 (M = 48; F = 63). 
b Only calculated for P2 participants; smoking history unavailable for P1 participants (M = 36; F = 41). 
 
Proportionally, there was little difference in cigarette smoking frequency and amount between 
males and females (Table 16), similarly to smoker status. For frequency, the largest proportions 
of both males and females smoked “Daily” (M = 50.00%; F = 45.16%), whilst the smallest 
proportions smoked “Once a month” (M = 2.27%; F = 0.00%). These findings were concurrent 
with national statistics (Moodie et al., 2019), but also suggested that gender did not influence 
smoking frequency preference. Similarly, there was also no statistically significant difference 
between males and females when comparing mean number of cigarettes smoked per day (M = 
5.52 ± 547 (0.03-20); F = 5.64 ± 5.39 (0.16-20), p = .834) and mean pack years (M = 1.35 ± 
2.19 (0.02-9); F = 2.26 ± 4.71 (0.02-27); p = .561). Whilst the findings between gender 
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distributions were concurrent with national statistics, the mean number of cigarettes smoked 
was ~40-50% less in the study cohort (NHS Digital, 2016b).  
Despite there being no statistically significant difference in cigarette smoking frequency and 
amount between males and females, there were, however, significant differences when 
examining alternative tobacco smoking responses (Table 17). 
 
Table 17. Gender Comparisons of Tobacco & Non-Tobacco Related Substance Smoking. Number 
of responses (n) and percentage (%) of smoking cohort (current and former) per gender. Statistically 
analysed in SPSS using Chi-square tests for nominal categorical data (2 x 2 crosstabulations) and 
Cramer’s V for effect size, unless otherwise indicated. 
 
a Includes all tobacco-based substances stated below in the table (cigars, shisha/water pipes and tobacco pipes). 
b Fisher’s Exact test used due to expected counts being <5. 
Cramer’s V effect sizes; Minimal = <.10; Small = .10-.30; Medium = .30-.50; Large = >.50 (for 1 df) (Kim, 2017). 
 
Overall, males smoked more tobacco-based substances (other than cigarettes) than females (M 
= 29.17%; F = 11.11%, p = .016, V = .228), especially cigars (M = 12.50%; F = 0.00%, p = 
.005, V = .274) (Table 17). Despite the small number of males and females engaging in other 
tobacco-based substance smoking, all these findings were concurrent with the latest national 
statistics available (Office for National Statistics, 2009b; ASH, 2016; Jawad et al., 2016). 
Cannabis smoking was also numerically higher in males in comparison to females, despite 
showing no statistical significance (M = 16.85%; F = 11.15%, p = .086). Alternatively, 
vaping/e-cigarette usage was numerically higher in the female cohort, despite also showing no 
statistical significance (M = 0.56%; F = 1.92%, p = .408),  and a low prevalence in both genders 
overall. The difference between males and females in cannabis smoking was supported by 
Natsal-3 data on young adults (Paquette et al., 2017), whilst vaping/e-cigarette usage was not 
as national statistics reported a 2.7% higher prevalence in males than females (Office for 
National Statistics, 2019). 
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In summary, there was no statistically significant difference between males and females whilst 
examining smoker status (Figure 20) and characteristics (Table 16), except for males smoking 
more alternative tobacco-based substances than females in the cohort (Table 17). This indicated 
that both genders were equally at risk of oral mucosa damage from smoking due to similar 
smoking amounts and frequencies.  
 
6.2.2 Alcohol Consumption vs Gender 
Alcohol consumptions characteristics were compared with gender to further identify which 
population was engaging with riskier behaviours associated with HPV infections and OPSCCs 
development, in accordance with national data. Despite little difference in alcohol consumption 
status (Figure 21), drinking characteristics comparisons revealed statistically significant 
differences in the amount, frequency and type of alcohol consumed between males and females 
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Figure 21. Gender Comparison of Alcoholic Units Consumed per Week. Generated and statistically 
analysed in SPSS using Mann-Whitney U test for non-parametric continuous data. Mild outliers = 
circles; ≥1½ times the interquartile range away from the quartiles. Extreme outliers = y-axis asterisks; 
≥3 times the interquartile range away from the quartiles. M = 127; F = 161. * p ≤ .05, ** p ≤ .01, *** p 
≤ .001. 
 
Comparisons between number of alcoholic units consumed per week and gender revealed a 
large, statistically significant difference between males and females (Figure 21). Participants 
were asked what type of alcohol they preferred and how many drinks they consumed in each 
sitting which, in combination, allowed for calculation of alcoholic units consumed per week 
(see Chapter 5, Section 5.1.3). Males consumed a higher number of alcoholic units per week 
than females (M = 17.51 ± 16.79 (1.00-79.60); F = 12.18 ± 14.34 (1.00-73.60), p < .001) which 
was concurrent with national statistics for gender differences in weekly unit consumption (NHS 
Digital, 2017; Office for National Statistics, 2017). To examine drinking characteristics further, 
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Table 18. Alcohol Type & Binge Drinking per Gender. Number of responses (n) and percentage (%) 
of drinking cohort (current and former) per gender. Statistically analysed in SPSS using Chi-square tests 
for nominal categorical data (2 x 2 crosstabulations) and Cramer’s V for effect size, unless otherwise 
indicated. 
 
a Only calculated for participants that provided data on alcohol amount, type and frequency (M = 127; F = 161). 
Cramer’s V effect sizes; Minimal = <.10; Small = .10-.30; Medium = .30-.50; Large = >.50 (for 1 df) (Kim, 2017). 
 
When asked what types of alcohol participants drank, the most common answer for both 
genders was “Spirits & Mixer” (M = 55.83%; F = 76.47%, p < .001, V = .217) (Table 18). The 
second and third most popular responses for males specifically, also with the strongest statistical 
associations, was “Beer/Ale” (M = 49.69%; F = 18.91%, p < .001, V = .326) and “Lager” (M = 
40.49%; F = 10.08%, p < .001, V = .358). Alternatively, “Wine” was the more popular response 
for females than males (M = 23.31%; F = 47.90%, p < .001, V = .249). Overall, six out of seven 
alcohol types analysed presented significant statistical differences in preference between the 
two genders, most of which were comparable with national statistical gender preferences (NHS 
Digital, 2017). 
Furthermore, males exhibited a higher frequency of binge drinking than females (M = 59.84%; 
F = 47.20%, p = .032, V = .126) but were less likely to have a large variation in the types of 
alcohol consumed, represented by the “≥2 types of alcohol consumed” sub-level (M = 40.99%; 
F = 59.00%, p = .846). Both findings were also concurrent with national statistics as UK adult 
males are more likely to binge drink but exhibit less variance in their alcoholic drink preference 
than females (NHS Digital, 2017; Office for National Statistics, 2017).  
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Interestingly, when cross-examining binge drinking with types of alcohol, it was found that 
“Beer/Ale” drinkers (45.00%, p = .054), “Neat Spirits” drinkers (68.18%, p = .004, V = .168), 
and “Spirits & Mixer” drinkers (57.44%, p = .022, V = .135), regardless of gender, were the 
most likely to binge drink (statistical significance determined via Chi-square tests). As males 
preferred drinking two out of the three types of alcohol associated with binge drinking, this 
further supported the statistics suggesting males were more likely to binge drink than females.  
To further explore alcohol consumption characteristics, comparisons between the genders and 
drinking frequency were made (Figure 22). 
 
 
Figure 22. Gender Comparisons of Drinking Frequency. Generated and statistically analysed in 
SPSS using Mann-Whitney U tests for non-parametric ordinal ranked data (for overall analysis of 
frequency vs gender), and Chi-square tests for nominal categorical data (2 x 2 crosstabulations) and 
Cramer’s V for effect size (for individual analysis of frequency sub-levels vs gender). M = 163; F = 238. 
* p ≤ .05, ** p ≤ .01, *** p ≤ .001. Cramer’s V effect sizes; Minimal = <.10; Small = .10-.30; Medium 
= .30-.50; Large = >.50 (for 1 df) (Kim, 2017). 
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There was a statistically significant difference in frequency of alcohol consumption between 
males and females (p < .001) with the largest individual proportional differences exhibited 
within “3-5 times/week” (40.54%, p < .001, V = .202), “Once a month” (53.33%, p = .045, V = 
.118) and “Few times/year” (47.83%, p = .307) sub-levels, revealing that males drink alcohol 
more frequently than females overall (Figure 22). These findings were concurrent with NHS 
national statistics which concluded that males drink on more days per week than females (NHS 
Digital, 2016b). Due to the statistically significant difference in drinking frequency between 
males and females, this data was then cross-examined with binge drinking (Figure 23), similarly 
to types of alcohol. 
 
 
Figure 23. Binge Drinking vs Drinking Frequency per Gender. Generated and statistically analysed 
in SPSS using Fisher’s Exact tests instead of Mann-Whitney U tests due to heterogeneity of variance in 
the two gender datasets and expected counts <5 (for overall analysis of frequency vs binge drinking; 
treated as independent sub-levels instead of ordinal ranked data). Chi-square tests were also used for 
nominal categorical data (2 x 2 crosstabulations) and Cramer’s V for effect size (for individual analysis 
of frequency sub-levels vs binge drinking). M = 163; F = 238. * p ≤ .05, ** p ≤ .01, *** p ≤ .001. 
Cramer’s V effect sizes; Minimal = <.10; Small = .10-.30; Medium = .30-.50; Large = >.50 (for 1 df). 
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For females, there was an overall statistically significant and strong relationship and between 
binge drinking and drinking frequency (p = .005, V = .312) not seen in the male cohort (p = 
.171) (Figure 23). Both gender cohorts exhibited high levels of binge drinking for “3-5 
times/week” (M = 65.38%; F = 54.55%), “1-2 times/week” (M = 55.77%; F = 51.39%) and 
“Few times/month” (M = 75.86%; F = 58.33%); the latter for males exhibited the largest 
numerical difference indicating that males were more likely to binge drink if they drank 
intermittently throughout the month than weekly or yearly (p = .045, V = .178). Binge drinking 
significantly reduced in less frequent drinkers, in both gender cohorts, especially in females 
than only drank alcohol a “Few times/year” (11.76%, p = .002, V = .244).  
In summary, study cohort males were drinking larger quantities of alcohol (Figure 21), on 
weekly basis (Figure 22), more frequently than females, whilst also exhibiting higher levels of 
binge drinking (Table 18). This indicated that the male cohort were at higher risk of oral mucosa 
damage due to “riskier” drinking behaviours. Due to this, it was then important to compare 
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Figure 24. Gender Comparisons of NHS/NICE Health Risk Status. Generated and statistically 
analysed in SPSS using Chi-square tests for nominal categorical data (for overall analysis of NHS/NICE 
Health Risk Status (NICE, 2010; Department of Health and Social Care, 2016; NHS Digital, 2016b) vs 
gender and individual analysis of sub-levels vs gender) and Cramer’s V for effect size. M = 142; F = 
183. * p ≤ .05, ** p ≤ .01, *** p ≤ .001. Cramer’s V effect sizes; Minimal = <.10; Small = .10-.30; 
Medium = .30-.50; Large = >.50 (for 1 df) (Kim, 2017). 
 
Overall, there was no statistically significant difference between the NHS/NICE health risk 
status related to alcohol consumption between males and females (p = .070), despite individual 
sub-levels revealing significance. The largest proportional difference between males and 
females existed between lower-risk status (23.76%, p = .008, V = .157) (Figure 24). A higher 
number of males also belonged to the increasing-risk and higher-risk sub-levels with 
proportional differences from females of 5.71% (p = .090) and 13.33% (p = .143), respectively. 
These findings were comparable to the differences between genders reported by NHS national 
statistics but overall higher than the national averages (NHS Digital, 2016b), further supporting 
the data suggesting a higher number of young adult males were engaging with “riskier” drinking 
behaviours than females in the study. 
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6.2.3 Sexual Practice vs Gender 
Sexual practice characteristics were analysed between the genders to further identify which 
population exhibited riskier behaviours linked to contracting HPV. All gender comparison 
results were also compared to Natsal-3 data as a representative database of current national 
statistics for sexual practice (Mercer et al., 2013; Khadr et al., 2016; Woodhall et al., 2016). 
The first comparisons made were between gender and general sexual practice descriptors (such 
as open-mouth kissing and sexual intercourse) and sexual activity (Table 19 and Figure 25). 
 
Table 19. Gender Comparisons of Sexual Practice Descriptors & Activity. Number of responses (n) 
and percentage (%) of cohort per gender. Statistically analysed in SPSS using Chi-square tests for 
nominal categorical data (2 x 2 crosstabulations) and Cramer’s V for effect size, unless otherwise 
indicated. 
 
a Data shown for sexually active cohort; n = 369 (M = 150; F = 219). 
b Fisher’s Exact test used due to expected counts being <5. 
Cramer’s V effect sizes; Minimal = <.10; Small = .10-.30; Medium = .30-.50; Large = >.50 (for 1 df) (Kim, 2017). 
 
There were no statistically significant differences between males and females for all general 
sexual practice descriptors (Table 19), for instance, sexual intercourse was proportionally 
almost identical for both genders (M = 84.27%; F = 84.23%, p = .991). These findings suggested 
that gender did not influence open-mouth kissing preference or whether an individual was 
sexually active or not, which was concurrent with Natsal-3 data for males and females aged 
between 16-24 years old (Mercer et al., 2013; Khadr et al., 2016).  
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In contrast, there were some statistically significant differences in sexual activity preferences 
between males and females (Table 19), with the most popular response for both genders being 
vaginal sex (M = 94.00%; F = 100.00%, p < .001, V = .191). The second and third most popular 
responses were oral sex (M = 91.33%; F = 87.10%, p = .205) and foreplay (M = 91.33%; F = 
85.71%, p = .103), but neither exhibited a statistically significant difference between the 
genders. Anal sex (M = 36.00%; F = 21.66%, p = .002, V = .158) and masturbation (M = 
91.33%; F = 54.38%, p < .001, V = .395), however, were found to be more popular amongst 
sexually active males than females, especially masturbation which resulted in a 36.95% 
difference between genders. Natsal-3 did not support the findings for the gender difference in 
anal sex, but did for masturbation frequency (Mercer et al., 2013; Natsal-3, 2019). 
As oral-genital sexual activity and diversity of activity has been linked to oral HPV transmission 
(Hu & Peng, 2016; Ali, Ping & Prajapati, 2018), it was important to further explore sexual 
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Figure 25. Sexual Activity Engagement Levels per Gender. Generated and statistically analysed in 
SPSS using Chi-square test instead of Mann-Whitney U test due to heterogeneity of variance in the 
dataset (for overall analysis of engagement levels vs gender; treated as independent sub-levels instead 
of ordinal ranked data) and for nominal categorical data (for individual analysis of sub-levels vs gender), 
and Cramer’s V for effect size. M = 150; F = 217. * p ≤ .05, ** p ≤ .01, *** p ≤ .001. Cramer’s V effect 
sizes; Minimal = <.10; Small = .10-.30; Medium = .30-.50; Large = >.50 (for 1 df). Cramer’s V effect 
sizes; Minimal = <.05; Small = .05-.15; Medium = .15-.25; Large = >.25 (for 4 df) (Kim, 2017). 
 
There was a significant difference and strong statistical association between increasing number 
of sexual activities and gender (p < .001, V = .308), revealing that the male cohort exhibited 
more sexual diversity that the female cohort (Figure 25). Females were ~60-65% more likely 
to engage in two (M = 17.24%; F = 82.76%, p = .007, V = .141) or three (M = 20.00%; F = 
80.00%, p < .001, V = .224) different sexual activities, whilst males were 12.82% more likely 
to engage in all five (M = 56.41%; F = 43.59%, p = .002, V = .164). 
Sexual activity was then compared to diversity to determine which activities were being 
performed amongst the most sexually diverse participants due to the link with HPV infection. 
All participants that engaged in one sexual activity only (M = 4; F = 11), engaged in vaginal 
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sex (100.00%). Of those that engaged in two sexual activities (M = 5; F = 24), vaginal sex was 
the most common again (100.00%) along with either oral sex (34.48%), foreplay (41.88%), or 
masturbation (24.14%). Therefore, anal sex engagement was limited to participants that 
engaged in three (M = 16; F = 64) or more sexual activities, but frequency was much lower in 
comparison to other activities (three = 2.5%; four = 12.73%). Of those that engaged in four (M 
= 81; F = 84) or more sexual activities, oral sex (four = 100.00%; five = 100.00%) and foreplay 
(four = 98.18%; five = 100%) were the most popular sexual activities amongst the more 
sexually diverse cohort. 
Oral-genital sexual activity was then investigated and compared between genders to further 
determine those in the cohort exhibiting “riskier” behaviours for contracting HPV. Overall, 
85.91% of the sexually active cohort engaged in both oral and vaginal sex (n = 317/369, with 
more females than males (M = 40.38%; F = 59.62%, p = .793) engaging in oral-vaginal activity 
(no statistical significance determined via Chi-square tests). Furthermore, 27.37% of the 
sexually active cohort engaged in both oral and anal sex (n = 101/369), with more males than 
females (M = 53.47%; F = 46.53%, p = .002, V = .160) engaging in oral-anal activity (statistical 
significance determined via Chi-square tests). These findings could not be compared to Natsal-
3, as combined sexual activity engagement and diversity was not explored within their study 
cohort (Mercer et al., 2013). 
As increasing numbers of sexual partners has also been linked to HPV transmission (Tanton et 
al., 2015), it was important to further explore sexual practice in relation to partner 
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Figure 26. Gender Comparisons of Sexual Partner Descriptors. Generated and statistically analysed 
in SPSS. a) Total Number of Sexual Partners - Chi-square tests for nominal categorical data (for 
overall analysis of sexual partners vs gender and individual analysis of sub-levels vs gender) and 
Cramer’s V for effect size. M = 150; F = 218. * p ≤ .05, ** p ≤ .01, *** p ≤ .001. Cramer’s V effect 
sizes; Minimal = <.10; Small = .10-.30; Medium = .30-.50; Large = >.50 (for 1 df) (Kim, 2017). b) One-
Night Stand (ONS) Frequency - Fisher’s Exact test instead of Mann-Whitney U tests due to 
heterogeneity of variance in the dataset and expected counts <5 (for overall analysis of frequency vs 
gender; treated as independent sub-levels instead of ordinal ranked data) and Chi-square tests for 
nominal categorical data (for individual analysis of sub-levels vs gender), and Cramer’s V for effect 
size. M = 149; F = 217. * p ≤ .05, ** p ≤ .01, *** p ≤ .001. Cramer’s V effect sizes; Minimal = <.10; 
Small = .10-.30; Medium = .30-.50; Large = >.50 (for 1 df). Cramer’s V effect sizes; Minimal = <.05; 
Small = .05-.15; Medium = .15-.25; Large = >.25 (for 4 df) (Kim, 2017). 
 
There was no statistically significant difference between number of sexual partners and gender 
within the study cohort (p = .073), despite individual sub-levels revealing significance. The 
largest numerical differences between males and females were between those that reported 
having 1-5 partners (M = 38.00%; F = 62.00%, p = .117), despite being statistically non-
significant, and >20 partners (M = 34.78%; F = 65.22%, p = .014, V = .129) (Figure 26a). As 
numbers of partners increased, female responses decreased, indicating a trend that revealed 
males had numerically marginally more sexual partners than females overall. These findings 
were comparable in terms of proportional responses to Natsal-3 data collected for males and 
females aged between 16-24 years old (Mercer et al., 2013). 
In addition to having a higher number of sexual partners, the male cohort also exhibited an 
overall higher frequency of one-night stands (ONS) than the female cohort (p = .002, V = .212) 
(Figure 26b). Most females stated none of their sexual partners were ONS (M = 32.20%; F = 
67.80%, p < .001, V = .196), whilst the highest frequencies for males were for half (or ~50%) 
(M = 60.00%; F = 40%, p = .025, V = .117) and most (or ~75%) (M = 57.58%; F = 42.42%, p 
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= .039, V = .108) of their sexual partners being ONS. Similarly, to the baseline study 
characteristics, these findings could not be compared to Natsal-3 as only attitudes to ONS, 
rather than engagement, was measured (Mercer et al., 2013; Khadr et al., 2016). 
 
6.2.4 HPV-Related Data vs Gender 
The final cohort comparisons made were between gender and HPV-related data, including 
previously diagnosed/known HPV infections and HPV vaccination status. Where possible, all 
results were also compared to Natsal-3 HPV data (Tanton et al., 2015; Paquette et al., 2017). 
The first comparisons made were between gender and HPV vaccination status (Figure 27). 
 
 
Figure 27. Gender Comparisons of HPV Vaccination Status. Generated and statistically analysed in 
SPSS using Chi-square tests for nominal categorical data (2 x 3 crosstabulation for overall analysis of 
HPV Vaccination Status vs gender) and Cramer’s V for effect size. M = 178; F = 260. * p ≤ .05, ** p ≤ 
.01, *** p ≤ .001. Cramer’s V effect sizes; Minimal = <.07; Small = .07-.21; Medium = .21-.35; Large 
= >.35 (for 2 df) (Kim, 2017). 
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There was a statistically significant difference and strong statistical association between 
vaccination status and gender within the study cohort (p < .001, V = .724) (Figure 27). Most 
male participants had not received the HPV vaccination (M = 91.57%; F = 20.38%) or were 
unsure (M = 7.87%; F = 10.77%), whilst a large proportion female participants had received 
the vaccination in comparison to males (M = 0.56%; F = 68.85%), particularly if they were 
aged between 18-25 years old as that would make them part of the post-2008 vaccination 
programme (18-21 year olds) or catch-up programme (21-25 year olds) age group. Vaccination 
uptake was ~10% higher than the Natsal-3 female cohort (not measured in males) which 
reported a three-dose coverage of 52.00% in females aged 18-20 years old (Tanton et al., 2017). 
Furthermore, participants were asked if they had previously been diagnosed with an HPV 
infection and/or HPV-related cancer/precursor prior to taking part in the study. Prevalence of 
both was low within the study cohort and neither exhibited statistically significant differences 
between the genders, for instance, ~2% more females than males reported a previous HPV 
infection diagnosis (M = 0.56%; F = 2.69%, p = .150), whilst equal proportions of males and 
females reported a HPV-related cancer/precursor diagnosis (M = 0.56%; F = 0.77%, p = 1). 
Statistical significance was determined via Chi-square tests and similarly, to the baseline study 
characteristics, these findings could not be compared to Natsal-3 as they were not measured 
(Mercer et al., 2013; Khadr et al., 2016). 
 
6.2.5 Summary of Gender Comparisons of Lifestyle Data 
In summary, the study gender comparisons of lifestyle data were comparable with national 
statistics databases and Natsal-3, further indicating that the study cohort was a good 
representative for the wider UK young adult (student) population. 
In terms of statistical analysis, it was found that there was no difference between smoking and 
gender besides other tobacco-based substance smoking with males partaking more often than 
females. For alcohol consumption statistical analysis, it was found that males were more likely 
to engage in riskier alcohol-related behaviour such as consuming large quantities of alcohol, 
regularly, whilst binge drinking. This then resulted in males exhibiting a higher frequency of 
increasing-risk and higher-risk individuals in term of NHS health risk status than females, 
despite all sub-levels not being individually statistically significant. 
Furthermore, there was also some statistically significant differences in sexual practice and 
gender within the cohort. There was no statistically significant differences between males and 
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females for sexual intercourse, open-mouth kissing engagement, foreplay and oral sex. 
Alternatively, male participants exhibited a higher number of sexual partners (numerically, 
rather than statistically), more one-night stands, more diversity in sexual activities, and engaged 
in anal sex and masturbation more frequently than female participants.  
For HPV-related data comparisons to gender, unsurprisingly, more females had received the 
HPV vaccination than males within the cohort, whilst there was no difference in genders when 
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Chapter 7:  
SCREENING RESULTS OF ORAL HPV STUDY 
 
The aim of the study was to establish oral HPV infection rates and viral load within the UK 
young adult (student) population to determine if prevalence and abundance of infection was 
influenced by HPV type, vaccination status, and lifestyle choices of an individual. Oral mucosal 
swabs were collected for HPV screening, alongside questionnaire data for comparisons of HPV 
positive individuals and their lifestyle data associated with the development of OPSCCs and 
contraction of HPV. At the second stage of data collection (see Figure 18 in Chapter 6), 438 
samples were taken forward for beta-actin screening to assess the viability of the DNA samples. 
 
7.1 Reference Gene Screening  
Prior to beta-actin (ACTB) screening, the concentration and purity ratios of all 438 extracted 
DNA samples were measured via Nanodrop 2000. The mean DNA concentration of the 
extracted samples was 6.87 ng/μL, with a mean 260/280 purity ratio of 2.32 and a mean 260/230 
purity ratio of 0.71. The samples were screened for ACTB, the house-keeping gene, using real-
time qPCR Taqman chemistry for viability and to quantify the number of copies of ACTB 
present per sample, to calculate cell number/5μL. The mean cell number/5μL for the sample 
cohort was calculated to be 7.93x103 cells (see Chapter 4, Section 4.8.1 and 4.9 for method 
details of this assay and calculation). 
Overall, 93.15% (n = 408/438) of the samples collected from the cohort (with usable consent 
and questionnaire data available) were viable to continue testing and screening for HPV, whilst 
the remaining 6.85% (n = 30/438) were omitted from downstream assays. These were omitted 
as the ACTB reference gene screen did not detect a signal, therefore a copy number, and then 
a cell number for the sample could not be calculated for use in viral load calculations. 
 
7.2 Consensus HPV Screening 
Following DNA viability screening, 408 samples were taken forward for HPV consensus 
screening using MY09/11 primers that detect a range of HPV types to determine an estimated 
overall prevalence of oral HPV within the screened cohort (Table 20). According to the final 
consensus screening method devised (see Section 3.4, Chapter 3), samples were either 
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categorised as HPV positive, Borderline/Unknown (U) or HPV negative to determine which 
samples would be taken forward for type-specific HPV screening. 
 
Table 20. HPV Consensus Screening Results. Number of participants (n) and prevalence (%) within 
the screened cohort (n = 408) per screening result, determined via real-time PCR melt curves and gel 
electrophoresis, using the final MY09/11 consensus screening methodology as described in Chapter 3, 
Section 3.4. HPV positive = +ve; HPV negative = –ve, 
 
a Sum of total number of HPV +ve and Unknown/Borderline (U) samples. 
 
The initial MY09/11 consensus screen for oral HPV revealed an estimated overall prevalence 
of 9.80% (n = 40/408), whilst 60.05% (n = 245/408) of samples were deemed HPV negative 
due to no product peak within the real-time PCR melt curves or by revealing non-specific 
binding of the MY09/11 primers via gel electrophoresis (Table 20). There were 18 samples that 
could not be accurately screened using the SYBR-based real-time PCR assay due to suspected 
interaction between extraction reagents and intercalating dyes via unusual fluorescence signals. 
These 18 samples were included in the “unknown” sample set, however, as they had been 
successfully screened using the beta-actin Taqman real-time PCR assay so it was theorised that 
the HPV type-specific Taqman probe-based assays would also be successful due to different 
dyes. As the 18 samples were included in the “unknown” sample set, in total, 39.95% (n = 
163/408) of samples were deemed as either HPV positive (n = 40/408) or unknown/borderline 
positive (n = 123/408), therefore, were taken forward for type-specific screening for HPV-6, 
HPV-11, HPV-16 and HPV-18. 
 
7.3 Type-specific HPV Screening 
Following the HPV consensus screening, 163 samples were screened for HPV-6, HPV-11, 
HPV-16, and HPV-18, to determine the final overall HPV prevalence within the cohort and 
individual HPV type prevalence (Table 21). This also enabled for the determination of any co-
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infections between HPV-6, HPV-11, HPV-16, and HPV-18, and determination of types not 
covered by the quadrivalent vaccination that could have been present within the population by 
cross-examining the total HPV positive samples determined by consensus screening and total 
type-specific HPV positive samples. 
 
Table 21. Final Overall & Type-Specific HPV Cohort Prevalence. Number of participants (n) and 
prevalence (%) within the screened cohort (n = 408) per screening result, determined via real-time PCR 
and gel electrophoresis, using the final MY09/11 consensus screening methodology and the final type-
specific screening methodologies (for HPV-6, HPV-11, HPV-16 and HPV-18) as described in Chapter 
4. HPV type positive = +ve; HPV type negative = –ve. 
  
a Co-infections of HPV-16 and HPV-18 only; no other combinations were found. 
 
After HPV type-specific screening, the overall prevalence of oral HPV within the screened 
cohort was recalculated to be 22.79% (n = 93/408), with 0.49% (n = 2/408) attributed to HPV-
6, 0.25% (n = 1/408) attributed to HPV-11, 19.12% (n = 78/408) attributed to HPV-16, and 
1.72% (n = 7/408) attributed to HPV-18 (Table 21). Therefore, HPV-16 was the most prevalent 
of the four HPV types within the HPV positive cohort (83.87%; n = 78/93) and out of the two 
high-risk (HR) HPV types, with a difference of 17.40%. Furthermore, 0.98% (n = 4/408) of the 
cohort had a co-infection of two HPV genotypes, all of which were HPV-16 and HPV-18, and 
2.21% (n = 9/408) of the cohort were HPV positive from the consensus screen but did not test 
positive for any of the four specific HPV types screened for. Therefore, these samples were 
deemed to be positive for non-quadrivalent vaccination HPV types. Due to the production of 
primer dimers within the MY09/11 assay and low stock volumes of DNA after multiple screens, 
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these samples could not be sent off for sequencing to determine which HPV genotypes were 
present so have been labelled as “unknown HPV type”. 
By subjecting the samples to type-specific screening following the HPV consensus screening, 
12.99% (n = 53/123) more samples were determined to be HPV positive, from the 
unknown/borderline positive samples identified using the novel combined consensus screen 
method established in Chapter 3. In studies using non-combined consensus HPV screening, 
these samples may have been missed due to end-point PCR not detecting low HPV copy 
numbers, whilst in studies using type-specific HPV screening only, samples that were not one 
of the quadrivalent vaccination HPV types (HPV-6, HPV-11, HPV-16, and HPV-18) equally 
may have been missed, thus proving the usefulness of a combined approach. 
 
 
Figure 28. Calculated HPV Viral Load per HPV Type. Generated in SPSS. Mild outliers = circles; 
≥1½ times the interquartile range away from the quartiles. Extreme outliers = y-axis asterisks; ≥3 times 
the interquartile range away from the quartiles. HPV-16 = 74; HPV-18 = 3; HPV-6 = 2; HPV-11 = 1; 
HPV-16 & HPV-18 = 4. 
 
Following screening, HPV viral load was calculated by determining HPV DNA copy 
number/million cells using the previous ACTB screening results per HPV positive sample 
(apart from 2.21% determined to be alternative HPV genotypes as these were not quantified) 
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(see Section 4.8.1, Chapter 4). This was done to determine if oral HPV prevalence and 
abundance within the cohort was influenced by HPV type. 
As well as being the most prevalent within the cohort, the two HR-HPV types, HPV-16, and 
HPV-18, exhibited the highest viral loads of all quantified sub-types (Figure 28). HPV-16 
positive infections exhibited the highest mean viral load at 1.08x105 copies/million cells, with 
a range of 5.12x103–2.10x106 copies/million cells. HPV-18 positive infections, therefore, 
exhibited the second highest viral load at 1.89x104 copies/million cells, with a range of 
1.27x102– 5.13x104 copies/million cells. The difference between mean HPV-16 and HPV-18 
viral loads (excluding co-infections; n = 77) was deemed statistically significant (p = .033) via 
Mann-Whitney U testing. The two low-risk (LR) HPV types, alternatively, exhibited much 
lower mean viral loads at 4.50x102 copies/million cells for HPV-6, with a range of 1.93x101 – 
8.81x102 copies/million cells, and 1.06x102 copies/million cells for HPV-11, which did not 
have a range as there was only one HPV-11 positive sample. The difference between mean 
HPV-6 and HPV-11 viral loads (n = 3) was deemed statistically non-significant (p = 1) via 
Mann-Whitney U testing. Those with co-infections of HPV-16 and HPV-18, unsurprisingly, 
also exhibited high viral loads, with a mean of 1.07x105 copies/million cells and the highest 
median out of all four types individually at 9.72x104 copies/million cells. The difference 
between mean viral load of all four HPV types and co-infections (n = 84) was deemed 
statistically significant (p = .006) via Kruskal-Wallis testing. These results overall indicated 
that the most prevalent and abundant HPV type present in the mouth, out of the HPV types 
targeted in this study, was HPV-16.  
 
7.4 Comparisons of Oral HPV Results & Cohort Characteristics 
Following screening, it was then important to determine if oral HPV prevalence and abundance 
within the cohort was influenced by demographics, vaccination status and lifestyle choices of 
an individual. Due to this, the screening results were compared to the cohort characteristics and 
lifestyle data that was highlighted and explored in Chapter 6. This allowed for the determination 
of any associations between oral HPV and known risk factors for the development of OPSCCs 
and contraction of HPV, such as smoking, heavy alcohol consumption and “riskier” sexual 
practices.  
The following section compares overall HPV and type-specific HPV prevalence and abundance 
to relevant lifestyle data, in order of the themes set out in Chapter 5, using statistical analyses 
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for significance. Due to limited numbers of participants in the HPV positive cohort, 
comparisons between the screening results and cohort characteristics and/or lifestyle data were 
only made where possible (all data was run through appropriate statistical tests but omitted if 
statistical analyses could not be computed due to low response [n] numbers). 
 
7.4.1 Oral HPV Results vs Gender 
The first comparisons made were between cohort demographics and the HPV screening results 
for prevalence and abundance, to determine if gender, age and/or ethnicity influenced oral HPV 
status. When comparing gender and overall HPV prevalence, only 2.21% more females were 
deemed to have an oral HPV infection within the screened cohort (n = 408) in comparison to 
males (M = 10.29%; F = 12.50%, p = .546), which was determined to be statistically non-
significant via Chi-square analysis. Overall HPV viral load, via mean copy number/million 
cells, in comparison to gender was also found to be statistically non-significant via Mann-
Whitney U analysis but, numerically, viral load was higher in males than females (M = 1.48x105 
copies/million cells; F = 6.38x104 copies/million cells, p = .602), with a difference of 8.45x104 
copies/million cells. 
To examine overall HPV prevalence further, gender was compared to individual HPV type to 
establish if there were any proportional differences between males and females and HPV types 
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Figure 29. Gender Distribution per HPV Type. Statistically analysed in SPSS using Chi-square or 
Fisher’s Exact tests for nominal categorical data, dependent on expected counts being <5 or not (M/F = 
2 x 2 crosstabulation per HPV type; “Unknown” HPV status participants were omitted to enable 
computation of statistical analyses). Figure generated in Microsoft Excel. M = 42; F = 51. 
 
Individual HPV type comparisons within the positive cohort (n = 93) revealed some 
proportional differences between the genders per HPV type present, despite none exhibiting 
statistically significant differences via Chi-square and Fisher’s Exact testing (Figure 29). Alike 
overall HPV prevalence, numerically, more females tested positive for HPV-16 (M = 44.87%; 
F = 55.13%, p = .375), HPV-18 (M = 28.57%; F = 71.43%, p = .706) and other unknown HPV 
types (M = 44.44%; F = 55.56%, p = 1) than males with differences between 10.26% to 42.86%, 
with all determined to be statistically non-significant. Equal proportions of males and females, 
however, exhibited co-infections of both HPV-16 and HPV-18 (M = 50.00%; F = 50.00%, p = 
1), whilst only males tested positive for LR-HPV types, HPV-6 (M = 100.00%; F = 0.00%, p = 
.163) and HPV-11 (M = 100.00%; F = 0.00%, p = .404), with all differences determined to be 
statistically non-significant. These results revealed some proportional disparity in the 
prevalence, abundance and types of HPV infections presenting in the mouth between the female 
cohort and male cohort, but with no statistical significance. 
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Figure 30. Calculated Viral Load per Gender & HPV Type. Generated and statistically analysed in 
SPSS using Mann-Whitney U test for non-parametric continuous data. Mild outliers = circles; ≥1½ times 
the interquartile range away from the quartiles. Extreme outliers = y-axis asterisks; ≥3 times the 
interquartile range away from the quartiles. HPV type was split into two groups for HPV viral load 
analysis to avoid statistical bias due to limited participant numbers; HPV-16 = 78; Other Types = 6.  
 
To examine oral HPV abundance, total HPV type viral load, via mean copy number/million 
cells, for HPV-16 and all other HPV types combined was compared within the cohort, overall 
and between males and females (Figure 30). HPV-16 was selected for individual comparison 
as it was previously determined to be the most prevalent and abundant genotype in the cohort. 
Viral loads for all other HPV types were combined for comparison to HPV-16 as, individually, 
total positive participant numbers were too small for statistical comparison.  
In terms of overall abundance,  HPV-16 mean viral load was significantly higher than the mean 
viral load of all other types of HPV types combined (HPV-16 = 1.09x105 copies/million cells; 
Combined Types = 6.20x103 copies/million cells, p <.001), resulting in a large numerical 
difference of 1.03x105 copies/million cells, determined by Mann-Whitney U testing (Figure 
30). HPV-16 viral load, via mean copy number/million cells, was then compared between the 
male cohort and female cohort, taking gender into account (Figure 30). Similarly to overall 
HPV viral load comparisons, there was large numerical difference of 9.47x104 copies/million 
cells between males and females (M = 1.60x105 copies/million cells; F = 6.57x104 
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copies/million cells, p = .385), but this was determined not to be significant via statistical 
testing. There was also a numerical difference of 1.17x104 copies/million cells between males 
and females for all other quantified HPV types combined (M = 3.36x102 copies/million cells; 
F = 1.21x104 copies/million cells, p = .127), but similarly, this was determined not to be 
significant via statistical testing. 
In summary, there were no statistically significant differences between the male and female 
cohorts in relation to prevalence and abundance of oral HPV, despite slight numerical or 
proportional differences, such as prevalence for the female HPV positive cohort, and abundance 
(viral load) for the male cohort. Of all four HPV types targeted, LR-HPV types, HPV-6 and 
HPV-11, were only detected in male participants, HPV-16 was equally distributed between 
genders, whilst HPV-18 was more prevalent in females. 
 
7.4.2 Oral HPV Results vs Age & Ethnicity 
The screening results for HPV prevalence and abundance were compared to cohort age and 
ethnicity to further determine if cohort demographics influenced oral HPV status. As a large 
proportion of the cohort population were young adults (n = 376), the cohort was split into two 
age groups for HPV prevalence analysis to avoid statistical bias due to limited participant 
numbers; 18-25-year-olds (A1) compared to >18-25-year-olds (A2). There was no difference 
in oral HPV status between the two age categories (A1 = 22.61%; A2 = 25.00%, p = .757), 
analysed via Chi-square analysis. HPV-16 prevalence was also compared between the two age 
groups, but again, there was no difference (A1 = 19.41%; A2 = 15.63%, p = .601), also analysed 
via Chi-square analysis. The prevalence of HPV-6, HPV-11 and HPV-18 could not be 
statistically compared due to limited participant numbers within the positive cohort, but instead 
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Figure 31. Comparison of HPV Status & Ethnicity (2-Way). Generated and statistically analysed in 
SPSS using a Chi-square test for nominal categorical data (2 x 2 crosstabulations). The cohort was split 
into two ethnicity categories for HPV prevalence analysis to avoid statistical bias due to limited 
participant numbers when split 5-ways; White British (WB) = 336; Other White, BAME & Unknown 
(OBU) = 72. “Unknown” HPV status participants were omitted to enable computation of statistical 
analyses. 
 
Similarly to age, a large proportion of the cohort population were “White British” (n = 336) so 
the cohort was split into two categories for ethnicity (2-Way) for HPV prevalence analysis to 
avoid statistical bias due to limited participant numbers; “White British” (WB) compared to 
“Other White, BAME & Unknown” (OBU). There was no statistically significant association 
between HPV status and ethnicity but numerically a larger proportion of WB participants tested 
HPV positive than OBU participants (WB = 24.40%; OBU = 15.28%, p = .094) (Figure 31). 
When examining the original five categories for ethnicity (5-Way) described in Section 5.1.1, 
Chapter 5, it was found that the highest proportions of OBU HPV positive participants at 4.30% 
identified as “Asian/Asian British” and 2.15% identified as “Mixed/Multiple Ethnic Groups”. 
Ethnicity (2-Way) was also compared to HPV-16 prevalence within the cohort. Alike overall 
HPV prevalence, a larger proportion of WB participants tested HPV-16 positive than OBU 
participants (WB = 20.24%; OBU = 13.89%, p = .214) but this was deemed non-significant via 
Chi-square analysis. To investigate abundance of infection, ethnicity (2-Way) was also 
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compared to overall HPV viral load and HPV-16 viral load. WB participants exhibited non-
statistically significant higher viral loads, via mean copy number/million cells, than OBU 
participants for both overall HPV and HPV-16 infections with differences of 1.16x104 
copies/million cells (p = .516) and 1.88x104 copies/million cells (p = .731), respectively. Both, 
differences however, were determined to be statistically non-significant via Mann-Whitney U 
analyses. 
In summary, ethnicity may have a potential effect oral HPV status, but little difference was 
found whilst comparing age. However, both demographic factors would need more 
investigation due to limited participant numbers in the positive cohort and bias in the data 
preventing inferences being made.  
 
7.4.3 Oral HPV Results vs Smoking Characteristics 
The screening results for HPV prevalence and abundance were compared to cohort smoking 
characteristics to determine if engaging with riskier behaviours associated with HPV infections 
and OPSCCs development influenced oral HPV status. Due to the associations between oral 
HPV and smoking, it was important to fully explore the characteristics including smoker status, 
smoking frequency, amount, and engagement in alternatives types of smoking. 
The first comparison made was smoker status (current, former, or never) and overall HPV 
prevalence, analysed via Chi-square testing. Numerically, there was little difference in the 
proportions of the cohort that tested HPV positive across the three smoker sub-levels, ranging 
from 21.43% (former) to 23.18% (never), indicating smoker status had no effect on whether an 
individual was HPV positive or not (p = .952). HPV-16 prevalence was also compared to 
smoker status, also analysed via Chi-square testing. Similarly, there was little difference 
numerically in the proportions of the cohort that tested HPV-16 positive across the three smoker 
sub-levels, ranging from 17.95% (current) to 21.43% (former), further indicating smoker status 
had no influence on oral HPV status and type (p = .920).  
To investigate abundance of infection, smoker status was compared to overall HPV viral load 
and HPV-16 viral load. Former smokers exhibited average viral loads, via mean copy 
number/million cells, higher than that of current or never smokers for both overall HPV and 
HPV-16 infections with differences between the highest (former) and lowest (current) viral 
loads of 3.13x105 copies/million cells (p = .966) and 3.08x105 copies/million cells (p = .883), 
respectively. These numerical differences, however, were determined to be statistically non-
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significant via Kruskal-Wallis H analyses, indicating smoker status also had no effect on oral 
HPV abundance.  
To further analyse smoking characteristics in relation to oral HPV prevalence, smoking 
frequency and overall HPV status were compared (Figure 32). 
 
 
Figure 32. Comparison of HPV Status & Smoking Frequency. Generated and statistically analysed 
in SPSS using Mann-Whitney U tests for non-parametric ordinal ranked data (for overall analysis of 
frequency vs status), and Chi-square tests for nominal categorical data (2 x 2 crosstabulations) and 
Cramer’s V for effect size (for individual analysis of frequency sub-levels vs status). “Unknown” HPV 
status participants were omitted to enable computation of statistical analyses; +ve = 23; –ve = 78. * p ≤ 
.05, ** p ≤ .01, *** p ≤ .001. Cramer’s V effect sizes; Minimal = <.10; Small = .10-.30; Medium = .30-
.50; Large = >.50 (for 1 df) (Kim, 2017). 
 
Overall, there was a significant association between smoking frequency and an individual’s 
HPV status (p = .024) (Figure 32). Other than “Few times/year”, there was a correlation between 
frequent smoking and HPV positive infections as the highest proportions of HPV positive 
smokers smoked “1-2 times/week” (+ve = 33.33%; -ve = 66.67%, p = .422), “Daily” (+ve = 
31.91%; -ve = 68.09%, p = .041, V = .203), or “3-5 times/week” (+ve = 21.43%; -ve = 78.57%, 
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p = 1). When cross-comparing frequency and HPV status with gender, there was an overall 
significant difference between smoking frequency and HPV positive females (p = .035, V = 
.394) but no difference in males (p = .465). For females, the largest proportional differences 
were also between “1-2 times/week” (+ve = 50.00%; -ve = 50.00%, p = .202), “Daily” (+ve = 
33.33%; -ve = 66.67%, p = .047, V = .256) and “3-5 times/week” (+ve = 20.00%; -ve = 80.00%, 
p = 1), further indicating that there was an association between smoking frequency and oral 
HPV status. 
Similarly, there was also a significant correlation between frequent smoking and HPV-16 
positive infections with the highest proportions of HPV-16 positive smokers smoking cigarettes 
“Daily” at 27.66%, “1-2 times/week” at 22.22%, and “3-5 times/week” at 21.43% (p = .043) 
also, determined via Mann-Whitney U analysis. Gender could not be cross-compared with 
HPV-16 status and smoking frequency due to limited participants numbers for viable statistical 
analysis. 
Alongside smoking frequency, overall HPV status was compared with mean number of 
cigarettes smoked per day to determine if smoking quantity also correlated with oral HPV 
status. Those that were HPV positive smoked 1.85 cigarettes more per day than those that were 
HPV negative (+ve = 6.88 ± 5.77; –ve = 5.03 ± 5.30, p = .133), determined to be statistically 
non-significant via Mann-Whitney U analysis. Similarly, whilst comparing HPV-16 status to 
mean number of cigarettes smoked per day, those that were HPV-16 positive smoked 2.06 
cigarettes more per day than those that were HPV negative (+ve = 7.10 ± 6.01; –ve = 5.04 ± 
5.24, p = .146), also determined to be statistically non-significant via Mann-Whitney U analysis. 
To further analyse smoking characteristics in relation to oral HPV prevalence, lifetime pack 
years and overall HPV status were compared (Figure 33). 
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Figure 33. Lifetime Pack Years per Gender & HPV Status. Generated and statistically analysed in 
SPSS using Mann-Whitney U tests for non-parametric continuous data. Mild outliers = circles; ≥1½ 
times the interquartile range away from the quartiles. Extreme outliers = y-axis asterisks; ≥3 times the 
interquartile range away from the quartiles. “Unknown” HPV status participants were omitted to enable 
computation of statistical analyses. M = 36 (+ve = 7); F = 41 (+ve = 10). 
 
Overall, there was no statistically significant difference between those that were HPV positive 
and those that HPV negative for calculated pack years, determined via Mann-Whitney U 
analysis, but HPV positive smokers were calculated to have a numerically higher mean number 
of pack years than HPV negative smokers (+ve = 2.13 ± 2.82; –ve = 1.75 ± 3.99, p = .079).  
Due to this, further comparisons were made between HPV status and pack years, taking gender 
into account (Figure 33).  
The results indicated a possible correlation between HPV status and long-term female smokers 
as HPV positive females were calculated to have a numerically higher mean number of pack 
years in comparison to HPV negative females (+ve = 2.98 ± 3.43; –ve = 2.03 ± 5.08, p = .058), 
but statistical analysis deemed this difference non-significant. When comparing the male 
cohort, the numerical difference in mean pack years between HPV positive and HPV negative 
males was smaller than females at 0.53 pack years, and therefore, also determined not to be 
statistically significant (p = .704). When comparing HPV status and pack years between the 
genders, HPV positive females exhibited a numerically higher mean number of pack years than 
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HPV positive males (F = 2.98 ± 3.43; M = 0.92 ± 0.84, p = .172), but again, this was statistically 
non-significant. In contrast, HPV-16 negative smokers exhibited no difference in mean number 
of pack years than HPV-16 positive smokers (+ve = 1.68 ± 2.09; –ve = 1.87 ± 4.06, p = .232), 
determined to be statistically non-significant via Mann-Whitney U analysis. Gender could not 
be cross-compared with HPV-16 status and pack years due to limited participants numbers for 
viable statistical analysis. 
 
Table 22. Overall HPV Prevalence vs Tobacco & Non-Tobacco Related Substance Smoking. 
Number of responses (n) and percentage (%) of cohort per HPV status. Statistically analysed in SPSS 
using Fisher’s Exact tests for nominal categorical data (3 x 2 crosstabulations), unless otherwise 
indicated. 
 
a Includes all tobacco-based substances such as cigars and shisha/water pipes. 
b Number of participants less than data shown (+ve = 13; –ve = 43; U = 3). 
Data on tobacco pipe smoking and vaping/e-cigarettes was omitted due to limited participants numbers for viable 
statistical analysis. 
 
Additionally, to cigarette smoking, other tobacco-based substance smoking and non-tobacco-
based smoking was compared to overall HPV status to determine if there were any differences 
between those that were HPV positive and HPV negative (Table 22). A higher number of HPV 
positive individuals smoked other tobacco-based substances overall (cigars and shisha/water 
pipes) than HPV negative individuals and those with an unknown HPV status (+ve = 21.74%; 
–ve = 18.07%; U = 20.00%, p = .901) but proportionally, this difference was not large enough 
to be statistically significant. When comparing other tobacco-based substance smoking to HPV-
16 status, HPV-16 positive individuals smoked more than HPV-16 negative (+ve = 25.00%; –
ve = 17.44%, p = .526), but again, this was determined to be statistically non-significant via 
Fisher’s Exact analysis. 
When examining other tobacco-based substances individually, there were no statistically 
significant differences between HPV positive individuals and HPV negative and unknown 
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individuals either. Proportionally, however, cigar smoking was more prevalent in those that 
were HPV positive compared to HPV negative participants (+ve = 13.04%; –ve = 3.61%; U = 
0.00%, p = .240), whilst shisha/water pipe smoking was more prevalent in HPV negative 
participants (+ve = 8.70%; –ve = 15.66%; U = 0.00%, p = .664) (Table 22). When examining 
other tobacco-based substances individually to HPV-16 status, cigar smoking prevalence was 
also numerically higher in those that were HPV positive compared to HPV negative (+ve = 
15.00%; –ve = 3.49%, p = .080), but this was not statistically significant, determined via 
Fisher’s Exact analysis. Similarly, shisha/water pipe smoking was also more prevalent in HPV-
16 negative individuals (+ve = 10.00%; –ve = 15.12%, p = .731), but again, determined to be 
statistically non-significant via Fisher’s Exact analysis. 
In terms of non-tobacco-based substance smoking, cannabis smoking prevalence was compared 
to HPV status (Table 22). There was no difference in cannabis smoking prevalence between 
those that were HPV positive and HPV negative (+ve = 13.98%; –ve = 13.65%; U = 10.00%, p 
= .941), similarly to HPV-16 positive and HPV-16 negative individuals also (+ve = 14.10%; –
ve = 13.64%, p = .914), analysed via Fisher’s Exact testing. Cannabis smoking frequency, 
tobacco pipe smoking and vaping/e-cigarette usage was omitted from the analysis due to limited 
participants numbers. 
In summary, there was little difference in oral HPV prevalence and abundance between those 
that smoked in the cohort and those that abstained. The larger and more statistically significant 
differences emerged when taking frequency of cigarette smoking and pack years (length and 
quantity) into account, especially within the female cohort. For more definitive results, 
however, a larger sample size would be needed for future analyses. 
 
7.4.4 Oral HPV Results vs Alcohol Consumption Characteristics 
The screening results for HPV prevalence and abundance were compared to cohort alcohol 
consumption characteristics to determine if engaging with riskier behaviours associated with 
HPV infections and OPSCCs development influenced oral HPV status. Due to the associations 
between oral HPV and alcohol consumption, and the large differences found in drinking habits 
between males and females previously (Chapter 6), it was important to fully explore the 
characteristics including alcohol consumption status, drinking frequency, amount, type and 
NHS health risk status. First to be compared was alcohol consumption status (current, former, 
or never) and overall HPV prevalence (Figure 34). 
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Figure 34. Comparison of HPV Status & Alcohol Consumption Status. Generated and statistically 
analysed in SPSS using a Fisher’s Exact test for nominal categorical data (3 x 2 crosstabulations). 
“Unknown” HPV status participants were omitted to enable computation of statistical analyses; +ve = 
93; –ve = 315. 
 
When examining participant responses per alcohol consumption status sub-level within HPV 
positive individuals, there was a difference of ~5% between each, starting with current drinkers 
at 24.10%, followed by former drinkers at 15.38% and never drinkers at 11.76% (Figure 34). 
Despite the positive correlative trend between alcohol consumption and oral HPV status, the 
difference in responses was not large enough to be determined as statistically significant (p = 
.240). When comparing HPV-16 prevalence and alcohol consumption status, there were even 
larger numerical differences between HPV-16 positive current drinkers (20.50%), former 
(7.69%), and never drinkers (8.82%), but this also resulted in a statistically non-significant 
result determined via Fisher’s Exact analysis (p = .170). Further research, with higher response 
rates for each sub-level, may indicate that consuming alcohol has some correlation with oral 
HPV and HPV-16 prevalence, but this analysis was unfortunately limited by participant 
numbers. 
To investigate abundance of infection, alcohol consumption status was also compared to overall 
HPV viral load and HPV-16 viral load. Current drinkers exhibited higher viral loads, via mean 
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copy number/million cells, than former or never drinkers for both overall HPV and HPV-16 
infections with differences between the highest (current) and lowest (former) viral loads of 
9.01x104 copies/million cells (p = .477) and 7.98x104 copies/million cells (p = .720), 
respectively. Both differences, however, were determined to be statistically non-significant via 
Kruskal-Wallis H analyses. Further research, with higher participant numbers, may indicate 
that consuming alcohol has some correlation with oral HPV and HPV-16 abundance, but this 
viral load analysis was also unfortunately limited by participant numbers. 
To further analyse alcohol consumption characteristics in relation to oral HPV prevalence, 
drinking frequency and overall HPV status were compared. There was no statistically 
significant correlation between frequent drinking and HPV positive infections,  with the highest 
proportions of HPV positive drinkers drinking “1-2 times/week” at 38.20% and “Few 
times/month” at 21.35% (p = .454), determined via Mann-Whitney U analysis. Similarly, there 
was also no statistically significant correlation between frequent drinking and HPV-16 
prevalence as the highest proportions of HPV16 positive drinkers drank “1-2 times/week” at 
40.00% and “Few times a month” at 17.33% as well (p = .322), also determined via Mann-
Whitney U analysis. 
Alongside drinking frequency, overall HPV status was compared with mean number of units 
consumed per week to determine if quantity correlated with oral HPV status. Those that were 
HPV positive drank 1.84 units more per week than those that were HPV negative (+ve = 16.02 
± 16.87; –ve = 14.18 ± 15.44, p = .451), determined to be statistically non-significant via Mann-
Whitney U analysis. Similarly, whilst comparing HPV-16 status to mean number of units 
consumed per week, those that were HPV-16 positive drank 1.65 units more per week than 
those that were HPV-16 negative (+ve = 15.93 ± 16.31; –ve = 14.28 ± 15.68, p = .467), also 
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Table 23. HPV Status vs Types of Alcohol & Binge Drinking. Number of responses (n) and 
percentage (%) of cohort per HPV status. Statistically analysed in SPSS using Chi-square tests for 
nominal categorical data (3 x 2 crosstabulations) and Cramer’s V for effect size, unless otherwise 
indicated. 
 
a Only for participants that provided data on alcohol amount, type and frequency (+ve = 72; –ve = 209; U = 7). 
b Fisher’s Exact test used due to expected counts being <5. 
Cramer’s V effect sizes; Minimal = <.07; Small = .07-.21; Medium = .21-.35; Large = >.35 (for 2 df) (Kim, 2017). 
 
Alcohol type preferences were compared to overall HPV status to determine if there were any 
differences between those that were HPV positive and HPV negative (Table 23). The only type 
of alcohol that had a statistically significant association with HPV prevalence was wine, as a 
higher number of wine drinkers were HPV positive compared to HPV negative (+ve = 44.94%; 
–ve = 37.54%; U = 18.52%, p = .045, V = .124). No other types of alcohol were statistically 
significant when comparing with HPV status, but most were more popular in terms of numerical 
responses amongst those that tested HPV positive (ranging from 1.20-7.40% higher in 
prevalence), apart from cider and neat spirits.  
Due to exhibiting statistical significance, wine drinking was further compared with HPV status 
within males and females, taking gender into account. Overall, a higher proportion of HPV 
positive females drank wine than HPV negative females (+ve = 52.94%; –ve = 48.26%, p = 
.198), determined to be statistically non-significant via Chi-square analysis. Similarly, a higher 
proportion of HPV positive males drank wine than HPV negative males (+ve = 34.21%; –ve = 
21.24%, p = .108), also determined to be statistically non-significant via Chi-square analysis. 
Due to the high numbers of HPV positive wine drinkers, abundance of infection was also 
investigated by comparing overall HPV viral load between those that drank wine (Y) and those 
that did not (N). Despite the small numerical difference in HPV viral load, via mean copy 
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number/million cells, between those that drank wine and those that did not (Y = 1.05x105 
copies/million cells; N = 1.06x105 copies/million cells, p = .035), the difference was determined 
to be statistically significant difference via Mann-Whitney U analysis. 
Furthermore, overall HPV status was also compared to binge drinking and whether the 
participants consumed ≥2 types of alcohol per sitting (Table 23). There was no difference in 
binge drinking between HPV positive and HPV negative individuals (+ve = 54.17%; –ve = 
53.11%; U = 28.57%, p = .459) but drinking ≥2 types of alcohol was significantly more popular 
in HPV positive individuals (+ve = 74.16%; –ve = 64.21%; U = 44.44%, p = .015, V = .145).  
 
Table 24. HPV-16 Status vs Types of Alcohol & Binge Drinking. Number of responses (n) and 
percentage (%) of cohort per HPV-16 status. Statistically analysed in SPSS using Chi-square tests for 
nominal categorical data (2 x 2 crosstabulations) and Cramer’s V for effect size, unless otherwise 
indicated. 
 
a Only for those participants that provided data on alcohol amount, type and frequency (+ve = 63; –ve = 218). 
 
Alongside overall HPV status, HPV-16 status was also compared to each individual alcohol 
type, but none were found to be statistically significant, including wine drinking (Table 24). All 
alcohol types, however, were consistently more popular in terms of numerical responses in 
HPV-16 positive individuals than their HPV-16 negative counterparts; ranging from 7.54% 
higher for “Beer/Ale” drinkers (p = .232) to 0.60% higher for “Neat Spirit” drinkers (p = .912). 
When comparing HPV-16 status and drinking ≥2 types of alcohol, it was 10.12% more popular 
in HPV-16 positive than HPV-16 negative individuals (+ve = 74.67%; –ve = 64.55%, p = .097), 
but only 3.24% higher in HPV-16 positive individuals in comparison to those that were positive 
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for other HPV types (+ve = 74.67%; –ve = 71.43%, p = .751); both were consequently 
statistically non-significant. 
Alcohol type preferences were also compared within the HPV positive cohort (n = 93), rather 
than screened cohort (n = 408), to determine if HPV-16 positive individuals (P) exhibited 
alternative drinking habits to those that tested positive for other HPV types (N), due to the link 
between HPV-16 and OPSCCs. The largest proportional difference was in cider drinking, with 
a 27.53% difference between HPV-16 positive individuals and those that tested positive for 
another HPV type (P = 34.67%; N = 7.14%, p = .056), but this was determined to be statistically 
non-significant via Fisher’s Exact analysis. The second largest proportional difference was in 
neat spirit drinking, with a 8.38% difference between HPV-16 positive individuals and those 
that tested positive for another HPV type (P = 22.67%; N = 14.29%, p = .725), but again, this 
was determined to be statistically non-significant via Fisher’s Exact analysis. Alternatively, 
beer/ale drinking was 15.33% more prevalent in those that tested positive for other HPV types 
than HPV-16 (P = 34.67%; N = 50.00%, p = .276), but this was determined to be statistically 
non-significant via Chi-square analysis. All other alcohol types exhibited numerically smaller 
differences that were also non-significant between HPV-16 positive drinkers and those that 
were positive for other HPV types, determined either by Chi-square or Fisher’s Exact analyses 
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Figure 35. Comparison of HPV Status & ≥2 Types of Alcohol per Gender. Generated and 
statistically analysed in SPSS using Chi-square tests for nominal categorical data (2 x 2 crosstabulations) 
and Cramer’s V for effect size. “Unknown” HPV status participants were omitted from figure but were 
included in statistical analyses; M = 163 (+ve = 38); F = 238 (+ve = 51). * p ≤ .05, ** p ≤ .01, *** p ≤ 
.001. Cramer’s V effect sizes; Minimal = <.07; Small = .07-.21; Medium = .21-.35; Large = >.35 (for 2 
df) (Kim, 2017). 
 
As there was a statistically significant difference between HPV positive and HPV negative 
individuals for drinking ≥2 types of alcohol, a three-way comparison was made taking gender 
into account (Figure 35). For the female cohort, 68.63% of HPV positive females drank ≥2 
types of alcohol compared to 31.37% that did not (p = .287). For the male cohort, the difference 
was larger as 81.58% of HPV positive males drank ≥2 types of alcohol compared to 18.42% 
that did not (p = .023, V = .281), resulting in a statistically significant result. Due to the high 
numbers of HPV positive drinkers that drank ≥2 types of alcohol, abundance of infection was 
also investigated by comparing overall HPV viral load between those that drank ≥2 types of 
alcohol (Y) and those that did not (N). Despite ≥2 types of alcohol drinkers exhibiting a 
numerically higher HPV viral load, via mean copy number/million cells, compared to those that 
did not (Y = 1.13x105 copies/million cells; N = 8.23x104 copies/million cells, p = .281), the 
difference was determined to be statistically non-significant via Mann-Whitney U analysis. 
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Figure 36. HPV Status vs NHS/NICE Health Risk Status. Generated and statistically analysed in 
SPSS using Chi-square tests for nominal categorical data (for overall analysis of NHS/NICE Health 
Risk Status (NICE, 2010; Department of Health and Social Care, 2016; NHS Digital, 2016b) vs HPV 
status and individual analysis of sub-levels vs HPV status) and Cramer’s V for effect size. +ve = 76; –
ve = 239. * p ≤ .05, ** p ≤ .01, *** p ≤ .001. Cramer’s V effect sizes; Minimal = <.10; Small = .10-.30; 
Medium = .30-.50; Large = >.50 (for 1 df) (Kim, 2017). 
 
Overall, there was no significant difference between the NHS/NICE health risk status related 
to alcohol consumption between HPV positive and HPV negative individuals (p = .067) (Figure 
36). However, when comparing individual risk status with oral HPV status, those with a no-risk 
status (i.e. former or non-drinkers) were significantly more likely to be HPV negative (+ve = 
10.00%; –ve = 90.00%, p = .025, V = .126). When cross-comparing NHS/NICE health risk 
status and HPV status with gender, there was an overall significant difference within the female 
cohort (p = .010, V = .218) but no difference in males (p = .574), determined by Fisher’s Exact 
analysis. For females, the largest proportional difference was also within the no-risk status sub-
level as 0.00% of the no-risk female cohort were HPV positive (+ve = 0.00%; –ve = 17.04%, p 
= .004, V = .216), analysed via Chi-square testing. 
NHS/NICE health risk status was then compared to HPV-16 status using Fisher’s Exact 
analysis. There was a statistically significant difference between the NHS/NICE health risk 
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status related to alcohol consumption between HPV-16 positive and HPV-16 negative 
individuals (p = .040, V = .175), with the largest proportional difference existing between those 
with a no-risk status again (+ve = 7.50%; –ve = 92.50%, p = .040, V = .175). When cross-
comparing NHS/NICE health risk status and HPV-16 status with gender, there was an overall 
significant difference within the female cohort (p = .018, V = .207) but no difference in males 
(p = .269), determined by Fisher’s Exact analysis. For females, the largest proportional 
difference was within the no-risk status sub-level (+ve = 0.00%; –ve = 16.55%, p = .005, V = 
.202), but also the increasing-risk status sub-level (+ve = 29.63%; –ve = 16.55%, p = .011), 
both analysed via Chi-square testing. 
In summary, there were some differences in oral HPV prevalence and abundance between those 
that consumed alcohol in the cohort and those that abstained, with current drinkers exhibiting 
numerically higher viral loads and prevalence rates overall. However, larger and statistically 
significant differences only emerged when examining types of alcohol consumed individually 
and collectively, especially within the male cohort.  
 
7.4.5 Oral HPV Results vs Sexual Practice Characteristics 
The screening results for HPV prevalence and abundance were compared to cohort sexual 
practice characteristics to determine if engaging with riskier behaviours associated with genital 
HPV infections influenced oral HPV status. Due to the associations between oral HPV and 
sexual practice, and the differences found between males and females previously (Chapter 6), 
it was important to fully explore the characteristics including open-mouth kissing, sexual 
intercourse, sexual activity, number of sexual partners, one-night stand frequency and condom 
use. First, sexual practice descriptors (open mouth kissing and sexual intercourse) and overall 
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Table 25. HPV Status vs Sexual Practice Descriptors & Activity. Number of responses (n) and 
percentage (%) of cohort per HPV status. Statistically analysed in SPSS using Chi-square tests for 
nominal categorical data (3 x 2 crosstabulations) and Cramer’s V for effect size, unless otherwise 
indicated. 
 
a Data shown for sexually active cohort; n = 369 (+ve = 82; –ve = 267; U = 20). 
b Fisher’s Exact test used due to expected counts being <5. 
Cramer’s V effect sizes; Minimal = <.07; Small = .07-.21; Medium = .21-.35; Large = >.35 (for 2 df) (Kim, 2017). 
 
A higher proportion of HPV positive individuals engaged in open-mouth kissing (+ve = 
92.47%; –ve = 85.40%, p <.001, V = .188) and sexual intercourse (+ve = 88.17%; –ve = 84.76%, 
p = .026, V = .136) than those that were HPV negative (Table 25). These findings suggest that 
open-mouth kissing and sexual intercourse may influence oral HPV status. However, within 
the sexually active cohort (n = 369), there was no difference in oral HPV prevalence for those 
that reported being sexually active in the last year (+ve = 92.68%; –ve = 91.76%, p = .884), or 
for those that reported diagnoses of other STIs (+ve = 8.54%; –ve = 6.37%, p = .805). 
In order to analyse oral HPV status and sexual practices further, overall HPV status was also 
compared with individual types of sexual activity to determine if there were any differences 
between those that were oral HPV positive and oral HPV negative (Table 25). A higher 
proportion of those with an oral HPV infection engaged in oral sex (+ve = 93.90%; –ve = 
88.30%, p = .049, V = .128) compared to those that were HPV negative. Proportionally, more 
HPV positive individuals also engaged in masturbation compared to HPV negative individuals 
(+ve = 79.27%; –ve = 66.42%, p = .087), but this difference was deemed to be statistically non-
significant unlike oral sex. Similarly, those that were HPV positive were also more likely to 
engage in anal sex and foreplay compared to HPV negative individuals, with differences of 
5.67% and 3.91%, respectively, but again these findings were statistically non-significant. In 
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summary, the results suggest that sexual activity, and specifically oral sex, may influence oral 
HPV status. 
 
Table 26. HPV-16 Status vs Sexual Practice Descriptors & Activity. Number of responses (n) and 
percentage (%) of cohort per HPV-16 status. Statistically analysed in SPSS using Chi-square tests for 
nominal categorical data (2 x 2 crosstabulations) and Cramer’s V for effect size, unless otherwise 
indicated. 
 
a Data shown for sexually active cohort; n = 369 (+ve = 68; –ve = 281). 
b Fisher’s Exact test used due to expected counts being <5. 
Cramer’s V effect sizes; Minimal = <.10; Small = .10-.30; Medium = .30-.50; Large = >.50 (for 1 df) (Kim, 2017). 
 
All sexual practice descriptors and activities were also compared to HPV-16 status within the 
cohort (Table 26). For general sexual practice descriptors, engagement was consistently higher 
amongst those that were HPV-16 positive than those that were HPV-16 negative with 
differences of 4.97% for open-mouth kissing, 2.03% for sexual intercourse, and 4.24% for 
STD/STI status, despite these being statistically non-significant. Similarly, the comparisons of 
the sexual activities were not statistically significant, but engagement was also consistently 
higher within those that were HPV-16 positive than those that were HPV-16 negative. The 
largest numerical differences were exhibited for anal sex (4.36%), oral sex (5.59%), and 
foreplay (3.37%). Of all sexual activities, masturbation exhibited the largest difference as it was 
significantly more popular in those that were HPV-16 positive compared to those that were not 
(+ve = 83.82%; –ve = 65.95%, p = .004, V = .154), further demonstrating a correlation in 
increased sexual activity/practice and oral HPV-16 infections. 
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Furthermore, the general sexual practice descriptors and sexual activities were also compared 
within the HPV positive cohort (n = 93) to determine if HPV-16 positive individuals (P) 
exhibited alternative sexual practices those that tested positive for other HPV types (N). The 
only characteristic to exhibit a large difference between HPV-16 positive individuals and those 
that were positive for another HPV type was masturbation (26.68%; p = .063), but this was 
deemed statistically non-significant via Fisher’s Exact analysis. 
As open-mouth kissing, sexual intercourse, oral sex and masturbation were found to be 
statistically significant whilst comparing HPV status or HPV-16 status, each were then cross-
compared with gender to determine if there were any differences between males and females. 
The first to be cross-compared was open-mouth kissing (Figure 37). 
 
 
Figure 37. Comparison of HPV Status & Open-Mouth Kissing per Gender. Generated and 
statistically analysed in SPSS using Fisher’s Exact tests for nominal categorical data (3 x 2 
crosstabulations) and Cramer’s V for effect size. “Unknown” HPV status participants were omitted from 
figure but were included in statistical analyses; M = 178 (+ve = 42); F = 260 (+ve = 51). * p ≤ .05, ** p 
≤ .01, *** p ≤ .001. Cramer’s V effect sizes; Minimal = <.07; Small = .07-.21; Medium = .21-.35; Large 
= >.35 (for 2 df) (Kim, 2017). 
 
When cross-comparing open-mouth kissing with HPV status and gender, both genders were 
statistically significant (Figure 37). For the female cohort, 96.08% of HPV positive females 
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engaged in open-mouth kissing compared to 82.81% of HPV negative females (p <.001, V = 
.238). For the male cohort, the difference was smaller but still statistically significant due to 
88.10% of HPV positive males engaging in open-mouth kissing compared to 89.43% of HPV 
negative males (p = .003, V = .262). Due to the high prevalence of open-mouth kissing in the 
HPV positive cohort, abundance of infection was also investigated by comparing overall HPV 
viral load, via mean copy number/million cells, between those that engaged in open-mouth 
kissing (Y) and those that did not (N). In contrast, the difference in HPV viral load was found 
to be statistically non-significant via Mann-Whitney U analysis (Y = 7.70x104 copies/million 
cells; N = 3.77x105 copies/million cells, p = .134). 
When cross-comparing open-mouth kissing with HPV-16 status and gender, only the female 
cohort was statistically significant, determined by Chi-square analysis. For the female cohort, 
95.35% of HPV-16 positive females engaged in open-mouth kissing compared to 83.50% of 
HPV-16 negative females (p = .045, V = .129). For the male cohort, the difference was smaller 
and therefore, statistically non-significant due to 85.71% of HPV-16 positive males engaging 
in open-mouth kissing compared to 90.00% of HPV-16 negative males (p = .541). Open-mouth 
kissing in the HPV-16 positive cohort was also compared to HPV-16 viral load, via mean copy 
number/million cells, between those that engaged in open-mouth kissing (Y) and those that did 
not (N). Similarly, to overall HPV viral load, the difference was found to be statistically non-
significant via Mann-Whitney U analysis (Y = 8.16x104 copies/million cells; N = 3.77x105 
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Figure 38. Comparison of HPV Status & Sexual Intercourse per Gender. Generated and statistically 
analysed in SPSS using Chi-square and Fisher’s Exact tests for nominal categorical data (3 x 2 
crosstabulations) and Cramer’s V for effect size. “Unknown” HPV status participants were omitted from 
figure but were included in statistical analyses; M = 178 (+ve = 42); F = 260 (+ve = 51). * p ≤ .05, ** p 
≤ .01, *** p ≤ .001. Cramer’s V effect sizes; Minimal = <.07; Small = .07-.21; Medium = .21-.35; Large 
= >.35 (for 2 df) (Kim, 2017). 
 
When cross-comparing sexual intercourse with HPV status and gender, only the male cohort 
was statistically significant (Figure 38). For the female cohort, 90.20% of HPV positive females 
engaged in sexual intercourse compared to 83.33% of HPV negative females (p = .303). For 
the male cohort, 85.71% of HPV positive males engaged in sexual intercourse compared to 
86.99% of HPV negative males (p = .017, V = .235). Due to the high prevalence of sexual 
intercourse in the HPV positive cohort, abundance of infection was also investigated by 
comparing overall HPV viral load, via mean copy number/million cells, between those that 
engaged in sexual intercourse (Y) and those that did not (N). Despite those that engaged in 
sexual intercourse exhibiting a numerically higher HPV viral load, via mean copy 
number/million cells, than those that did not (Y = 1.08x105 copies/million cells; N = 6.18x104 
copies/million cells, p = .776), the difference was determined to be statistically non-significant 
via Mann-Whitney U analysis. 
When cross-comparing sexual intercourse with HPV-16 status and gender, neither genders were 
statistically significant, determined by Chi-square and Fisher’s Exact analysis. For the female 
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cohort, 88.37% of HPV-16 positive females engaged in sexual intercourse compared to 84.00% 
of HPV-16 negative females (p = .469), whilst 85.71% of HPV-16 positive male cohort engaged 
in sexual intercourse compared to 86.92% of HPV-16 negative males (p = .786).  
 
 
Figure 39. Comparison of HPV Status & Oral Sex per Gender. Generated and statistically analysed 
in SPSS using Fisher’s Exact tests for nominal categorical data (3 x 2 crosstabulations) and Cramer’s V 
for effect size. “Unknown” HPV status participants were omitted from figure but were included in 
statistical analyses; M = 150 (+ve = 36); F = 217 (+ve = 46). * p ≤ .05, ** p ≤ .01, *** p ≤ .001. Cramer’s 
V effect sizes; Minimal = <.07; Small = .07-.21; Medium = .21-.35; Large = >.35 (for 2 df) (Kim, 2017). 
 
When cross-comparing oral sex with HPV status and gender, neither cohort were statistically 
significant despite overall significant and high prevalence within HPV positive individuals 
(Figure 39). For the female cohort, 93.48% of HPV positive females engaged in oral sex 
compared to 86.08% of HPV negative females (p = .186). For the male cohort, 94.44% of HPV 
positive males engaged in oral sex compared to 91.59% of HPV negative males (p = .134). Due 
to the high prevalence of oral sex in the HPV positive cohort, abundance of infection was also 
investigated by comparing overall HPV viral load, via mean copy number/million cells, 
between those that engaged in oral sex (Y) and those that did not (N). Despite those that engaged 
in oral sex exhibiting a numerically higher HPV viral load, via mean copy number/million cells, 
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than those that did not (Y = 1.11x105 copies/million cells; N = 6.78x104 copies/million cells, p 
= .827), the difference was determined to be statistically non-significant via Mann-Whitney U 
analysis. 
When cross-comparing oral sex with HPV-16 status and gender, neither genders were 
statistically significant, determined by Fisher’s Exact analysis. For the female cohort, 94.74% 
of HPV-16 positive females engaged in oral sex compared to 86.14% of HPV-16 negative 
females (p = .179), whilst 93.33% of HPV-16 positive male cohort engaged in oral sex 
compared to 92.04% of HPV-16 negative males (p = 1).  
 
 
Figure 40. Comparison of HPV Status & Masturbation per Gender. Generated and statistically 
analysed in SPSS using Chi-square and Fisher’s Exact tests for nominal categorical data (3 x 2 
crosstabulations) and Cramer’s V for effect size. “Unknown” HPV status participants were omitted from 
figure but were included in statistical analyses; M = 150 (+ve = 36); F = 217 (+ve = 46). * p ≤ .05, ** p 
≤ .01, *** p ≤ .001. Cramer’s V effect sizes; Minimal = <.07; Small = .07-.21; Medium = .21-.35; Large 
= >.35 (for 2 df) (Kim, 2017). 
 
When cross-comparing masturbation with HPV status and gender, only the male cohort was 
statistically significant (Figure 40). For the female cohort, 63.04% of HPV positive females 
engaged in masturbation compared to 50.63% of HPV negative females (p = .179). For the male 
cohort, the difference was larger and therefore statistically significant due to 100.00% of HPV 
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positive males engaging in masturbation compared to 89.72% of HPV negative males (p = .020, 
V = .220). Due to the high prevalence of masturbation in the HPV positive cohort, abundance 
of infection was also investigated by comparing overall HPV viral load, via mean copy 
number/million cells, between those that engaged in masturbation (Y) and those that did not 
(N). Those that engaged in masturbation also had a numerically higher HPV positive viral load, 
but the difference was found to be statistically non-significant via Mann-Whitney U analysis 
(Y = 1.16x105 copies/million cells; N = 7.14x104 copies/million cells, p = .978). 
When cross-comparing masturbation with HPV-16 status and gender, only the female cohort 
was statistically significant, determined by Chi-square and Fisher’s Exact analysis. For the 
female cohort, 71.05% of HPV-16 positive females engaged in masturbation compared to 
49.40% of HPV-16 negative females (p = .016, V = .169). For the male cohort, the difference 
was smaller and therefore, statistically non-significant due to 100.00% of HPV-16 positive 
males engaging in masturbation compared to 90.27% of HPV-16 negative males (p = .120). 
Masturbation in the HPV-16 positive cohort was also compared to HPV-16 viral load, via mean 
copy number/million cells, between those that engaged in masturbation (Y) and those that did 
not (N). Similarly, to overall HPV viral load, those that engaged in masturbation exhibited a 
numerically higher HPV-16 viral load, but the difference was found to be statistically non-
significant via Mann-Whitney U analysis (Y = 1.20x105 copies/million cells; N = 8.55x104 
copies/million cells, p = .449). 
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Figure 41. Comparison of HPV Status & Sexual Activity Engagement Levels. Generated and 
statistically analysed in SPSS using Mann-Whitney U tests for non-parametric ordinal ranked data (for 
overall analysis of engagement levels vs status) and Chi-square tests for nominal categorical data (2 x 2 
crosstabulations) and Cramer’s V for effect size (for individual analysis of engagement sub-levels vs 
status). “Unknown” HPV status participants were omitted to enable computation of statistical analyses; 
+ve = 82; –ve = 265. * p ≤ .05, ** p ≤ .01, *** p ≤ .001. Cramer’s V effect sizes; Minimal = <.10; Small 
= .10-.30; Medium = .30-.50; Large = >.50 (for 1 df) (Kim, 2017). 
 
There was a significant statistical association and correlation between increasing number of 
sexual activities and HPV status (p = .043), revealing that the more sexually diverse a 
participant was, in terms of number of activities engaged in, the more likely they were to be 
HPV positive (Figure 41). This was demonstrated by the increasing prevalence of oral HPV 
from those that only engaged in one sexual activity (6.67%) to those that engaged in all five 
sexual activities (30.56%). When cross-comparing sexual activity diversity and HPV status 
with gender, there were no statistically significant differences between number of sexual 
activities engaged in and HPV positive females (p = .100) than males (p = .356), analysed via 
Mann-Whitney U tests. For females, the largest proportional difference was between four (+ve 
= 60.00%; -ve = 38.61%, p = .021, V = .167) sexual activities, further indicating that there was 
an association between increased sexual activity diversity and oral HPV status. 
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When comparing sexual diversity, via number of sexual activities engaged in, and HPV-16 
status, there was also a significant statistical association and correlation between increasing 
number of sexual activities and HPV-16 status (p = .044), determined via Mann-Whitney U 
analysis. Similarly to overall HPV status, prevalence of HPV-16 increased from those that only 
engaged in one sexual activity (0.00%) to those that engaged in all five sexual activities 
(23.61%). When cross-comparing sexual activity diversity and HPV-16 status with gender, 
there was also a larger difference between number of sexual activities engaged in and HPV-16 
positive females (p = .030) than males (p = .741), as determined via Mann-Whitney U analyses. 
For females, the largest proportional differences were between three (+ve = 13.16%; -ve = 
34.594%, p = .009, V = .184) and four (+ve = 63.64%; -ve = 36.75%, p = .004, V = .203) sexual 
activities, determined by Chi-square analyses, further indicating that there was an association 
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Table 27. HPV Status vs Sexual Partners, One-Night Stand (ONS) & Condom Practice. Number 
of responses (n) and percentage (%) of cohort per HPV status. Statistically analysed in SPSS using 
Mann-Whitney U tests for non-parametric ordinal ranked data (for overall analysis of each sexual 
practice characteristic vs status, unless otherwise indicated. 
 
a Chi-square test used for nominal categorical data (4 x 2 crosstabulation). 
 
The final sexual practice characteristics compared between HPV positive and HPV negative 
individuals were number of sexual partners, one-night stand (ONS) frequency, and condom 
usage to determine influence on oral HPV status (Table 27). There was no statistically 
significant difference between increasing number of sexual partners and oral HPV status, but 
proportionally, more HPV positive individuals reported higher numbers of sexual partners than 
HPV negative with differences of 1.37% for 6-10 partners, 2.15% for 11-20 partners, and 0.93% 
for >20 partners (p = .862). Similarly, there were no statistically significant differences between 
HPV positive and HPV negative individuals when comparing different sub-levels of ONS 
frequency (p = .845) and condom usage (p = .334), indicating neither traditional genital HPV 
risk factor had an effect on oral HPV status. However, 8.46% more participants that reported 
never using condoms as a form of barrier contraception were HPV positive compared to HPV 
negative. 
Number of sexual partners, ONS frequency and condom usage was also compared between 
HPV-16 positive and HPV-16 negative individuals using Chi-square and Mann-Whitney U 
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tests. Alike the comparisons between overall HPV status and sexual partners, higher numerical 
proportions of the cohort were HPV-16 positive than HPV-16 negative within those that 
reported 11-20 sexual partners (+ve = 7.35%; –ve = 6.69%) and >20 sexual partners (+ve = 
8.82%; –ve = 6.07%), despite exhibiting no statistical significance (p = .820). There were also 
no trends or statistically significant differences between HPV-16 positive and HPV-16 negative 
individuals when comparing different sub-levels of ONS frequency alike overall HPV status (p 
= .616), indicating ONS frequency also had no effect on oral HPV-16 status. For condom usage, 
8.76% more participants that reported never using condoms as a form of barrier contraception 
were HPV-16 positive compared to HPV-16 negative but overall frequency was also 
statistically non-significant (p = .464). 
In summary, some sexual practice characteristics presented significant differences between 
those that were HPV positive and HPV negative in terms of HPV prevalence and abundance, 
particularly within descriptors and types of sexual activity. Most notably, factors associated 
with genital HPV infections, such as number of sexual partners and vaginal sex, did not 
influence oral HPV status. Instead, factors such as open-mouth kissing, oral sex and increasing 
levels of sexual activity (and diversity) correlated with HPV prevalence, and specifically HPV-
16 prevalence, with some variance between the genders. 
 
7.4.6 Oral HPV Results vs Vaccination Data 
From the cohort HPV-related data, vaccination status only was selected for comparison with 
the screening results for HPV prevalence, abundance, and type, due to limited participant 
numbers within the HPV descriptors data including diagnosed HPV infections and diagnosed 
HPV-related precursor/cancer. The first comparisons were made between overall HPV status 
and vaccination status, whilst also taking gender into account (Figure 42). 
 
 
Page | 163  
 
 
Figure 42. Comparison of HPV Status & Vaccination Status per Gender. Generated and statistically 
analysed in SPSS using Chi-square and Fisher’s Exact tests for nominal categorical data (3 x 2 
crosstabulations) and Cramer’s V for effect size. “Unsure” participants were omitted from figure but 
were included in statistical analyses, whilst “Unknown” HPV status participants were omitted from both 
groups to enable computation of statistical analyses; M = 165 (+ve = 42); F = 243 (+ve = 51). * p ≤ .05, 
** p ≤ .01, *** p ≤ .001. Cramer’s V effect sizes; Minimal = <.07; Small = .07-.21; Medium = .21-.35; 
Large = >.35 (for 2 df) (Kim, 2017). 
 
Overall, there was no statistically significant difference between HPV positive and HPV 
negative individuals when comparing HPV vaccination status (Y, N and Unsure), without 
taking gender into account. The prevalence of HPV was 4.52% numerically higher in those that 
had not received the HPV vaccination in comparison to those that had (Y = 20.36%; N = 
24.88%; Unsure = 22.50%, p = .589) but this difference was not large enough to indicate a 
statistical relationship. When removing unsure participants from the analysis, this numerical 
difference increased to 6.35% (p = .304), both determined via Chi-square analyses. When cross-
comparing HPV vaccination status and overall HPV status with gender, both the male and 
female cohort exhibited a numerically higher prevalence of HPV in those that had not been 
vaccinated (Figure 42). The prevalence of HPV was 3.52% higher in non-vaccinated females 
than those that had been vaccinated (Y = 20.48%; N = 24.00%; Unsure = 18.52%, p = .819), 
but again, this difference was not large enough to indicate a statistical relationship. The 
difference between non-vaccinated and vaccinated male cohort was much larger at 25.17% but 
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this was to be expected as none of the HPV positive males were vaccinated (Y = 0.00%; N = 
25.17%; Unsure = 30.77%, p = .807). This difference, however, was not large enough to 
indicate a statistical relationship also. 
HPV-16 status was also compared to HPV vaccination status. Overall, there was no statistically 
significant difference for HPV16 (p = .885), analysed by Chi-square test. The prevalence of 
HPV-16 was 1.94% higher in those that had not received the HPV vaccination in comparison 
to those that had (Y = 17.96%; N = 19.90%; Unsure = 20.00%, p = .885), determined via Chi-
square analysis. When cross-comparing HPV vaccination status and HPV-16 status with 
gender, the male cohort exhibited a higher prevalence of HPV-16 in those that had not been 
vaccinated (Y = 0.00%; N = 20.53%; Unsure = 30.77%, p = .589), whilst HPV-16 prevalence 
was similar in both vaccinated and non-vaccinated females (Y = 18.07%; N = 18.00%; Unsure 




Figure 43. Comparison of Viral Load & Vaccination Status. Both generated and statistically 
analysed in SPSS using Mann-Whitney U tests for non-parametric continuous data. Mild outliers = 
circles; ≥1½ times the interquartile range away from the quartiles. Extreme outliers = y-axis asterisks; 
≥3 times the interquartile range away from the quartiles. “Unsure” participants were omitted to enable 
computation of statistical analyses. a) Overall HPV Viral Load per Vaccination Status – Yes = 31; 
No = 45. b) HPV-16 Viral Load per Vaccination Status – Yes = 30; No = 40. 
 
To investigate abundance of infection alongside prevalence, the viral load of those that were 
HPV positive and HPV-16 positive was compared with vaccination status also (Figure 43). 
Despite not testing statistically significant, there were numerical differences between non-
vaccinated and vaccinated individuals in viral load, via mean copy number/million cells. For 
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HPV viral load, non-vaccinated individuals (NV) exhibited a viral load that was 8.39x104 
copies/million cells higher than vaccinated participants (V) (V = 5.49x104 copies/million cells; 
NV = 1.38x105 copies/million cells, p = .463) (Figure 43a). Both the vaccinated and non-
vaccinated cohort exhibited high variances in HPV viral load, but the range was larger in non-
vaccinated individuals, with the highest individual viral load being 2.09x106 copies/million 
cells, compared to 2.99x105 copies/million cells for the vaccinated cohort. Similarly, when 
comparing HPV-16 viral load, via copy number/million cells, the non-vaccinated (NV) cohort 
exhibited a viral load that was 1.00x105 copies/million cells higher than vaccinated participants 
(V = 5.42x104 copies/million cells; NV = 1.54x105 copies/million cells, p = .176) (Figure 43b). 
Furthermore, there was also a high variance in HPV-16 viral load within both the vaccinated 
and non-vaccinated cohort, but the range was larger in non-vaccinated individuals, with the 
highest individual viral load being 2.09x106 copies/million cells, compared to  2.96x105 
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Figure 44. Comparison of HPV Type Prevalence & Vaccination Status. Generated and statistically 
analysed in SPSS using Chi-square tests for nominal categorical data (2 x 2 crosstabulations) and 
Cramer’s V for effect size (for individual type analysis vs vaccination status), comparing vaccination 
status and cohort HPV type prevalence for HPV-6, HPV-11, HPV-16, HPV-18, co-infections (HPV-16 
& HPV-18), & other unknown HPV types. Not all HPV types were statistically analysed due to limited 
participant numbers. “Unsure” participants were omitted to enable computation of statistical analysis; 
Y (+ve) = 34; N (+ve) = 50. Cramer’s V effect sizes; Minimal = <.10; Small = .10-.30; Medium = .30-
.50; Large = >.50 (for 1 df) (Kim, 2017). 
 
The final comparison made was between HPV type prevalence and vaccination status within 
the positive cohort (Figure 44). When comparing HPV type to vaccination status, non-
vaccinated participants exhibited a higher prevalence rates within all HPV types other than 
HPV-16 (Y = 82.35%; N = 76.00%, p = .486), and by association, co-infections of HPV-16 & 
HPV-18 (Y = 5.88%; N = 4.00%). The differences in prevalence, however, were not statistically 
significant. HPV-6 (Y = 0.00%; N = 4.00%), HPV-11 (Y = 0.00%; N = 2.00%), and HPV-18 
(Y = 2.94%; N = 4.00%) ranged from being ~1-4% higher in prevalence in non-vaccinated 
individuals than vaccinated, which again, were not statistically significant. The prevalence of 
other HPV types was also numerically higher in non-vaccinated individuals (Y = 8.82%; N = 
10.00%) but could not be compared statistically due to limited participant numbers. 
In summary, oral HPV prevalence was proportionally higher in non-vaccinated individuals 
compared to vaccinated individuals when examining the numerical differences in the data, 
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especially for all types other than HPV-16. However, there were no statistically significant 
differences due to limited participant numbers for analysis. For HPV abundance, the differences 
in HPV viral load between non-vaccinated and vaccinated individuals were also numerically 
larger but not statistically significant, with non-vaccinated individuals exhibiting more 
abundant oral infections in terms of viral load overall. 
 
7.4.7 Summary of Oral HPV Results & Lifestyle Data Comparisons 
The key finding of the oral HPV screening results was the overall oral HPV prevalence rate of 
22.79%. Within this prevalence rate, type-specific screening revealed the most prevalent and 
abundant HPV type in the mouth was HPV-16. When statistically comparing this screening 
data with gender, there was little difference in overall prevalence, but LR-HPV prevalence and 
HPV abundance was higher in the male cohort, similarly to non-vaccinated individuals. 
When comparing the screening data to cohort lifestyle risk factors for OPSCC development and 
contraction of HPV, smoker and alcohol consumption status exhibited little effect on oral HPV 
prevalence. The larger differences emerged when examining the risk factors in more detail. For 
instance, frequent smoking and higher numbers of pack years were associated with oral HPV, 
especially within the female cohort. For alcohol consumption, specific types of alcohol 
consumed and variation in the types consumed was associated with oral HPV, but within the 
male cohort. For sexual practice characteristics, open-mouth kissing, oral sex, masturbation, 
and increasing levels of sexual activity correlated with oral HPV prevalence, with some 
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Chapter 8:  
DISCUSSION OF STUDY METHODS & RESULTS 
 
The aim of the study was to establish oral HPV prevalence and abundance within the UK young 
adult population and to determine if either were influenced by HPV type, vaccination status, 
and lifestyle choices of an individual. To achieve this aim, a novel consensus screening 
methodology was established for the detection of oral HPV within the study cohort (Chapter 
3). Using this method, study participants were screened for oral HPV, and the quadrivalent 
vaccination subtypes (HPV-6, HPV-11, HPV-16 and HPV-18) via subsequent type-specific 
screening. Alongside screening, cohort identity was explored to determine those partaking in 
lifestyle risk factors associated with the development of OPSCCs and contraction of HPV. The 
lifestyle data was compared between gender and the HPV screening results to determine if there 
were any correlations between risk factors and oral HPV prevalence, type, and abundance. The 
following chapter will discuss the established novel screening methodology, cohort identity and 
HPV screening results with reference to comparative literature, limitations. and future 
implications. 
 
8.1 Screening Methodology 
The successful establishment and implementation of the novel consensus screening 
methodology to detect multiple types of HPV (MY09/11) within this study demonstrates the 
importance of method design, optimisation and pilot testing. As demonstrated, several factors 
such as real-time PCR sensitivity, reaction efficiency, type of primers, cycling conditions and 
reagents required consideration, with primer design being the most important (Vet & Marras, 
2005) 
For ~30 years, HPV consensus screening has been carried out using numerous broad-spectrum 
primers within traditional end-point PCR (Şahiner et al., 2014; Gautam et al., 2019). As 
demonstrated from the pilot testing of GP5/GP6+ and MY09/11, not all consensus primer sets 
can be utilised within newer real-time PCR methods. Consensus primers contain degenerative 
bases which allow for non-specificity across multiple viral subtypes (Remmerbach et al., 2004; 
Gautam et al., 2019). By increasing the number of these degenerative bases, and therefore the 
likelihood of detecting multiple HPV types, consensus primers decrease target amplicon 
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specificity leading to non-specific binding and primer dimer formation (Şahiner et al., 2014). 
As demonstrated, this can have problematic effects on the interpretation of HPV screening 
results without method optimisation. Selecting MY09/11 as the most effective primer set for 
HPV consensus screening using real-time PCR has since become increasingly more popular 
amongst the oral HPV research field (Torrente et al., 2005). Numerous studies have started to 
use MY09/11 primers to determine HPV prevalence in oral rinse samples (Schlecht et al., 
2019), oropharyngeal squamous cell carcinomas (OPSCCs) (Pandey et al., 2018) and tonsillar 
tissue (Sünter et al., 2019), reaffirming the primer choice within this study. The GP5/GP6+ 
primer set have also been used recently but for nested end-point PCR, rather than real-time PCR 
(de Souza et al., 2018), and less often with oral swab screening. 
As with any PCR-based laboratory study, the most effective primer sets available are custom-
designed sets but these are often costly and are tailored to perform well under specific 
conditions outlined by the manufacturer, designed to incur additional costs by purchasing 
recommended PCR mastermixes (Noorbazargan et al., 2018; Gautam et al., 2019). By 
establishing a home-made assay, this study reduced costs and demonstrated that ready-available 
primer sets can be optimised “in-house”. Home-made assays have also been shown to be more 
sensitive than purchased real-time PCR kits due to the ability to calibrate methods using sample 
type being screened (Noorbazargan et al., 2018).  
However, the methodology development of the HPV consensus screen did reveal the 
importance of testing different purchased PCR mastermixes with alternate compositions. 
Bioline’s SensiFAST mastermix was less suitable for this assay than Primerdesign’s 
PrecisionFAST as the latter produced cleaner amplification with less non-specific binding. 
Similar studies have also demonstrated the importance of testing PCR mastermixes prior to use 
in screening assays (Vet & Marras, 2005; Tesena et al., 2017). One study tested five different 
mastermix DNA polymerase enzymes and six different mastermix buffer compositions and 
found that changing these components had large effects on real-time PCR efficiency and varied 
standard curve R2 values, which would affect downstream quantification (Wolffs et al., 2004). 
Due to this, reaction efficiency was consistently calculated to monitor the effects of any minor 
changes made to the PCR amplification conditions throughout the methodology development. 
The methodology development also demonstrated the importance of primer concentration 
optimisation on target amplification and efficiency. It was discovered that using incorrect 
primer concentrations for the assay could result in falsely categorising positive samples as 
negative due to primer dimerisation. In support, real-time PCR experts state that primer 
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optimisation is the most important aspect in real-time PCR assay design due to the effect of 
primer concentration on reaction efficiency and target amplicon affinity (ThermoFisher 
Scientific, 2014). However, careful consideration is still required whilst interpreting results as 
late amplification whilst using low primer concentration of ~60-100 nM, can be misinterpreted 
as positive via amplification signals (ThermoFisher Scientific, 2016). The use of the 
dissociation (melt) curves counteracted this as the number of products amplified by the 
MY09/11 primer set could be visualised and then compared to uMeltSM predictive software 
(Dwight, Palais & Wittwer, 2011). This allowed for the successful interpretation of the 
screening results and validity testing when comparing produced melting temperature (Tm) 
values to the predicted Tm values for target HPV amplicons. Increasingly, virological screening 
assays with SYBR® Green fluorescence dyes and/or consensus primer sets are using the 
dissociation (melt) curves to help interpret screening results due to the ability to distinguish 
primer dimer dissociation peaks and amplicon dissociation peaks (ThermoFisher Scientific, 
2014; Promega, 2020). One study revealed that the benefits of using dissociation curves for 
distinguishing number of products present, rather than relying on the amplification plot alone 
as the signal can originate from amplification of multiple dsDNA products, not only the 
amplified target (Robinson, Monis & Dobson, 2006). 
However, there is always an element of deduction required when using qualitative screening 
methods so it is important to increase replicate numbers (Ellison et al., 2006; ThermoFisher 
Scientific, 2014), validate results and use a secondary visualisation technique to fully estimate 
the prevalence of the target amplicon in the screening cohort (Promega, 2020). For this study, 
samples were screened for HPV multiple times for reliability, compared to uMeltSM predictive 
dissociation curves for validity, and electrophoresed for confirmation of target amplification, 
where possible. Individually these approaches have been used by other virological studies but 
not combined, making this study’s approach overall more comprehensive. In fact, one of the 
only recorded uses of uMeltSM predictive software in HPV research was to help design HPV-
68 primers (Jaworek et al., 2019). The software has, however, been shown to help validate 
assays for other viruses; sheeppox virus (Chibssa et al., 2019), canine parvovirus type 2 (Bingga 
et al., 2014), and Kyasanur Forest disease virus and Alkhurma hemorrhagic fever virus 
(Sudheesh et al., 2020). The use of screening replicates, on the other hand, are central to all 
real-time PCR screening (Ellison et al., 2006), whilst Wen et al., (2019) recently reinforced the 
advantages of combining gel electrophoresis, sequencing and dissociation (melt) curve analyses 
whilst screening for pig viruses. Within the HPV field, one study detecting LR-HPV in warts 
had  previously used a combination approach of dissociation (melt) curve comparison and gel 
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electrophoresis to confirm presence, then just using gel electrophoresis alone (Tai et al., 2012). 
Within this study, the use of the dissociation (melt) curve allowed for the determination of 
30.15% more samples that were borderline/unknown samples than if traditional end-point PCR 
had been used and the results visualised at the end-point. 
Furthermore, this study demonstrated the importance of optimisation of real-time PCR cycling 
conditions, balancing primer design with mastermix composition and machine 
recommendations. Every aspect of the thermocycling was explored within the methodology 
development of the HPV consensus screen to ensure the assay was fully optimised for purpose. 
This included the enzyme activation time, otherwise known as a “hot-start”, cycle number, 
denaturation time, annealing temperature and time, and the addition of an extension period. 
Most screening studies use manufacturer’s instructions for either the primer set or detection kit, 
the real-time PCR machine, or mastermix recommendation conditions used for sample 
screening without deviation (ThermoFisher Scientific, 2014), but this study used a combination 
of all three.  
Changing the annealing temperature produced the largest effects on sample determination and 
reaction efficiency in this study. Rodríguez et al., (2015) explains that primer structure and G-
C content influences optimum annealing temperature so it is important to design them 
appropriately for the target amplicon and test  optimum annealing temperature. To test multiple 
annealing temperatures in an efficient and simple approach, gradient PCR was used in this study 
via AB®’s VeriFlex™ block system. PCR methodological development studies have used 
gradient PCR to initially develop cycling conditions for >30 years (Zhang & Xing, 2010; 
Rowther, Kardooni & Warr, 2012), supporting the use in the development process within this 
study. The optimisation of the extension period produced the second largest effects on sample 
determination and reaction efficiency in this study. It has been shown that the larger the 
amplicon size, the longer the extension period is required (ThermoFisher Scientific, 2014), yet 
real-time PCR has seen the removal of this step via combination of annealing and extension 
periods for quicker reactions (ThermoFisher Scientific, 2016). The MY09/11 amplicon was 
~450 bp so was larger than the recommended real-time PCR amplicon size of ~80-150 bp 
(Thornton & Basu, 2011), requiring the additional step of extension to be reintroduced. Other 
studies have demonstrated a similar technique when developing assays but warned that there 
could be downstream complications of non-specific binding due to the efficiency of real-time 
PCR in comparison to traditional end-point methods (ThermoFisher Scientific, 2014). Utilising 
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the dissociation (melt) curve for product visualisation negated this as non-specific binding can 
be detected via Tm differentiation. 
Finally, the HPV consensus screen development also demonstrated the importance of target 
DNA concentration optimisation to ensure the real-time PCR system was not overloaded or 
oppositely, underloaded. Both have been shown to negatively affect sensitivity and produce 
false positive results, even with the use of positive controls (da Cunha Gonçalves-de-
Albuquerque et al., 2014). One study revealed that DNA mass affects SYBR Green 
fluorescence, which, if unbalanced, can skew the exponential phase of amplification resulting 
in inaccurate quantification cycle (Cq) values (Rutledge, 2004), as demonstrated in this study 
during pilot DNA concentration testing. Flawed purification processes during DNA extraction 
have also been shown to effect amplification (ThermoFisher Scientific, 2014). Leftover 
extraction buffers and ethanol in samples can be real-time PCR reaction inhibitors that either, 
inhibit the enzymatic function of DNA polymerase or, inhibit the annealing of the primers to 
the target amplicon (Gallup & Ackermann, 2006; Opel, Chung & McCord, 2010). To control 
this, Qiagen DNeasy Blood & Tissue kits were used to extract and purify sample DNA as they 
have been shown to reduce residual inhibitors and produce the highest quality extracts (Hellberg 
et al., 2014), despite the possible loss of sample DNA yields through the use of filtered spin 
columns (Eriksson et al., 2017). To develop the methodology, future research could compare 
DNA yield and purity from multiple extraction kits/processes, similarly to this study’s 
mastermixes comparisons. 
Overall, the lengthy and rigorous testing of every element of the established novel HPV 
consensus screening methodology provides confirmation that the initial sample screening 
results were reliable and accurate. Type-specific screening built upon this and was used to 
distinguish HPV subtype prevalence within the positive cohort. Most samples identified to be 
HPV positive from the consensus screen could be typed, apart from 2.21% that did not appear 
to be HPV-6, HPV-11, HPV-16 or HPV-18 positive, therefore the type-specific screening 
results reaffirmed the reliability of the established consensus method.  
The four HPV type-specific screening assays also determined 12.99% of the 
borderline/unknown samples to be HPV positive. These samples would not have been 
determined if normal end-point MY09/11 screening had been employed as an initial screening 
method, as these samples were flagged due to the dissociation (melt) curve rather than via gel 
electrophoresis. When the samples were electrophoresed, the ~450 bp amplicons could not be 
visualised due to small HPV copy numbers present in the samples, as demonstrated previously. 
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In support, research has shown that using gel electrophoresis increases the chances of obtaining 
false-negative results, as ~100 copies to 1 copy of an amplicon exhibit weak or indistinguishable 
band fluorescence under UV (Espiñeira et al., 2010). Therefore, this study demonstrates the 
importance of using combined screening approaches and sensitive methods for future oral HPV 
screening work. 
As described in the introduction, many studies now use multiplexing assays and premade kits 
to determine the presence of multiple HPV types at once. Whilst these methods are rapid, they 
are compromised by cost, real-time PCR machine limitations (Takács et al., 2008), primer 
dimerisation (Wen et al., 2019), the inability to fully differentiate between HPV type, and the 
inability to quantify HPV types present (Takács et al., 2008; Rodríguez et al., 2015). Due to 
multiplexing kits regularly using the same fluorophores for multiple high-risk (HR) HPV type 
probes and for multiple low-risk (LR) HPV type probes, there can be cross-reactivity, making 
it is impossible to distinguish individual HPV types present in samples (Takács et al., 2008), 
for instance, HPV-16 type amplification from HPV-18 type amplification. Using individual 
type-specific screening for each HPV type of interest, after consensus screening, allows for 
definitive detection, quantification of viral load and determination of the presence of co-
infections (Yu et al., 2020). This study found an HPV-16 and HPV-18 co-infection prevalence 
of 0.98%, which would have been overlooked if a multiplexing kit assay had been employed. 
The use of type-specific screening also allowed for the quantification of HPV positive samples, 
if they were determined to be either HPV-6, HPV-11, HPV-16 and HPV-18. As useful and 
reliable as the HPV consensus screen was, it could only provide an estimate of HPV copy 
number within the oral samples, therefore viral load, whilst the type-specific screening allowed 
for absolute quantification via copy number standard curve calculations (ThermoFisher 
Scientific, 2014). Therefore, this further supports the use of a combination approach for future 
oral HPV screening. 
 
8.2 Cohort Identity 
The exploration of the baseline characteristics, in conjunction with national statistical databases 
(Office for National Statistics, NHS Digital and Natsal-3), indicated that the study cohort was 
an overall good representative for the wider UK young adult population. As previously 
described, the characteristics that were found to be concurrent with the lifestyle and practices 
of 16-24-year-olds included smoker status, binge drinking, NHS/NICE health risk status, sexual 
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intercourse frequency, STD/STI prevalence, numbers of sexual partners and condom usage 
(Mercer et al., 2013; Khadr et al., 2016; NHS Digital, 2016b; Woodhall et al., 2016; NHS 
Digital, 2017; Office for National Statistics, 2017). The only baseline characteristic that differed 
to the comparative databases was types of sexual activity, sexual orientation, and vaccination 
uptake (Mercer et al., 2013; Tanton et al., 2017; Natsal-3, 2019). Furthermore, demographics 
and characteristics such as gender distribution, ethnicity, cannabis smoking, vaping/e-cigarette 
usage, alcohol consumption status and average units per week were also similar to national UK 
data (Mercer et al., 2013; NHS Digital, 2016b; Office for National Statistics, 2018; Office for 
National Statistics, 2019a; Office for National Statistics, 2019b), further indicating that the 
study cohort could be used to represent the wider UK young adult population. Based on these 
findings, oral HPV screening results can be reliability discussed in relation to cohort identity. 
 
8.2.1 Oral HPV Prevalence 
One of the key findings of this study was the oral HPV prevalence rate of 22.8% found within 
the healthy UK-based young adult cohort. In contrast, recent world-wide meta-analyses 
predicted oral HPV prevalence rates to be lower at 5.5-7.7%, indicating a difference of ~15%. 
(Shigeishi & Sugiyama, 2016; Wood et al., 2017b; Tam et al., 2018). However, individual 
studies have reported prevalence values ranging from 4.0% in Italy (Lupato et al., 2017), 5.7% 
in Japan (Cho et al., 2020), 6.8% in Peru (Rosen et al., 2016) to a higher 26.0% in the Caribbean 
(Auguste et al., 2017), demonstrating a high degree divergence depending on geography. This 
can also be seen within other UK-based literature within the few studies that have conducted 
research into oral HPV prevalence rates. Reported rates range from 4.0-18.7% in healthy 
individuals across England and Scotland (Conway et al., 2016; Knight et al., 2016; Mehanna 
et al., 2019), demonstrating a large national divergence as well as globally. Due to the large 
variance in oral HPV prevalence rates, locally and globally, it is important to consider what 
screening techniques were used within comparative studies for HPV detection, type prevalence 
rates, and each set of cohort demographics and/or lifestyle risk factors. 
Consistently, studies reporting lower HPV prevalence rates of 4.0-6.8% have used commercial 
screening kits, such as Roche Linear Array® HPV Genotyping Test or the SPF10 PCR‐DEIA‐
LiPA25 system (Rosen et al., 2016; Hirth et al., 2017; Lupato et al., 2017), whilst studies 
reporting  higher oral HPV prevalence rates of 18.7-19.7% have used combinations of 
consensus PCR and secondary screening approaches (Bui et al., 2017; Mehanna et al., 2019), 
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similar to this study. This further demonstrates the importance of implementing secondary 
screening approaches for increased sensitivity, especially within oral samples from healthy 
individuals which exhibit low DNA concentrations. The study reporting the oral HPV 
prevalence of 26.0% did, however, use the SPF10 PCR‐DEIA‐LiPA25 system (Auguste et al., 
2017), but this has recently been shown to be more sensitive for oral HPV screening than Roche 
Linear Array® HPV Genotyping Test (Bettampadi et al., 2020). 
Many of these studies also recruited older individuals up to the age of ~85 years old (Conway 
et al., 2016; Rosen et al., 2016; Mehanna et al., 2019), providing representation of the general 
population rather than the young adult population. The few studies that have sampled an 
equivalent student and/or young adult population reported higher average oral HPV prevalence 
rates ranging from 9.3-20.0% (Du et al., 2012; Edelstein et al., 2012; D’Souza et al., 2014), 
revealing more comparable results and demonstrating the necessity to also consider cohort age. 
Other demographics to consider include gender and ethnicity. This study found a higher oral 
HPV prevalence in young adult females than males, but this could have been as a result of bias 
in the study gender distribution. One recent study reported a similar distribution of 19.5% in 
females and 17.4% in males (Mehanna et al., 2019) but most studies have frequently either 
reported equal distributions (Sastre-Cantón et al., 2019), or  higher oral HPV prevalence rates 
in males than females (Antonsson et al., 2014; D’Souza et al., 2014; Shigeishi & Sugiyama, 
2016; Bui et al., 2017). The difference has been suggested to indicate that males are more likely 
to contract oral HPV and/or are less likely to clear the infection than females. In fact, oral HPV 
persistence has been theorised and recently shown to be higher in males than females, especially 
for HR-HPV types (Colon-López et al., 2014; Sastre-Cantón et al., 2019; D’Souza et al., 2020), 
but further longitudinal studies are required to provide definitive evidence. 
Specific ethnic groups have also been linked to higher oral HPV prevalence rates. This study 
found those identifying as White British had a higher prevalence than any other ethnic group, 
but analysis was limited by cohort diversity. In support, a large-scale oral HPV screening study 
in the United States found non-Hispanic White and non-Hispanic Black individuals exhibited 
higher oral HPV prevalence rates than Asian and Hispanic groups (Sanders, Slade & Patton, 
2012; McQuillan et al., 2017). Another study, conducted in Australia, also found an oral HPV 
prevalence rate as high as 35.3% within a large Indigenous Australian population (Jamieson et 
al., 2020), demonstrating that population isolation may also influence oral HPV prevalence. 
Despite evidence of disparity between ethnicity and isolated groups in relation to oral HPV 
prevalence, there are limited studies investigating this relationship. This is even more pertinent 
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as research has recently reported a higher HR-HPV type prevalence within oral samples from 
Black ethnic groups (Pickard et al., 2012; Auguste et al., 2017; Raymond, Liu & Taioli, 2018), 
revealing White and Black Anglo-American populations may be at higher risk of developing 
HPV positive HNSCC/OPSCCs but more research is required. 
 
8.2.2 Oral HPV Type Prevalence 
Currently, there is much debate as to which HPV sub-types are the most prevalent in oral 
samples due to large variation in the screening methodologies employed and type of populations 
sampled. Out of the four HPV sub-types (HPV-6, HPV-11, HPV-16, and HPV-18) screened for 
in this study, the most prevalent was HR-HPV type, HPV-16. Several studies have also found 
HPV-16 to be the most prevalent in oral samples (Wimardhani et al., 2015; Lupato et al., 2017; 
Hearnden et al., 2018), especially within White individuals (Raymond, Liu & Taioli, 2018). 
However, many studies have limited their sample populations to HIV positive individuals as 
immunocompromisation has also been linked to the development of HPV positive 
HNSCC/OPSCCs (King et al., 2016; D’Souza et al., 2020; Méndez-Martínez et al., 2020; 
Pérez-Quintanilla et al., 2020). Other studies have found HR-HPV types, HPV-18 (Seifi et al., 
2013; Le et al., 2019), the second most prevalent type determined in this study, and HPV-52 
(Auguste et al., 2017) to be the most prevalent in oral samples. Despite variation in sub-type 
prevalence, most studies agree that HR-HPV types are more prevalent in healthy oral samples 
than LR-HPV types overall. Due to HR-HPV sub-types being linked with malignant 
transformation, it is important to also determine HR-HPV co-infection prevalence rates, 
abundance through viral load, and the effect of these on oral persistence. 
HR-HPV co-infection prevalence rates in this study were low at 0.98% but comparable with 
large-scale oral HPV screening studies conducted in China and the United States, which 
reported HR-HPV co-infection prevalence rates of 0.1-1.5%, respectively (Hang et al., 2014; 
Bui et al., 2017). Small-scale studies on oral HPV have found much higher HR-HPV co-
infection prevalence rates of 28.1% (Vergori et al., 2018) and 47.3% (Fakhry et al., 2010), but 
these studies, once again, sampled HIV positive populations. Research has shown HPV co-
infections with other viruses, such as HIV, increase infectivity and transmissibility of both 
viruses (Martín-Hernán et al., 2013); this could explain the significantly high co-infection 
prevalence rates with most HPV/HIV screening studies. To develop this study in the future, 
additional screening could be performed for another oncogenic or lysogenic virus to determine 
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the effect of multiple viruses on prevalence and abundance. This research has been conducted 
in pre-malignant oral lesions and malignant lesions, especially for HPV and Human 
Polyomaviruses (HPyV) (Herberhold et al., 2017), but has yet to be investigated in clinically 
healthy individuals. 
 
8.2.3 Oral HPV Type Abundance 
Despite frequent detection of HR-HPV co-infections in oral samples, little research has yet to 
be conducted investigating HR-HPV abundance via viral load and the effect on oral persistence. 
One of the few studies, alongside this one, to determine oral HPV-16 prevalence and abundance 
in healthy individuals found a comparably high HPV-16 viral load of 1.60x105 copies/million 
cells (Shigeishi et al., 2016). This is important as higher HR-HPV viral loads have recently 
been determined to be strong predictors of oral HPV persistence (D’Souza et al., 2020), and 
therefore OPSCC progression (Aldalwg & Brestovac, 2017). Until now, HR-HPV 
quantification of viral load has only occurred in pre-malignant oral lesions and malignant 
lesions to determine effect on disease progression and grade (Herberhold et al., 2017; Khanal 
et al., 2018). Apart from the study by D’Souza et al., (2020), there is a current lack of 
longitudinal investigations into oral HPV persistence, clearance, and role in malignant 
transformation, especially within clinically healthy populations. Using this information, healthy 
individuals exhibiting high HR-HPV viral loads within oral infections could be monitored for 
lesion development and treated before malignant transformation occurs. 
This is even more pertinent as males in this study were found to exhibit a higher overall HPV 
and HPV-16 viral loads than females by 8.45x104 copies/million cells and 9.47x104 
copies/million cells, respectively. This could provide evidence for why males have been 
exhibiting higher rates of HPV positive HNSCCs than females for the past ~15-20 years – 
higher viral loads combined with higher persistence rates and lower clearance rates (Fakhry et 
al., 2018; D’Souza et al., 2020). Research has also found that White males are, for the first 
time, exhibiting higher rates of HNSCC/OPSCCs than Black populations, indicating the 
potential influence of ethnicity amongst other risk factors, on HPV positive OPSCCs 
development (Peterson et al., 2017; Fakhry et al., 2018; Mainous et al., 2020). This 
demonstrates the importance of demographic and risk factor exploration alongside oral HPV 
prevalence and abundance rates. 
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8.2.4 Oral HPV & Smoking 
Cigarette smoking has frequently been shown to be a main risk factors for HNSCC development 
(Dalla Torre et al., 2015), especially within adult males (Mainous et al., 2020), and has 
therefore also been frequently associated with oral HPV prevalence and other risk factors 
(Rosen et al., 2016; Shigeishi & Sugiyama, 2016; Steinau et al., 2017). Previous studies 
investigating oral HPV prevalence and smoker status have found an increased prevalence rate 
in cigarette smokers (Knight et al., 2016; Shigeishi & Sugiyama, 2016; Steinau et al., 2017), 
some with prevalence rates as high as 11.5% (Sonawane et al., 2017). This study, alternatively, 
found no significant differences between smokers and non-smokers for oral HPV prevalence 
but the analysis was limited by smoker numbers as there has been a significant reduction in 
young adult smokers in the past ~10 years (ASH, 2016; Jung et al., 2017). Other studies have 
also investigated smoking amount via cigarettes per day and found heavy smoking to be 
associated with oral HPV prevalence in healthy individuals (Gillison et al., 2012a; Farsi et al., 
2017). One study oral HPV infection was highest amongst those who smoked more than 20 
cigarettes daily (Sonawane et al., 2017).  This study also found a slight correlation between 
increased number of cigarettes per day and oral HPV prevalence, including HPV-16 prevalence, 
further demonstrating a relationship between oral HPV and increased smoking amount. A study 
by Fakhry, Gillison & D’Souza (2014) investigated HR-HPV prevalence and smoking amount 
and found HPV-16 linked to smoking a higher number of cigarettes per day than other HR-
HPV types. It has been previously suggested that heavy smokers are more likely to engage in 
other riskier activities that may result in the contraction of HR-HPV, this however was in 
relation to genital HPV, so more research is required for oral infections (Tanton et al., 2015). 
Despite frequent investigations into smoking and oral HPV prevalence, many studies have 
overlooked other smoking characteristics that may correlate and/or influence oral HPV status 
and worsen OPSCC progression, such as smoking frequency. Many studies assume that heavy 
smokers are always daily smokers (Nguyen & Zhu, 2009), but recent investigations into social 
smoking have found those that claim to only smoke whilst drinking and/or in social situations 
still smoke ~5 cigarettes per sitting (Nichter et al., 2010), with 70% of young adults engaging 
in social smoking (Waters et al., 2006). As such, this study investigated other smoking 
characteristics alongside status and amount, including smoking frequency, and it was found that 
frequent smoking in females correlated with oral HPV prevalence, and HPV-16 prevalence in 
both genders overall. Research has shown that females are more likely to feel pressured to 
 
Page | 179  
 
smoke due to body image (Saules et al., 2007), but more research is needed to explore the link 
between smoking in females and increased oral HPV prevalence. 
Furthermore, this study also found a significant correlation between pack years and oral HPV 
prevalence, especially within females, suggesting a correlation between oral HPV status and 
long-term smoking. There is a lack of literature investigating pack years and oral HPV 
prevalence in healthy individuals, but a few studies have shown links with long-term smoking 
without using a clinical indicator (Sanders, Slade & Patton, 2012; Colon-López et al., 2014). 
Many studies have, however, shown long-term (heavy) smoking as a cause of HNSCCs, 
independent of oral HPV status (Mirghani et al., 2018). A combination of oral HPV and long-
term smoking could accelerate malignant transformation, so it is important to establish rates of 
both in healthy individuals before lesions develop, especially for OPSCCs as these are linked 
more frequently to oral HPV than HNSCCs. Other studies have also suggested that long-term 
frequent damage to the oral mucosa and immune response inhibition via carbon monoxide in 
cigarette smoking increases the likelihood of HPV infecting epithelium (Kumar et al., 2015; 
Shigeishi & Sugiyama, 2016), especially within the tonsils (Hong et al., 2013). Research has 
theorised HPV to infect tonsils at the basal membrane due to the squamo-columnar (SC) 
junctions in the epithelium of tonsil crypts (Morbini et al., 2015); this combined with cellular 
damage from smoking could increase risk of establishment of infection. 
Other tobacco-based substances have also been linked to HNSCC development, such as cigar 
smoking and betel nut chewing (Wang et al., 2019), but little research has cross-examined oral 
HPV prevalence and related the data to OPSCCs also. This study found HPV positive 
individuals smoked more tobacco-based substances than their HPV negative counterparts, 
especially for cigars. This is important as cigar, shisha/water pipe and tobacco pipe smoking 
expose individuals to the equivalent of ~2.5-10 cigarettes per sitting (Masters & Tutt, 2010; 
Jawad, Khaki & Hamilton, 2012; Masters, Tutt & Yaseen, 2012; NHS Scotland, 2014), 
increasing the likelihood of oral mucosa damage (NHS Scotland, 2014), therefore oral HPV 
infection establishment (Frazer, 2004). Shisha/water pipe smoking has also increased in 
popularity in UK-based young adults in recent years due to the social aspect and lack of 
awareness that shisha/water pipes contain tobacco (Mugyenyi, Haberer & O’Neil, 2018). 
Studies have hypothesised that social shisha/water pipe smoking could increase oral HPV 
transmission due to the sharing of the pipe mouthpiece (Cook et al., 2014; Wollina, 2015), 
whilst other studies have found links between shisha/water pipe smokers and engagement of 
other riskier activities that may further result in the contraction of HPV (Mugyenyi, Haberer & 
 
Page | 180  
 
O’Neil, 2018). This is even more pertinent as this study revealed a slight increase in HR-HPV 
type HPV-16 in smokers of other tobacco-based substances too, and as previously described, 
tobacco and HR-HPV have been strongly linked to OPSCC development (Babiker et al., 2013). 
In addition to tobacco-based smoking, cannabis smoking has frequently been linked to oral 
HPV prevalence (Shewale et al., 2019). One study found an oral HPV prevalence rate as high 
as 81.9% in clinically healthy drug users, including cannabis (Ribeiro et al., 2019). Studies have 
suggested, like shisha/water pipe smoking, sharing cannabis cigarettes in social situations may 
increase oral HPV transmission (Cook et al., 2014). Despite this, this study found no association 
between cannabis smoking and oral HPV prevalence and HPV-16 prevalence, but this could be 
explained by the infrequent engagement exhibited by the cohort. Research has revealed oral 
HPV prevalence rates to be higher in daily cannabis smokers (Zwenger et al., 2009; Shewale et 
al., 2019) but little research has been conducted linking oral HPV to cannabis overall. 
 
8.2.5 Oral HPV & Alcohol Consumption 
Similar to smoking, alcohol consumption has also frequently been shown to be a main risk 
factor for HNSCC development (Kawakita & Matsuo, 2017; Bumrungthai et al., 2019), 
particularly within adult males (León et al., 2009). Unlike smoking, oral HPV prevalence has 
been frequently associated with alcohol consumption in those that engage in unsafe and/or 
dangerous level of drinking (Ortiz et al., 2014), and therefore, previous studies investigating 
oral HPV prevalence and alcohol consumption have found varying rates in current drinkers 
(Rosen et al., 2016). This study found a slight increase of ~5% oral HPV prevalence from never 
drinkers to former drinkers to current drinkers, which was even larger for HPV-16. These 
findings were concordant with the NHANES study conducted in the United States (Sonawane 
et al., 2017), further indicating that drinking alcohol has some correlation with oral HPV. In 
contrast, other studies have found alcohol drinking only to be associated with oral HPV in the 
presence of other factors such as smoking (Ortiz et al., 2014), and young age (Golusinski, 
2017).  
This study was also one of the first to investigate alcohol consumption and oral HPV viral load 
in healthy young adults. Current drinkers exhibited higher viral loads than former or never 
drinkers for both overall HPV and HR-HPV type HPV-16. Further investigation is required to 
determine what effect this may have on oral HPV persistence and HNSCC development within 
drinkers, but one study investigating the progression of cervical carcinogenesis suggested that 
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high HR-HPV viral load and alcohol drinking may exacerbate progression in combination with 
HR-HPV persistence (Oh et al., 2014).  
Of those that drank alcohol in this study, frequent drinkers were also associated with HPV and 
HR-HPV prevalence, especially those that drank 1-2 times/week. Frequent drinking has been 
linked to oral HPV prevalence previously (Golusinski, 2017), but more frequently within 
individuals with pre-malignant or malignant oral lesions than healthy individuals to determine 
disease progression (Kariche et al., 2018). Those studies that have linked oral HPV prevalence 
in healthy young adult populations to frequent drinking have, instead, been investigating the 
effect of risk-taking behaviours whilst under the influence of alcohol (D'Souza & Dempsey, 
2011). Research has shown that frequent (heavy) drinkers are more likely to take sexual risks 
(such as omitting barrier contraception) whilst under the influence of large quantities of alcohol 
(Vagenas et al., 2013), which can lead to oral HPV transmission (D'Souza & Dempsey, 2011). 
In support, this study also found HPV positive individuals drank more alcoholic units per week 
and exhibited a higher level of binge drinking than HPV negative individuals, despite being 
statistically non-significant, but due to limited participant numbers, this could not cross-
compared with sexual practice.  
Binge drinking, similar to drinking frequency, has also been linked to higher oral and genital 
HPV prevalence rates due to risk-taking behaviour (Tanton et al., 2015; Marek et al., 2016; 
Mainous et al., 2020). Examples recently theorised to be associated with oral HPV include 
sexual risks (D'Souza & Dempsey, 2011), poor hygiene and hand washing practices when using 
public toilets (Abulizi et al., 2017; Wong et al., 2020), and drug use (Ortiz et al., 2014; Ribeiro 
et al., 2019). Research has also shown that individuals often do not know how many units they 
consume per sitting (Buykx et al., 2018), which is exacerbated whilst already under the 
influence of alcohol, leading to further dangerous levels of drinking (Hingson & Zha, 2009). 
Alongside the associations of risk-taking behaviour and oral HPV prevalence, binge drinking 
has also been shown to damage the oral mucosa (Reidy, McHugh & Stassen, 2011). Alcoholic 
drinks with high alcohol and acid content have been shown to further damage the oral mucosa 
more so than weaker beverages (Ogden & Wight, 1998; Bujanda, 2000; Rocha et al., 2014), 
therefore this study was also one of the first to describe alcohol type association with oral HPV 
prevalence. Interestingly, the only type of alcohol that was found to have an association with 
oral HPV was wine within both males and females, whilst HPV-16 status was most associated 
with beer/ale drinking. When comparing HPV-16 positive individuals to those positive for other 
HPV types, cider and neat spirits were also associated with HPV-16, whilst beer/ale was 
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associated with the latter. All alcohol types bar neat spirits found to be linked with either overall 
HPV, HPV-16 or other HPV types (HPV-6, HPV-11 and HPV-18) were acidic, suggesting these 
drinkers may be at higher risk of oral mucosa damage (Ogden & Wight, 1998; Bujanda, 2000; 
Rocha et al., 2014), and therefore oral HPV infection establishment (D’Souza et al., 2020) but 
longitudinal studies are required to investigate this further. 
Furthermore, this study also found a significant association between those that preferred to 
drink ≥2 types of alcohol and oral HPV, especially within males. This is one of the first studies 
to also provide this tentative link between oral HPV, drinking multiple alcohol types and 
gender. Males are often associated with frequent, heavy, and divergent drinking more than 
females (NHS Digital, 2017; Office for National Statistics, 2017), but there are limited studies 
incorporating each of these aspects with oral HPV prevalence. This study also found an 
association, if somewhat weaker, between HPV-16 status and drinking ≥2 types of alcohol as 
well as higher HPV viral load in drinkers of ≥2 types of alcohol than those that did not, 
providing another tentative link between oral HR-HPV, viral load and drinking multiple alcohol 
types.  
Finally, this study also found a strong association of HPV and HPV-16 negative individuals 
with no-risk within NHS/NICE health risk status levels, especially for females. This indicated 
that HPV positive individuals were more often associated with higher risk levels (lower, 
increasing and higher), indicating that they exhibited unsafe and/or dangerous levels of drinking 
which will make them more likely to have health complications in the future, including 
HNSCCs (NICE, 2010; Department of Health and Social Care, 2016; NHS Digital, 2016b). 
This in combination with an oral HPV infection, especially an HR-HPV infection, could 
exacerbate malignant transformation. 
 
8.2.6 Oral HPV & Sexual Practice 
Sexual practice and behaviours have been directly linked to genital HPV prevalence for the past 
~30 years (Mercer et al., 2013; Tanton et al., 2015; Tanton et al., 2017). In comparison, oral 
HPV has only recently been linked to sexual practice following the detection of HPV in 
HNSCCs and the strong link to OPSCCs as well as genital cancers. However, emerging research 
has revealed that different types of sexual practices are linked to oral HPV than those associated 
with genital HPV (D’Souza et al., 2014), despite some concordance of HPV type (Pérez-
Quintanilla et al., 2020). There is also much debate and varying oral prevalence rates found 
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depending on gender, geography, sexual orientation, other associated risk factors, and screening 
methods, so it is important to consider all variables.  
This study found open-mouth kissing to be significantly associated with oral HPV prevalence 
within both genders but found no relationship with HPV viral load. Recent studies have also 
linked oral HPV to open-mouth kissing as a transmission route due to the ability of saliva to 
carry HPV particles (Pickard et al., 2012), but viral load has not been investigated. More 
research is also required to establish the effect of kissing multiple partners and duration of 
activity on prevalence rates (Cook et al., 2014), similar to research on sexual intercourse and 
genital HPV. When comparing sexual intercourse with oral HPV status, this study found a 
significant association, especially in males, but again, no relationship with HPV viral load. This 
suggests that sexual activity could be a predictor of oral prevalence due to transmission but has 
no effect on severity of infection. Recent studies have also reported an association of oral HPV 
incidence in sexually active individuals but no difference between the genders (D’Souza et al., 
2014). The higher prevalence of oral HPV in sexually active males in this study could be 
attributed to types of sexual activity performed as males have been shown to engage in sexual 
activity more frequently than females and take more sexual risks (Seth et al., 2012). 
When investigating individual types of sexual activity, this study found oral HPV prevalence 
to be significantly associated with oral sex. Viral load was also higher by 4.32x104 
copies/million cells in those that engaged in oral sex, but this was not statistically significant. 
There has been much discussion around the effect of oral sex on HPV transmission with some 
studies reporting concordant results (Giuliano et al., 2015; Hearnden et al., 2018), whilst others 
have not (Lupato et al., 2017). Some investigations have linked cunnilingus to oral prevalence, 
and subsequently reported higher oral HPV rates in males (Sánchez-Vargas et al., 2010; 
D'Souza et al., 2016), and lesbian couples (Bartzatt, 2014), whilst others have only linked 
fellatio to oral HPV status (Sánchez-Vargas et al., 2010), resulting in higher oral HPV rates in 
females and men who have sex with men (MSM) (Oliver et al., 2018). This study also found 
HR-HPV type HPV-16 was more prevalent in those that engaged in oral sex, but this was not 
statistically significant. This demonstrated high potential for transmission of HR-HPV types 
between genital and oral regions, which has only been investigated to a limited extent (Giuliano 
et al., 2015; Nguyen et al., 2016). This, coupled with 27.4% of the cohort engaging in oral-anal 
activity and 65.9% regularly engaging in four or more sexual activities, could lead to the 
transmission of HR-HPV to multiple anatomical sites (Giuliano et al., 2015).  
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Furthermore, this study also found an association between masturbation and oral HPV, which 
was statistically higher in males than females. Viral load was also higher by 4.46x104 
copies/million cells in those that engaged in masturbation, demonstrating a positive correlation 
for prevalence and abundance. Previous links between masturbation and oral HPV have 
tentatively been made in other studies in relation to increased sexual activity (Giuliano et al., 
2015), but more research is required to determine why masturbation, in particular, correlated 
with higher oral HPV rates. One study by Cook et al., (2014) suggested a lack of handwashing 
and/or good hygiene practices following ejaculation could cause transmission of genital HPV 
to oral regions, whilst another study has highlighted that sexual partners may mutually 
masturbate during sexual activity followed by foreplay, oral sex and/or sexual intercourse 
(Mills, Vanderpool & Crosby, 2011), which could therefore increase the chance of HPV 
transmission (Giuliano et al., 2015). This study also found HPV-16 prevalence and viral load 
was higher in those that masturbated than those that did not, but alternatively, in females. 
However, this can be explained by more females being HPV-16 positive in the cohort and HR-
HPV types frequently being shown to be more prevalent in female genital regions than male 
genital regions (Edelstein et al., 2012). 
Furthermore, this study also found a significant correlation between sexual diversity, in terms 
of number of different sexual activities performed, and oral HPV prevalence with 30.6% of 
positive individuals engaging in all five different sexual activities (vaginal sex, oral sex, anal 
sex, foreplay and masturbation). Several studies, conducted on adolescent or young adult 
populations, concurred with this data (Giuliano et al., 2015), whilst others, conducted in the 
general population, found a lesser correlation with oral HPV than with genital HPV (Edelstein 
et al., 2012). There was also a slight correlation between HPV-16 prevalence and increased 
sexual diversity found in this study, with 23.6% of positive individuals engaging in all five 
different sexual activities, indicating an increased risk of HR-HPV transmission with activity 
too. 
Sexual activities shown to be highly associated with genital HPV, such as increased number of 
sexual partners, one-night stand (ONS) frequency, and condom usage (Tanton et al., 2015; 
Tanton et al., 2017), were also measured in this study but none were found to have a significant 
association with oral HPV prevalence. In contrast, some studies have reported a higher oral 
HPV prevalence in those that abstain from using condoms or other forms of barrier 
contraception (Brown et al., 2011), whilst others have found an association in those with 
increased numbers of sexual partners (Chaturvedi et al., 2015). However, to date, no association 
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has been found with ONS frequency and oral HPV (Knight et al., 2016), indicating ONS 
frequency has little effect on overall HPV and HR-HPV status but more research is required. 
Unfortunately, viral load and subtype prevalence could not be compared for these variables due 
to limited participant numbers, but previous research has described a correlation between co-
infection prevalence and multiple sexual partners (Vogt et al., 2013). The oral HPV field have 
yet to investigate the effect if this on oral persistence, but as previously discussed, multiple viral 
infections increase infectivity and transmissibility overall (Martín-Hernán et al., 2013). 
 
8.2.7 Oral HPV & Vaccination Status 
Research has started to be published comparing oral HPV prevalence within vaccinated and 
non-vaccinated individuals to determine the effectiveness of the vaccination programme on oral 
infections (D’Souza et al., 2014; Malerova et al., 2020). Previously designed and licensed to 
protect against genital HR-HPV types, the UK HPV vaccination programme was launched in 
2008; ~12 years ago (Jo’s Cervical Cancer Trust, 2020), but HPV field has not been able to 
assess the efficacy until now. Over ~10-12 years later, the HPV vaccination has been shown to 
significantly reduce cervical cancer incidence (Brisson et al., 2020). The effect on HNSCC 
incidence, however, is not possible to measure as HPV was only recently linked to HNSCC 
development, and such cancers tend to present later in an individual’s lifetime than cervical 
cancer (Marur et al., 2010; D'Souza & Dempsey, 2011; Peterson et al., 2017). The only measure 
of vaccination effectiveness, is therefore, oral HPV prevalence rates but as highlighted 
previously, there is little research pre-2010 to make comparisons with. Instead, a few studies 
have started to compare oral HPV prevalence rates within cohorts, between vaccinated and non-
vaccinated individuals (D’Souza et al., 2014; Chaturvedi et al., 2019; Malerova et al., 2020), 
alike this study. This is one of the first UK-based studies to investigate the effect of the HPV 
vaccination on oral HPV prevalence, and one of the first globally to investigate the effect of the 
HPV vaccination on oral HPV abundance of the four HPV types targeted for by the quadrivalent 
vaccination (Gardasil-4) via viral load. 
This study found a higher overall oral HPV prevalence rate in non-vaccinated individuals 
compared to vaccinated as prevalence was only 3.52% higher in non-vaccinated females than 
those that had been vaccinated. Alternatively, the male cohort exhibited a larger difference due 
to none of the HPV positive males being vaccinated, as the HPV vaccination was only licensed 
for males in the UK in September 2019 (Jo’s Cervical Cancer Trust, 2020). In contrast, several 
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studies have reported much larger differences in oral prevalence between vaccinated females 
and non-vaccinated females of a similar age-range (Chaturvedi et al., 2019; Sastre-Cantón et 
al., 2019). Controversially, some studies have also reported little difference in prevalence rates 
between vaccinated and non-vaccinated individuals (Mehanna et al., 2019), supporting the 
findings of this study and further highlighting the inconsistencies in prevalence across the HPV 
field based on geography, cohort and study design. One study asked participants if they 
completed the course of vaccination doses to determine level of protection (Brotherton et al., 
2015). This study did not explore this avenue or ask what type of vaccination the participants 
received; bivalent (Cervarix) or quadrivalent (Gardasil-4). This would be beneficial to include 
in future research to determine coverage and assess reliability of oral prevalence rates. 
Furthermore, oral HPV-16 prevalence was equal between non-vaccinated females and 
vaccinated females (~18.0%), whilst the male cohort exhibited a larger prevalence (20.5%), 
again, due to none of the HPV positive males being vaccinated. As both Cervarix and Gardasil-
4 are designed to protect individuals from HPV-16, this finding was surprising but could be 
explained by several factors. Participants may not have completed the full course of injections 
so did not have full coverage (Brotherton et al., 2015), whilst some participants’ parents may 
have opted out due to religious reasons or concern over safety of the vaccination (Vamos et al., 
2008). A large proportion of the participants were also aged between 18-25 years old – females 
that were aged between 21-25 years old during sample collection in 2016 would have been part 
of the catch-up vaccination programme (Jo’s Cervical Cancer Trust, 2020), which means they 
may not have received the vaccination, or full coverage. Participants, especially 21-25-year-
olds, could have been exposed to HPV, genital and/or oral, before vaccination due to sexual 
activity before the UK legal age of 16 years old (Szarewski et al., 2012). One study has also 
found an oral HPV prevalence rate as high as 48.1% in children, even before puberty (Kojima 
et al., 2003), whilst another found 11.3% of children aged 3-11 years old harbour a 
transcriptionally active HPV-16 oral infection before puberty (Rice et al., 2000). To help 
explain, this study also explored HPV viral load and vaccination status as higher viral loads 
have been associated with long-term infections and oral persistence (D’Souza et al., 2020). 
This study found that HPV viral load in non-vaccinated individuals was 8.39x104 copies/million 
cells higher than vaccinated individuals, whilst HPV-16 viral load in non-vaccinated 
individuals was 1.00x105 copies/million cells higher. This is one of the first insights into the 
effect of vaccination on oral HPV abundance, tentatively suggesting that HPV vaccination 
could reduce viral load more than incidence, especially as participants may have already been 
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exposed to HPV pre-vaccination. Previous research on HIV and influenza has also linked 
vaccination to a reduction in viral load but this has not been shown in HPV to date (Belyakov 
et al., 2001; Rosendahl Huber et al., 2015). Non-vaccinated participants also exhibited higher 
prevalence rates of all HPV types other than HPV-16, and by association, co-infections of HPV-
16 and HPV-18. HPV-6, HPV-11 and HPV-18, all covered by the quadrivalent vaccination, 
ranged from being ~1-4% higher in prevalence in non-vaccinated individuals than vaccinated, 
which despite being small, could indicate a possible reduction in oral HPV within the cohort 
due to vaccination. Studies have reported a larger decrease in LR-HPV types in the oral cavity 
of females than HR-HPV types, thought to be linked with the vaccination (Chaturvedi et al., 
2019). In support, this study only detected HPV-6 and HPV-11 in unvaccinated male 
participants. 
 
8.3 Limitations & Future Developments 
This study is not without limitations, however. Using the literature exploration of the method 
development and screening results, the following section discusses the study limitations and 
developments to be considered if further research was to be conducted in this area in the near 
future. 
 
8.3.1 Study Design 
This study has provided the basis for undertaking a longitudinal screening study, in which those 
that test positive for oral HPV could be tracked and monitored over the course of 3-5 years. 
This would help to determine oral HPV clearance rates and track severity of infection, via viral 
load measurements, through interval screening (D’Souza et al., 2020). Most longitudinal HPV 
studies have focused on genital HPV persistence, clearance and malignant transformation, 
rather than oral HPV due to monitoring the success of the cervical screening programme. As 
oral HPV persistence has been linked to the development of OPSCCs, this research, if 
developed into a longitudinal study, could lead to the establishment of an oral screening 
programme for oral cancer/OPSCCs. 
Furthermore, as with most studies, the recruitment of a larger number of participants would be 
beneficial to provide a more representative sample of the wider population being sampled. This 
would also make the collated data more comparative with national databases (Natsal-3 and 
 
Page | 188  
 
Office of National Statistics) and make the statistical analysis of questionnaire data against the 
HPV positive cohort more robust and reliable due to larger sample numbers. Viral load could 
not be calculated for most of the smoking characteristics data as the number of participants in 
the smoker cohort corresponding to HPV positivity was low. 
 
8.3.2 Questionnaire Design 
The designed questionnaire(s) used in this study was informed by HPV-related lifestyle 
research previously conducted by Natsal-3 (Mercer et al., 2013; Khadr et al., 2016; Woodhall 
et al., 2016; Tanton et al., 2017), reinforcing the reliability and suitability of data to contribute 
to the current literature on HPV and related lifestyle choices. Adaptations were, however, 
required to tailor the questionnaire to collecting data on choices and behaviour linked to oral 
HPV instead of genital HPV. As there was a lack of wide-scale national studies, alike Natsal-
3, on lifestyle choices related to oral HPV at the time of design, questions were constructed 
using smaller scale studies and previously conducted work at the researcher’s institute (Knight 
et al., 2016). Since design, increasing numbers of oral HPV research articles have been 
published, linking transmission and prevalence to alternative risk factors for HNSCCs that were 
not previously considered. The questionnaire was also updated the between collection phases 
(P1 and P2) which was necessary for aligning to emerging literature and due to a change in 
project direction. However, this resulted in a large amount of data which required combining 
and cleansing, which also led to some data being omitted from the analysis altogether. Using 
this information and the study results, the following section discusses the recommended 
improvements that could be made to the questionnaire design, should the study be built upon 
in the future.  
Firstly, for smoking characteristics, the questionnaire could also be developed to ask if there 
were any differences in the number of cigarettes smoked during the week and at weekends. The 
Office for National Statistics has shown that numbers vary per day of week, with smoking levels 
at the heaviest on weekends (Office for National Statistics, 2017). If this information were to 
be investigated by the questionnaire, more accurate calculations would be needed when 
averaging cigarette numbers per day using the data provided by the participants. Furthermore, 
there were also limitations in terms of calculations to the data collected on other tobacco-based 
substance smoking. The equivalency estimates used for calculating number of cigarettes 
smoked per shisha/water-pipe smoking session were weak (Jawad, Khaki & Hamilton, 2012; 
 
Page | 189  
 
Masters, Tutt & Yaseen, 2012). This was because there are many variables to consider when 
measuring smoke exposure during shisha/water-pipe smoking such as magnitude of exposure, 
number of puffs taken, length/depth of each puff, sharing of the shisha pipe (and number of 
individuals it is shared between), and duration of smoking session (Jawad, Khaki & Hamilton, 
2012; Masters, Tutt & Yaseen, 2012). For the purpose of this study, it was not necessary to 
measure all variables but data on duration of smoking session would improve the accuracy of 
equivalency calculations, whilst data on group participant/sharing of the pipe mouthpiece 
would also allow for an additional risk factor for oral HPV transmission to be compared with 
prevalence (Cook et al., 2014). 
Despite the low prevalence of vaping/e-cigarette usage found within this study, it has been 
recognised that “safe” smoking alternatives have significantly increased in popularity in the UK 
since data collection (Cummings, Morris & Benowitz, 2018). Therefore, if this study was 
developed and aimed to collect similar data on vaping/e-cigarette usage, an original 
quantification strategy for duration of use per day and chemical exposure would be required as 
currently there is no “gold-standard” method of quantifying vaping/e-cigarette usage (Cooper, 
Harrell & Perry, 2016). This would allow for direct comparisons to be made to cigarette use, 
frequency and amount, which in turn, would allow for direct comparisons of oral HPV positive 
smokers and oral HPV positive vapers. The questionnaire could also be improved to ask 
participants if they smoked cigarettes previous to vaping/e-cigarette usage to determine 
smoking history alongside asking if they share equipment as, alike shisha/water-pipe smoking, 
oral HPV transmission has also been linked to sharing e-cigarettes (Cook et al., 2014).  
Further improvements could be made to the questionnaire regarding collecting data on cannabis 
smoking to allow for direct comparisons of smoking quantity. As there are large variations in 
cannabis cigarette size, type and composition (Macleod et al., 2015), weight (grams) of 
cannabis per day or per cannabis cigarette have been suggested to be good measures of 
quantification and exposure to tetrahydrocannabinol (THC), for use in clinical studies (Mariani 
et al., 2011). This study did not ask the participants to specify the weight of cannabis used, only 
number of cigarettes smoked so it was at the participants’ discretion to volunteer this 
information. Implementing additional questions clarifying weight of cannabis used per day 
would allow for more accurate calculations of quantity for direct comparison to tobacco 
cigarette smoking, THC exposure, and weight estimations of loose tobacco smoked per 
cannabis cigarette, as they almost always contain tobacco for reducing the psychoactive effects 
of THC (Macleod et al., 2015). Additionally, alike shisha/water-pipe smoking, research has 
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shown that cannabis smokers tend to smoke socially and share cigarettes, indicating additional 
risk of oral HPV transmission (Cook et al., 2014). To measure this and compare this with oral 
HPV prevalence, participants could be asked if they regularly share cannabis cigarettes. 
The questionnaire also could have been developed for collecting data on alcohol consumption 
characteristics. For alcohol consumption status, former drinkers were categorised based on 
participants disregarding the “current drinking” section and filling out the “previous drinking” 
section of the questionnaire. The questionnaire, however, did not specify that former drinkers 
should have abstained from drinking for 12 months before claiming teetotal status (NHS 
Digital, 2016b). This allowed for participants to self-identify alcohol consumption status, 
without clinical measure, irrespective of time spent abstaining from alcohol consumption. To 
improve the reliability and accuracy of the questionnaire data, this could be addressed in future 
surveying. The P2 questionnaire did also include a new question asking current drinkers if they 
partook in previous heavy drinking to address changes in behaviour throughout university 
enrolment but, as previously explained in Chapter 5, the data was omitted. To improve the 
collection of similar data in future research, the questionnaire should provide clear guidelines 
on the length of time “previous” drinking is defined by. 
Within clinical settings, Alcohol Use Disorders Identification Test (AUDIT), developed by 
World Health Organisation (WHO) and Public Health England (PHE), is currently used to 
determine alcohol use and dependence based on a scoring system (Public Health England, 
2017). This study, however, aimed to determine alcohol consumption prevalence and behaviour 
in relation to health risks and conditions associated, rather than alcohol dependence. As a result, 
the scoring system was initially deemed unsuitable, resulting in the use of the NHS/NICE health 
risk status classification system (NICE, 2010; NHS Digital, 2016b). Due to the emerging 
research linking risk-taking behaviour whilst under the influence of alcohol to oral HPV 
prevalence (D'Souza & Dempsey, 2011), future questionnaire developments could also include 
some questions from AUDIT to address behaviour associated with risk-taking from heavy 
drinking alongside oral HPV prevalence. 
The next prominent lifestyle theme within the questionnaire was sexual practice. To account 
for the increased trend of young adults identifying as “virgins” but still being sexually active 
by engaging with oral sex and foreplay (Markham et al., 2009), the questionnaire could include 
a statement explaining the definition of sexually active. The study questionnaire asked that 
participants only fill out the sexual practice questions if they had engaged in sexual intercourse. 
Unfortunately, recent research has shown that this may have excluded many participants that 
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engage in sexual activities other than penetrative sex (Markham et al., 2009). As the study was 
investigating the rates of oral HPV in relation to sexual practice, it would have been beneficial 
to know if participants were still engaging in sexual activities like oral sex, regardless if they 
have experienced penetrative sex. If this was the case for the participants in this study, there 
may have been more responses, so it is important to understand how the participants perceive 
the language used within the questionnaire as well as the questions themselves. Recent research 
conducted in UK schools with participants aged 12–13 years old has also shown that young 
people believe oral sex is risk-free in relation pregnancy and STI transmission so oral sex rates 
are steadily increasing (Knight & Roberts, 2020). This is important as oral sex and foreplay 
have been shown to transmit HPV (Leichliter et al., 2007; Oliver et al., 2018; Pérez-Quintanilla 
et al., 2020), supported by the findings in this study. As such, the questionnaire could also be 
developed to obtain data on knowledge and opinions on sexual practice and oral HPV, to 
determine the effect of knowledge linked to behaviour on prevalence. 
Furthermore, the questionnaire could also ask about other forms of sexual activity. Current 
research has linked the sharing of sex toys to HPV transmission between the sexual partners 
(Wood et al., 2017a), with the likelihood of transmission increasing if the toys have not 
sterilised between each use (Anderson et al., 2014).  Due to this, some studies have proposed 
that the higher rates of oral HPV found in lesbian couples are due to a combination of 
cunnilingus and sex toy usage (Cook et al., 2014), but other factors should be considered first 
as sex toys are designed for penetrative sex. Literature has suggested that those using sex toys 
are more “adventurous” sexually so are therefore more likely to engage in activities directly 
linked to oral HPV transmission (Grandahl et al., 2017). As such, further questions on sexual 
activity, such as sex toy usage – separate to masturbation – could be implemented for additional 
oral HPV prevalence exploration. 
Finally, the study questionnaire could be developed to gather more information about HPV 
vaccination to help draw definitive conclusions about the effect of HPV vaccination on oral 
prevalence and abundance within the cohort. In addition to vaccination status, it would be 
beneficial to ask the participant about what type of vaccination they received (Cervarix, 
Gardasil-4, Gardasil-9) and/or if they were part of the catch-up programme. Collection of this 
data would allow for investigations into vaccination efficacy in comparison to the HPV sub-
types each vaccine targets. Alternatively, the questionnaire could instead ask participants to 
specify their date of birth rather than select an age range. This would allow for calculation of 
their exact age so type of vaccination could be estimated, in the likely event the participant did 
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not know what type of vaccination they received. Furthermore, to determine if participants were 
fully vaccinated, the questionnaire could also ask the participant if they finished the full course 
of injections or how many doses they received. Only receiving one dose has been shown to be 
less effective in protecting individuals from genital HPV infections (Jo’s Cervical Cancer Trust, 
2020); oral regions could be similar but there has been limited research into vaccination efficacy 
for oral HPV to date. 
 
8.3.3 Screening Methods 
To develop the laboratory methods, future research could increase the number of individual 
HPV type-specific screening assays used for the detection and quantification of all HPV types 
covered by the nine-valent (Gardasil-9) vaccination. This would help to determine the presence 
and abundance of other HR-HPV types that current vaccinated individuals would not be 
protected against due to the quadrivalent-nature of Gardasil-4.  
Furthermore, oral samples could also be subjected to RNA extraction as well as DNA 
extraction. The detection of HPV DNA indicates the presence of HPV in the oral samples whilst 
RNA detection would allow for determining if the participants that tested positive for HPV also 
had a transcriptionally active HPV infection (Andersson et al., 2006). This would allow for 
determination of genome integration and provide an indication of HPV lifecycle stage, and 
therefore, severity of infection. Alongside absolute quantification real-time PCR, relative 
quantification could be also performed to examine the expression levels of the oncogenic 
proteins, E6 and E7. Relative quantification has many avenues for exploration including 
measuring the downregulation of tumour suppressor proteins in comparison to upregulation of 
oncogenic proteins or other cell cycle pathway transcription factors, to investigate if there are 
any differences between transcriptionally active HPV infections in oral regions compared to 
genital regions. Similar research within cervical cell lines has shown the importance of 
determining the presence of active infections in those diagnosed with cervical intraepithelial 
neoplasia (CIN I/II/III) precursors to determine risk of cancer progression and eventual 
treatment (Mittal et al., 2017). Such research in oral infections could lead to similar work 
allowing the monitoring and treatment of HPV-related HNSCCs. 
Oral HPV infection locality could also be investigated by comparing samples taken from 
different areas of the mouth, such as under the tongue or tonsils, and/or cross-compared with 
genital and oral rinse samples to determine prevalence of multi-site infections. As discussed in 
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the introduction, current research into HPV positive HNSCCs has revealed the oropharynx and 
tonsils to be the most common sites of HPV infection, oral persistence of HR-HPV infections, 
and subsequent malignant transformation (D’Souza et al., 2020). Therefore, future 
investigations could examine the likelihood of HNSCC development further by screening the 
oropharynx and tonsils using the methods devised in this study and comparing prevalence and 
locality. The questionnaire used could also be used in conjunction with partner and multi-site 
screening to further explore the role of sexual activity in oral HPV transmission. 
 
8.4 Implications & Knowledge Contributions 
This study has provided one of the first insights into oral HPV prevalence and abundance within 
the healthy young adult population in the UK. Current oral HPV research has largely focused 
on lifestyle risk factors linked to oral HPV or establishing oral HPV prevalence rates and 
abundance within those that have already been diagnosed with HPV positive pre-malignant 
lesion or HNSCCs, rather than those at risk of developing them (Herberhold et al., 2017; Khanal 
et al., 2018). This research is unique as not only does it explore lifestyle and behaviour linked 
with oral HPV, but also provides data on oral HPV prevalence rates and abundance within 
healthy adults, providing an idea of those at risk for developing HNSCCs before they occur. 
Not only does this inform the literature and bridge the gaps in current UK oral HPV research, 
but the findings could also have implications for developing campaigns and education to 
improve public oral HPV awareness.  
Over the past ~30 years, HPV awareness has been aligned to the awareness of the cervical 
screening programme that was introduced in 1988 (Herbert, 2000). This programme notably 
elevated public attention in 2009, and therefore awareness of HPV, due to the diagnosis and 
death of a well-known TV personality, Jade Goody (Casey et al., 2013; Brotherton et al., 2016; 
Castanon & Sasieni, 2018). Now named “The Jade Goody Effect”, there was a 2.23-fold 
increase in screening of female population in the UK post-Goody (early 2010-2011) (Casey et 
al., 2013). This has since reduced in recent years, proposed to correlate with the increased 
number of women that have received the HPV vaccination since 2008 (Castanon & Sasieni, 
2018). However, due to the consistent reinforcement of HPV causing cervical cancer, there has 
been a significant lack of acknowledgement of oral HPV and the link to other HPV-related 
cancers, such as HNSCCs, in the public domain. One study found that only 14.0% of 
adolescents were aware of the links between HPV and oral cancer (Jo’s Cervical Cancer Trust, 
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2020; Knight & Roberts, 2020), whilst another found that 23% of men were not aware that 
HNSCCs/oral cancer can be attributed to persistent oral HPV infections (Brewer et al., 2010). 
This demonstrates that not only does the current adult population need education on oral HPV, 
especially as this study found a prevalence rate of 22.8% in young adults, but education is also 
needed within UK schools as male adolescents have stated that they take more sexual risks due 
to HPV vaccination (Knight & Roberts, 2020). 
This study was also one of the first to explore oral HPV abundance via viral load quantification 
in healthy individuals. As previously described, the little research that has been conducted on 
oral HPV viral load has been limited to investigations into HPV positive HNSCCs patients, 
rather than healthy adults with no pre-existing medical conditions – HIV/AIDS. This is likely 
to be attributed to the lack of a sensitive enough screening methodology to detect and quantify 
HPV viral DNA within oral samples with low DNA concentrations (de Souza et al., 2018). 
Many studies also use premade kits for their screening methodologies, such as the Roche Linear 
Array® HPV Genotyping Test, which is considered the “gold standard” for consensus HPV 
detection (Nowak et al., 2017). This study notably not only established oral HPV abundance in 
healthy individuals which was previously unknown, but also develop a novel, accurate and 
reliable screening methodology capable of the sensitivity necessary to consensus screen for 
HPV in oral samples; a sample type widely recognised to be problematic for effective screening 
(Vesty et al., 2017). This established methodology is timely as many studies have just started 
to use consensus primers for real-time PCR screening of HPV but there is a lack of guidelines 
and consistency in the approaches. Publication of this methodology could address this, 
providing rapid and reproducible results, whilst also providing the instructions to accurately 
interpret consensus real-time PCR results as an equivalent to the MIQE guidelines of 
quantitative PCR (Bustin et al., 2009). 
This study is also one of the first in the UK to explore the effect of the HPV vaccination 
programme on oral HPV prevalence rates, abundance and type. Despite the findings not 
providing definitive evidence for a reduction of oral HPV in the healthy adult population within 
those that have been vaccinated, there were indications that this may be the case for viral load. 
This study has provided the rationale for why further investigations are required into oral HPV 
and vaccination status, which will be necessary over the next 10 years of UK oral HPV and 
genital HPV research in men, as the vaccination was only recently licensed for distribution to 
boys in school from September 2019 (Knight & Roberts, 2020). When also considering the 
prevalence of HPV positive HNSCCs in men, determining the impact of vaccination before 
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development of cancer has increased importance. Due to the large variance in HPV types being 
detected in the oral cavity, especially HR-HPV types not accounted for by the quadrivalent 
vaccination, it is possible that the participants in this study found to be positive for an unknown 
HPV types were harbouring a HR-HPV infection. Unfortunately, this could not be determined 
due to DNA concentration limitations preventing sequencing but further research, alongside 
current reports of alternative HR-HPV types to HPV-16 and HPV-18 being found in the oral 
cavity (Kiwerska et al., 2019), could provide evidence of alternative types being linked to 
HNSCCs development. This would then demonstrate that the nine-valent vaccination (Gardasil-
9) should be provided under the NHS rather than privately in the UK, where currently, each 










































This research successfully established a novel, reproducible and sensitive HPV screening assay 
for the detection of multiple HPV types in samples taken from the oral cavity of clinically 
healthy participants. Using this method, and type specific HPV assays, this study was one of 
the few UK-based studies to establish oral HPV prevalence in the young adult population, 
whilst also determining presence and viral load of HPV subtypes HPV-6, HPV-11, HPV-16 
and HPV-18, corresponding to the quadrivalent vaccination. Overall, prevalence was higher 
than previously reported rates, but this could be as a result of the screening assays used and 
participants lifestyle risk behaviours. Oral HPV was found to be significantly associated open-
mouth kissing, oral sex, masturbation in males, sexual intercourse, sexual activity diversity, 
frequent smoking, wine drinking and drinking ≥2 types of alcohol per sitting, especially in 
males. HPV-16 was also found to be most prevalent and abundant subtype in the cohort, with 
links to masturbation in males. Therefore, oral HPV prevalence did appear to be significantly 
influenced by sexual practice but less so by smoking and alcohol consumption, as traditionally 
reported in OPSCC research. This study was also one of the first to investigate the influence of 
the HPV vaccination programme on oral HPV prevalence and abundance, 10 years after 
implementation to reduce cervical cancer rates. No statistically significant differences were 
found between vaccinated and non-vaccinated individuals for HPV, individual subtype 
prevalence, or viral load despite lower copy numbers in vaccinated individuals. These results 
questioned the efficacy of the HPV vaccination on reducing oral prevalence indicating that 
further research is required, whilst also demonstrating the importance of measuring both 
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APPENDIX A: Positive Cohort Raw Data Profiles 
 
Table 28. HPV-6, HPV-11, HPV-18 & Other Type(s) Positive Cohort Profile 1. Raw cohort questionnaire data for demographics and HPV-related 
information of those that tested positive for HPV-6 (n = 2), HPV-11 (n = 1), HPV-18 (n = 7) & other types (n = 9). Yes = Y; No = N; Not Applicable = N/A.  
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Table 29. HPV-6, HPV-11, HPV-18 & Other Type(s) Positive Cohort Profile 2. Raw cohort questionnaire data for smoking characteristics of those that 
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Table 30. HPV-6, HPV-11, HPV-18 & Other Type(s) Positive Cohort Profile 3. Raw cohort questionnaire data for alcohol consumption characteristics of 
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Table 31. HPV-6, HPV-11, HPV-18 & Other Type(s) Positive Cohort Profile 4. Raw cohort questionnaire data for sexual practice characteristics of those 
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APPENDIX B: Supplementary Figures 
 
 
Figure 45. HPV-6 and HPV-11 Genome Alignment with Custom-designed Primers (Primerdesign 
Ltd). The forward and reverse HPV-6 and HPV-11 sets designed by Primerdesign Ltd  were subjected 
to BLAST [NCBI] using the complete genome sequences for HPV-6 and HPV-11 on NCBI databases 
(HPV-6 = NC_001355.1; HPV-11 = M14119.1), to determine if the primers amplified targets within the 
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Figure 46. HPV-16 E7 Primer Analysis Results. The forward and reverse HPV-16 primer set, and 
probe were analysed using Beacon Designer™ Free Edition Online qPCR Design Tool [PremierBiosoft] 
to determine if the primer exhibited any cross-dimerization, self-dimerization and hairpinning. The ΔG 
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Figure 47. HPV-18 E7 Primer Analysis Results. The forward and reverse HPV-18 primer set, and 
probe were analysed using Beacon Designer™ Free Edition Online qPCR Design Tool [PremierBiosoft] 
to determine if the primer exhibited any cross-dimerization, self-dimerization and hairpinning. The ΔG 
scores are a measure of likelihood of dimer formation; >-9 kcal/mol may cause problems in PCR 
amplification. 
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Figure 48. PCR Plate Layout Template. Example layout of each 96-well plate used in real-time PCR 
screen for consensus screening and type-specific screening. The number of controls used was dependent 
on the assay, which then affected the number of samples that could be screened. S = Standards, NTC = 
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APPENDIX C: Supplementary Tables 
 
Table 32. MY09/11 and GP5/GP6+ Alignments. Both primers sets were compared against 14 HPV subtypes, including HPV-6, HPV-11, HPV-16 and HPV-18, 
via alignments for sequence mismatches to HPV subtype L1 sequences and each other (Gravitt et al., 2000; Saini et al., 2009). Nucleotide homology = a dash; 
mismatches = a nucleotide change in the corresponding sequence. Degenerative sequence codes: M = A or C, W = A or T, Y = C or T, and R = A or G. 
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APPENDIX D: Plasmid Maps 
 
 
Figure 49. pBRHPV-6 Plasmid Map. The pBRHPV-6 (HPV-6) construct and information acquired 
from International HPV Reference Centre at the Karolinska Institutet in Stockholm, Sweden. 
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Figure 50. pBRHPV-11 Plasmid Map. The pBRHPV-11 (HPV-11) construct and information 




   




Figure 51. pBRHPV-16 Plasmid Map. The pBRHPV-16 (HPV16) construct acquired from Collins 
et al., 2009 including the backbone vector of pBR322 and the restriction site where the HPV16 
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Figure 52. pGEMII18-WT Plasmid Map. The pGEMII18-WT (HPV18) construct acquired from 
Collins et al., 2009 including the backbone vector of pGEMII (otherwise known as “pGEM-2”) and 
the restriction site where the HPV18 complete viral genome was inserted (Plasmid Map adapted from 
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Figure 53. pUC19 Plasmid Map. The control plasmid that was used measure transformation 
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APPENDIX E: Primer Data Sheets 
 
 
Figure 54. GP5/GP6+ HPV L1 Oligonucleotide Synthesis Report. Received alongside the primer order, used for primer resuspension, and to calculate 
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Figure 55. MY09/11 HPV L1 Oligonucleotide Synthesis Report. Received alongside the primer order, used for primer resuspension, and to calculate 





   
Page | XXXII  
 
 
Figure 56. HPV-16 & HPV-18 E7 Oligonucleotide Synthesis Report. Received alongside the primer/probe order, used for primer and probe resuspension, 
and to calculate molarity of primer and probe stocks (manufactured by Eurofins). 
 
 
   




Figure 57. HPV-6b E6/E7 Primer Data Sheet. Received alongside the primer/probe order as part 
of a custom-designed screening assay for the detection and quantification of HPV-6 in DNA samples 
(manufactured by Primerdesign Ltd). 
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Figure 58. HPV-11 E6/E7 Primer Data Sheet. Received alongside the primer/probe order as part 
of a custom-designed screening assay for the detection and quantification of HPV-11 in DNA 
samples (manufactured by Primerdesign Ltd). 
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APPENDIX H: Phase 1 (P1) Participant Questionnaire  
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APPENDIX I: Phase 2 (P2) Participant Questionnaire  
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